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Abstract 
Transmissible spongiform encephalopathies are fatal neurodegenerative diseases which 
affect many mammals, including humans. A unique feature involves the conversion of 
the prion protein (PrP) to an abnormal isoform. Previous studies indicate 
interconversion of PrP is associated with the binding of metals and glycosaminoglycans 
(GAGS) such as heparin. However, the impact of metals or heparin on the formation of 
disease-related PrP forms is not well understood. To determine whether metals and 
GAGs play a role in transfer of prion infection, a cell culture infection model was 
developed. Data from these studies show that prion infectivity was reduced with 
depletion of metals, but enhanced with the addition of heparin. Isothermal titration 
calorimetric experiments, a novel method to study heparin-PrP interactions, were 
performed to further classify heparin binding regions of PrP. Four sites were identified, 
and mutation analysis confirmed that at least two sites are located within the first 90 
residues of the N-terminus. Finally, to address whether the effects seen in the cellular 
infection model were due to PrP-metal or PrP-GAG interactions, a aggregation method 
was developed to characterise recombinant PrP under physiologically relevant 
conditions. This is important to do as many in vitro prion conversion studies are 
performed in conditions not seen in vivo including extreme temperature or pH or in the 
presence of denaturants. The results of these studies showed that metals are able to 
significantly increase the conversion of PrP mutants containing deleted regions within 
the octameric repeat domain. In contrast, no significant promotional effect was seen 
with the heparin aggregation experiments. This result suggests a possible explanation 
of the cell culture data is that other cellular interactions besides PrP-heparin 
associations must be considered to fully account for these findings. This body of work 
establishes that PrP interactions with metals and glycosaminoglycans play a role in 
transmissible spongiform encephalopathies through prion conversion. 
12 
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1. Introduction 
1.1 Transmissible spongiform encephalopathies 
Transmissible spongiform encephalopathies (TSEs) are a group of neurodegenerative 
disorders that are thought to be caused by the misfolded prion protein. These disorders 
affect humans, sheep, goats, cattle, mink, deer, elk, felines both domestic and wild, and 
wild ruminant species. 
TSEs were originally thought to be caused by a slow virus until recent evidence which 
has shown that this is not the case. Despite extensive work, the disease agent could not 
be classified as a nucleic acid nor have attempts to isolate the infectious particle been 
fruitful. Evidence supporting the hypothesis that the causative agent was a protein 
(Griffith, 1967) was provided by the discovery that the scrapie agent persisted despite 
treatment to inactivate nucleic acids (Alper et al., 1966, 1967; Haig and Clarke, 1968; 
Latarjet et al., 1970). Further work done by Bolton et al. identified a major component 
of the scrapie agent to be a sialoglycoprotein (Bolton et al., 1982), which in turn led to 
the more specific characterization that the agent responsible for inducing disease state 
was a proteinaceous infection particle labeled “prion” (Prusiner, 1982). This so called 
“prion theory” suggests that an abnormal conformation of the prion protein is 
responsible for transmission and propagation of TSEs. This theory is now widely, 
although not universally, accepted (Manuelidis, 2007) and has changed scientific 
interpretation of certain neurodegenerative diseases, including Parkinson’s disease and 
Huntington’s disease, as essentially protein conformation disorders. 
Human prion diseases can arise through inherited mutations, acquired (iatrogenic) 
means, or sporadically. Human diseases include Creutzfeldt - Jakob disease (CJD), 
variant Creutzfeldt-Jakob Disease (vCJD), kuru, Gerstmann-Sträussler-Scheinker 
disease (GSS), and fatal familial insomnia (FFI). CJD was first described by 
Creutzfeldt and Jakob in 1920 (Spielmeyer, 1922). CJD occurs throughout the world 
and the majority of these occurrences are sporadic in origin, although 10-15% of all 
cases are thought to be inherited. GSS and FFI arise from autosomal dominantly 
inherited mutations of the prion protein, with the most commonly seen mutation a 
proline to leucine substitution at amino acid 102 in GSS and substitution of asparagine 
for aspartic acid at position 178 in FFI. There are over 20 described mutations of PrP 
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which lead to prion diseases (Collinge, 2001). Transmissible causes of CJD have been 
attributed to iatrogenic means such as insufficiently decontaminated surgical 
instruments, dura matter grafts, cadaver derived human growth hormone, and blood 
transfusions (Brown, 2005; Llewellyn et al., 2004). A newly described variant version 
of CJD (vCJD) is thought to arise from consumption of BSE-contaminated meat 
products (Will et al., 1996; Hill et al., 2000). Kuru, a disease which affected the South 
Fore people of New Guinea, is thought to have been spread through their practice of 
ritualistic cannibalism (Gajdusek, 1957). 
The clinical signs of human prion diseases differ depending on disease type, but overall 
symptoms include depression, insomnia, behavioural changes, progressive cerebellar 
ataxia, and cognitive decline (dementia). Pathology includes widespread spongiform 
change, gliosis, and neuronal loss. Additionally in kuru and GSS abundant amyloid 
plaques are present. Inherited prion diseases have long incubation periods. In the case 
of sporadic CJD, age of onset is generally in the 5th or 6th decade of life, and 70% of 
patients die within 6 months. In contrast, vCJD has an altered pathology with a mean 
age of onset of 27 years of age (range 12-72 years), and length of incubation period 
anywhere from 4-30 years. Clinical disease duration of vCJD ranges from 9 to 35 
months. GSS has longer mean disease duration of 5 years, but an earlier age of onset 
(in the 3rd to 4th decade). Kuru disease progresses anywhere from 3 months to 3 years, 
with a mean duration of 12 months, and age of onset is anywhere between 5 to 60 
years. Disease progression occurs more quickly in children (Collinge, 2001; Collins et 
al., 2001). 
While the incidence of prion disease in humans is generally low, the emergence of 
vCJD in the 1990s brought prion diseases into the mainstream. Data from the UK 
national CJD surveillance unit indicate that while the known total deaths from vCJD 
are estimated at 164, the number of vCJD annual deaths has decreased since peaking in 
2000. Worldwide figures show a total of 217 cases of vCJD, including 6 patients who 
are still alive. While vCJD is very rare, a common risk factor was living in the UK 
between the years 1980-1996. 
The worldwide average occurrence of CJD, the most common human prion disease, is 
an incidence of 1 case per million, with an average annual mortality rate of 1.31 deaths 
per million (data from the EUROCJD project). In the UK, in the past five years, the 
average number of deaths from prion diseases including sporadic, iatrogenic, and 
18 
familial CJD, GSS and vCJD is 83 (NCJDSU, 2009). Despite the rarity of these 
diseases, the transmissible and nucleic-acid free nature of infectious agent, along with 
similarities to other neurodegenerative diseases highlight the need for further study. 
Besides humans, several mammalian species are also known to contract TSEs. Scrapie, 
a TSE which affects sheep and goats, has been known to be in existence for several 
hundred years (McGowan, 1918). Scrapie was shown to be transmissible to goats in 
the early 20th century (Cuille and Chelle, 1936). Prion diseases affecting other animals 
were subsequently described, including bovine spongiform encephalopathy (BSE) 
which affects cattle (Wells, 1987); chronic wasting disease (CWD) which affects deer 
and elk (Williams and Young, 1980); and transmissible mink encephalopathy (TME) 
which affects wild and farmed mink (Marsh and Hadlow, 1992). Wild and domestic 
felines are affected by feline spongiform encephalopathy (Wyatt et al, 1991; 
Willoughby et al., 1992) and wild and zoo ungulates can also contract a spongiform 
encephalopathy (Jeffrey and Wells, 1988; Kirkwood et al., 1990). 
C1.2 The cellular prion protein, PrP
The cellular prion protein, PrPC, is encoded from a single gene, Prnp (Oesch et al., 
1985). The Prnp gene is located on chromosome 20 in humans and on chromosome 2 
in mice. I Murine Prnp consists of three exons, with the entire coding sequence found 
in the third exon as shown in Figure 1.1A(Hsiao et al., 1987; Basler et al., 1988). PrP 
expression is controlled by the Prnp promoter (Goldman et al., 1993) and PrP mRNA 
is expressed throughout the body, although the highest expression levels are found in 
the central nervous system (CNS) and in particular neurones (Chesebro et al., 1985; 
Oesch et al., 1985; Kretzschmar et al., 1986). PrPC concentrations range from 40 to 
700 µg per gram of total protein in the CNS (Bendheum et al.,, 1988; Pan et al.,, 1992). 
Murine PrPC is 254 amino acids long and consists of two signal sequences that are 
cleaved during cellular processing (see Figure 1.1B). After synthesis, the protein is 
directed to the endoplasmic reticulum (ER), where residues 1-23 of the N terminus 
form a signal sequence which interacts with the Sec61 translocon (Chakrabarti and 
Hegde, 2009). Within the ER, PrPC is post-translationally modified by the addition of 
two asparagine-linked oligosaccharides, addition of a glycosylphosphatidylinositol 
(GPI) moiety at the C-terminus around amino acid residue 230, and correctly folded 
(Haraguchi et al., 1989; Endo et al., 1989; Stahl et al., 1990; Yost et al., 1990; 
Chakrabarti and Hegde, 2009). The protein is then trafficked to the Golgi apparatus, 
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where glycan and GPI anchor modification takes place. PrPC is attached to the 
membrane via the GPI anchor at the cell surface. The synthesis process takes about 30 
minutes. Once the mature PrPC is at the cell surface, the protein is internalised, 
possibly via clathrin-coated pits, membrane rafts, or caveoli (Taylor et al., 2007; 
Sunyach et al., 2003; Shyng et al., 1994; Galvon et al., 2005). The protein is then 
either recycled to the cell surface or sent to lysosomal/endosomal compartments for 
degradation. Total cycling times are estimated between 3-6 hours (Borchelt et al., 
1990; Shyng et al., 1993). 
Figure 1.1. Schematic representations of murine Prnp gene and murine PrPC. A) Murine Prnp consists of 
three exons, with the entire open reading frame (ORF) residing in exon 3 along with an untranslated region 
(UTR). B) Murine PrPC is 254 amino acids long with a N-terminal signal sequence of 22 amino acids that is 
cleaved during proteolytic processing. Structural elements within the C-terminal domain include 2 β-sheets 
(β1 128-131 and β2, 161-164) and three α-helices (α1, 144-154; α2, 179-193; α3, 200-217). A disulfide cysteine 
bridge links residues 179 and 214 and there are two asparagine linked glycosylation sites located at residues 
180 and 196, represented by asterisks, 
PrPC has a highly conserved nucleic acid sequence of the N-terminal tail between 
mammalian species (Rivera-Millar et al., 2006). Structural studies using Fourier-
transform infrared spectroscopy (FITR), circular dichromism (CD) spectroscopy and 
nuclear magnetic resonance (NMR) spectroscopy and have shown that PrPC consists of 
flexible N-terminal region spanning residues 23-125, containing five copies of the 
octameric repeat PHGGGWGQ in the N-terminus. The C-terminus consists of 2 short 
β-sheets and 3 α-helices with a disulfide bridge linking cysteine residues 179 and 214, 
and in the murine protein there are two asparagine linked oligosaccharides at residues 
180 and 196 (Riek et al., 1996, 1997; Donne et al., 1997; Zahn et al., 2000). 
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C1.3 Functions of PrP
The precise function of PrPC has not yet been agreed although many hypotheses exist 
regarding the normal function. 
The development of transgenic PrP-/- animals highlighted potential functions for PrP. 
PrP-/- animals have altered synaptic function (Collinge et al., 1994), circadian rhythms 
(Tobler et al., 1996), motor function (Katamine et al., 1998; Nazor et al., 2007), 
memory (Büeler et al., 1992), copper metabolism (Brown et al., 1997) and impaired 
response to oxidative stress (Brown et al., 1997; Klamt et al., 2001; Wong et al., 
2001a,c). These altered phenotypes have led to several hypotheses regarding the 
normal function of PrPC. 
C1.3.1 PrP functions in cellular signalling, processing, and survival 
A role for PrPC in cellular signalling arose from evidence suggesting the PrPC was 
capable of binding to several proteins which have a role in cell signalling pathways. 
Grb2 and casein kinase 2 have both been shown to interact with PrPC and these proteins 
have been shown to play a role in cell signal transduction (Spielhaupter and Schatzl, 
2001). In addition, the signalling molecule stress-inducible protein 1 (STI1) has been 
shown to bind PrPC, and upon endocytosis mediate signal transduction via protein 
kinase A (PKA) and ERK 1/2 pathways (Zanata et al., 2002; Lopes et al., 2005; 
Americo et al., 2007; Caetano et al., 2008). It has also been shown that PrPC-mediated 
signalling by P59Fyn kinase can modulate cellular survival although current data does 
suggest the involvement of another intermediate component (Mouillet-Richard et al., 
2000; Santuccione et al., 2005). While the precise mechanism is unknown, PrPC has 
been shown to modulate the cAMP/PKA pathway (Martins et al., 1997; Chiarina et al., 
2002). Other potential signalling pathways that PrPC may play a role in involve 
tyrosine kinases, protein kinase C, as well as the PI3 kinase/Akt pathway (Schnieder, et 
al., 2003; Stuermer et al., 2004; Botto et al., 2004; Santuccione et al., 2005; Kanaani et 
al., 2005, Vassallo et al., 2005; Weise et al., 2006; Krebs et al., 2006). 
Hypotheses that PrPC may function in cellular processing including cellular adhesion 
arose from studies which show PrP binds to neuronal cell adhesion molecules, or 
NCAMs (Manson et al., 1992; Schmitt-Ulms et al., 2001; Santuccione et al., 2005). 
Additionally PrPC may have a role in neuronal and non-neuronal cell proliferation 
(Cashman et al., 1990; Mabbott et al., 1997; Mazzoni et al., 2005), neuronal cell 
differentiation (Mobley et al., 1988; Graner et al., 2000 a,b; Chen et al., 2003; 
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Santuccione et al., 2005; Kanaani et al., 2005), and cell cycle regulation (Satoh et al., 
2000; Liang et al., 2007). 
A potential role for PrPC in cellular survival and/or protection has also been suggested 
following evidence that PrPC interacts with Bcl-2, an anti-apoptotic molecule as well as 
inhibiting Bax-mediated death (Kurshner and Morgan, 1995; Roucou et al., 2003; Chen 
et al., 2003; Kanaani et al., 2005). Conversely, however, it has been shown the PrPC 
may increase sensitivity of cells to staurosprine-induced death with increased caspase 3 
activity (Paitel et al., 2002). However, PrPC also seems to play a protective role in 
other cellular stress situations, including hypoxic ischaemia as PrPC expression is up-
regulated following an ischaemic insult (McLennon et al., 2004; Weise et al., 2004, 
2006; Sakurai-Yamashita et al., 2005; Shyu et al., 2005), as well as after other stress 
conditions such as heat shock and hypoglycaemia (Shyu et al., 2000, 2004). Further 
protective roles have been suggested including the theory that PrPC can act as an 
antioxidant as studies have shown that PrPC is able to detoxify superoxides (Brown, 
1999; Brown et al., 2001; Cui et al., 2003; Treiber et al., 2007; Stanczak et al., 2007) 
and that altering levels of PrPC induces changes to superoxide dismutase levels and vice 
versa (Brown and Besinger, 1998; Kralovicova et al., 2009). 
C1.3.2 PrP and metals 
A link between metals and prion diseases was proposed when Pattinson and Jebbett 
identified a similarity in brain lesion profiles of mice treated with the Cu2+ chelator 
cuprizone to those of scrapie infected mice (Pattison and Jebbett, 1971a,b). Since then 
several studies have shown PrP is capable of metal binding and there is evidence that 
copper, manganese, zinc, and iron have a further role in prion biology (Hornshaw 1995 
a, b; Brown et al., 1997, 2000; Whittal et al., 2000; Jackson et al., 2001; Thompsett et 
al., 2005; Leach et al., 2006; Pushie et al., 2007; Davies et al., 2009). Furthermore it 
has been demonstrated that the levels of some metals are altered during disease 
progression (Wong et al., 2001b; Thackray et al., 2002b), and that metals, in particular 
copper and zinc, are involved in PrP endocytosis (Pauly and Harris et al., 1998; Brown 
and Harris, 2003). 
1.3.2.1 Copper 
PrPC isolated from brains has copper bound (Brown et al., 2001), and in the absence of 
PrPC, synaptosomal preparations have decreased copper levels when compared with 
wild type controls (Herms et al., 1999; Brown, 2003). Exposure to copper has been 
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shown to increase and modulate the expression of PrP in cells (Brown et al., 1997; 
Hijazi et al., 2003; Varella-Nallar et al.; 2006; Toni et al., 2005) and in cells lacking 
PrPC copper uptake is decreased (Brown, 1999, 2004). Further evidence shows that 
dietary copper can affect PrPC expression (Mitteregger et al., 2009; Kralovicova et al., 
2009), and other proteins involved in copper metabolism are differentially expressed in 
mice during prion disease progression depending on PrP expression levels 
(Kralovicova et al., 2009). 
The N-terminus (residues 23-125) of PrP binds copper ions within the octameric repeat 
region (residues 51-90 mouse sequence) and at an additional site within the N-terminus 
(Hornshaw, 1995 a, b; Brown et al., 1997, 2000; Viles et al., 1999; Aronoff-Spencer et 
al., 2000; Jones et al., 2004; Thompsett et al., 2005). Copper binding to PrP has been 
demonstrated by a variety of methods and binding affinities vary largely from 
femtomolar to micromolar although recent evidence suggests binding is likely within 
the nanomolar range at pH 7.4 (Nadal et al., 2009). PrP-copper binding involves 
copper-histidine interactions, as identified by Raman spectroscopy (Mihauser et al., 
1999), and PrP binds five or possibly six copper ions within the N-terminal region of 
PrP. It is thought that there are 4 binding sites within the octameric repeat region and 
another binding site centred around His95, His110 (His96/His111 in human PrP) 
(Klewpatinoid et al., 2008; Davies et al., 2009). There are reports of copper binding 
elsewhere on PrP, including within the C-terminus at two sites involving His187 and 
potentially aspartic or glutamic acid residues (Cereghetti et al., 2001). There are also 
reports of non-specific binding during high copper concentrations at acidic pH (Davies 
and Brown, 2008). Furthermore it has been suggested that copper may bind via 
methionine residues within the central domain, at residues Met109, Met112 (Shearer et 
al., 2008). 
PrP-copper binding is thought to involve cooperativity, although the exact binding 
coordination is unknown. There are many models of copper binding cooperativity: 
three-nitrogen and one oxygen (3N1O) coordination involving three nitrogens (one 
imidazole and two glycines) and an oxygen from carbonyl of the last glycine, or four 
nitrogen (4N) coordination (Chattopadhyay et al., 2005; Davies and Brown, 2008). 
Binding coordination is dependent on copper occupancy and pH. Within the octameric 
repeats, the maximum copper occupancy (one copper ion per PHGGGWGQ repeat) 
occurs at pH 7.4 and is thought to have 3 nitrogen-1 oxygen (3N1O) coordination (del 
Pino et al., 2007; Davies et al., 2009). 
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Copper binding to PrP may play an important role in the normal function of PrP, and 
there is much evidence that points to copper involvement in prion biology. 
Additionally, copper binding in the octameric repeat region induces endocytosis of the 
prion protein in response to physiological concentrations of copper (Pauly and Harris, 
1998; Perera and Hooper, 2001; Brown and Harris, 2003; Haigh et al., 2005). Deletion 
of the octameric repeat region ablates copper-induced endocytosis and alterations of the 
numbers of octameric repeat sequence differentially regulates the copper-induced 
endocytosis effect (Pauly and Harris, 1998; Perera and Hooper, 2001; Haigh et al., 
2005). Expanded octapeptide repeat regions, similar to those seen with GSS, do not 
result in copper-mediated endocytosis (Krasemann et al., 1995). Endocytosed PrP is 
delivered to early endosomes and Golgi (Brown and Harris, 2003) and copper mediated 
endocytosis occurs via a clathrin-mediated mechanism (Madore et al., 1999; Sunyach 
et al., 2003; Taylor et al., 2005). 
Disease associated forms of PrP have an inability to be retained in copper-loaded resin 
(Sakaguchi et al., 1996; Thackray et al., 2002b; Hijazi et al., 2003) and purified PrP 
from prion-infected brains have decreased levels of bound copper. Analysis of blood, 
CNS, and other tissues from prion-infected animals show a decrease in copper levels by 
as much as 50% (Wong et al., 2001b; Thackray et al., 2002b; Hesketh et al., 2007, 
2008). Further, high concentrations of copper can reduce PrPSc accumulation in cells 
(Hijazi et al., 2003). In support of this, it has been shown that high doses of copper can 
delay disease onset in prion-infected hamsters (although at highly toxic concentrations) 
and that copper chelators can alter the onset of disease (Hijazi et al., 2003; Sigurdsson 
et al., 2003). This evidence suggests a definite role for copper in prion biology. 
PrP has also been shown to bind manganese, zinc, nickel, iron, cobalt, and other metals 
with much lower affinity than copper (Brown et al., 2000; Whittal et al., 2000; Jackson 
et al., 2001; Leach et al., 2006; Pushie et al., 2007; Kenward et al., 2007; Walter et al., 
2007; Davies et al., 2009). Although some studies have shown that PrP is capable of 
binding copper and manganese concurrently (Brown et al., 2000), copper has been 
shown to be the preferential metal binding partner within the octameric repeat region 
(Stockel et al., 1998; Pushie et al., 2007). 
1.3.2.2 Manganese 
Several studies have shown levels of manganese are altered in both animals and 
humans infected with prion diseases (Wong et al., 2001b; Thackray et al., 2002b; 
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Hesketh et al., 2007, 2008; Mitteregger et al., 2009). Brains from sCJD patients 
showed a ten-fold increase in manganese levels, and PrP purified from these brains had 
manganese bound (Wong et al., 2001b). Furthermore, in blood and the CNS of prion­
affected animals (cattle, sheep, and mice) manganese levels were increased (Thackray 
et al., 2002b; Hesketh et al., 2007, 2008). These studies have led to the suggestion that 
increased manganese levels could potentially be used as a marker for prion disease 
(Wong et al., 2001b; Hesketh et al., 2008). 
PrP binds manganese at two sites within the N-terminus of the protein: a high affinity 
site centred on His95 (murine numbering) and a low affinity site in the octameric repeat 
region (Brazier et al., 2008). The binding affinities of PrP to manganese are similar to 
other manganese-binding proteins, such as DMT-1, a known manganese transporting 
protein (Brown, 2009). 
1.3.2.3 Zinc 
PrP has been shown to bind zinc, although with lower affinity than copper (Whittal et 
al., 2000; Brown et al., 2000; Jackson et al., 2001; Qin et al., 2002; Walter et al., 2007; 
Kenward et al., 2007; Davies et al., 2009). Zinc binds at two sites within the octameric 
repeat region, one site with micromolar affinity and one site with millimolar affinity. 
PrP may additionally bind zinc within the His95/His110 region in the absence of the 
octameric repeat region (Davies et al., 2009). Zinc binding is only possible at low 
copper concentrations, as PrP preferentially binds copper (Walter et al., 2007). Zinc 
binding has been shown to promote PrP-PrP interaction (Kenward et al., 2007). 
As with copper, zinc can induce endocytosis of PrP (Watt et al., 2003; Brown and 
Harris, 2003). Recently it was shown that PrP can protect against zinc-mediated 
toxicity by modifying metallothionien and intracellular zinc levels (Rachidi et al., 
2009). 
1.3.2.4 Nickel, iron and other metals 
Studies suggest that PrP is able to bind other metals including nickel, iron, cobalt, 
palladium, and platinum although the reported affinities for these metals is very low 
and binding would inevitably be outcompeted by copper binding (Jackson et al., 2001; 
Pushie et al., 2007; Davies et al., 2009). Nickel binding occurs within the octameric 
repeatregion at pH 7 and possibly at His95/His110 in the absence of the octameric 
repeat region (Jackson et al., 2001; Davies et al., 2009). 
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Iron binds optimally around the His95/His111 site at acidic pH levels and at two sites 
within the N terminus at neutral pH (Davies et al., 2009). Of the other metals, only 
iron has a demonstrated physiological link. PrPC has been shown to modulate cellular 
iron uptake and intracellular iron content, as over-expression of PrPC increases the 
intracellular iron pool as well as the amount of iron stored in ferritin (Singh et al., 
2009a). PrP knockout mice have altered iron metabolism and are iron deficient in the 
brain and other major organs (Singh et al., 2009c). The altered iron metabolism is 
restored upon expression of PrPC. Iron homeostasis may also play a role in the disease 
state. Levels of iron and iron regulatory proteins are altered in brains of prion infected 
mice, hamsters, and humans during disease progression (Singh et al., 2009b) and 
ferritin, an iron storage protein, is found within aggregated PrP27-30 (Giorgi et al., 
2009). Iron imbalance is also seen in scrapie infected neuroblastoma cells, rendering 
the cells more susceptible to iron-induced oxidative stress (Kim et al., 2000; Fernaeus 
et al., 2005 a, b). 
This overwhelming amount of evidence suggesting metals play a role in either the 
normal function of PrPC or pathogenesis of prion disease. Despite - the numerous ­
suggested functions for PrP there is no consensus to date regarding the precise role of 
PrP in vivo. It is clear that expression of PrPC is required for disease pathogenesis. 
Prnp0/0 transgenic mice are phenotypically normal and deletion of the Prnp gene is non 
lethal. However, transgenic Prnp0/0 mice and cattle do not develop prion disease when 
innoculated with infectious scrapie, BSE, or TME isolates (Büeler et al., 1993; Prusiner 
et al., 1993; Weissmann et al., 1994a,b; Sakaguchi et al., 1995; Richt et al., 2007). 
Prion disease susceptibility is restored upon expression of even a single allele of Prnp, 
and incubation times appear inversely proportional to PrPC expression levels (Büeler et 
al., 1994; Fischer et al., 1996). 
Sc 1.4 PrP
The disease associated isoform of PrPC is referred to as PrPSc (Sc for scrapie). PrPC and 
PrPSc are encoded by the same gene and have the same primary amino acid sequence 
but their tertiary structure differs greatly (Basler et al., 1986). One of the most striking 
differences is a complete structural rearrangement of the globular C-terminal region 
from a mainly α-helical structure to a predominantly β-sheet structure. PrPC has about 
40% α-helical content with low β-sheet content. In contrast, PrPSc has 45% β-sheet 
content and 30% α-helical content, suggesting PrPSc undergoes a major rearrangement 
of the C-terminus (Pan et al., 1993; Safar et al., 1993). There are additional 
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distinguishing factors such as protease sensitivity and solubility. PrPSc is partially 
protease resistant and when digested with proteinase K (PK), the protein is cleaved in 
the N-terminus to produce a truncated core which is often referred to as PrP27-30 
(McKinley et al., 1983; Harrison et al., 1997). PK resistance is the most commonly 
used method to indicate whether the disease form is present, although several studies 
have shown that PK-resistant PrPSc levels are not directly correlated to the infectious 
transmissibility of the disease agent (Collinge et al., 1995; Wille et al., 1996; Lasmezas 
et al., 1997). However, PK-resistant PrP remains the standard for identification of 
TSEs. 
Furthermore, in afflicted individuals, PrPSc has been shown to accumulate in aggregates 
whereas PrPC does not (Prusiner et al., 1983). These accumulations can form amyloid 
plaques, which occur in 10-15% of sporadic CJD (sCJD) patients and are also found in 
kuru and GSS patients (Sikorska et al., 2009). These plaques differ depending on type 
of prion disease but can either be florid (dense and unicentric, surrounded by 
spongiform vacuoles) or multi-centric (a merged network of unicentric plaques). 
Plaques and other accumulations of PrPSc contain high amounts of PrP as well as other 
proteins such as ubiquitin, ferritin, tubulin, and apolipoprotein E, and molecules such as 
proteoglycans (Snow and Wright, 1989; Snow et al., 1990; Giorgi et al., 2009). 
It has been demonstrated that PrPSc is formed after PrPC reaches the cell surface 
(Caughey, 1991; Tarabolous et al., 1992; Gilch et al., 2001) as cleaving PrPC from the 
cell surfaces prevents PrPSc formation (Campana et al., 2005). However, the precise 
site of conversion of PrPC to PrPSc remains unclear. While a small percentage of PrPSc 
can be seen at the cell surface (Vey et al., 1996), the majority of PrPSc is located 
intracellularly (Tarabolous et al., 1992; Caughey, 1991; McKinley et al., 1991; 
Marijanovic et al., 2009). Therefore the proposed cellular location of prion protein 
conversion is either at the cell surface or within the endocytic pathway (Caughey et al., 
1991b; Caughey and Raymond, 1991; Borchelt et al., 1992; Taraboulos et al., 1992). 
Recently, the endocytic recycling compartment, part of the endocytic pathway, was 
identified as a likely site for conversion (Marijanovic et al., 2009). However, despite 
further narrowing down of the likely site of conversion, the actual mechanism and 
causes of conversion remain unclear. 
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1.5 Conversion of the prion protein to the disease-associated 
form 
The underlying mechanism behind the conversion of the normal PrPC to a disease-
associated form has been extensively studied but is not well understood. It is generally 
accepted that the normal cellular PrPC molecule undergoes a conformational conversion 
to the disease-associated form PrPSc, which is then able to aggregate and accumulate in 
the brain. 
1.5.1 Kinetic theories of prion conversion 
Conversion of PrP has been modelled using three kinetic theories, which include 
template assisted-aggregation (Cohen et al., 1994), nucleation-elongation 
polymerisation (Harper and Lansbury, 1997), and branched-chain polymerisation 
(Baskakov, 2007). Each of these theories employs the idea that a smaller unit of PrP is 
responsible for further catalysing protein aggregation. Initial studies led to the 
hypothesis that prion conversion followed a template assisted aggregation pathway 
wherein PrPSc acts as a template and upon binding to PrPC, recruits the normally folded 
molecule to refold into a PrPSc conformation (Cohen et al., 1994; Aguzzi, 2004). 
Branched-chain polymerisation means the rate of the formation of end products is 
dependent on the number and polymerisation of active centres, as well as the volume of 
the reaction. Once the end product is formed, the “lag time” of the multiplication of 
active centres is reduced and the reaction proceeds until a plateau is reached (Baskakov, 
2007). In nucleation-dependant polymerisation where monomeric protein is the 
predominant species until a critical concentration is achieved, then polymerisation to 
fibril precursors (nuclei) occurs. The length of time required for the fibril precursor 
nuclei to form is referred to as lag time (Harper and Lansbury, 1997). As yet there is 
no conclusive evidence that any of these kinetic theories is the correct model. 
1.5.2 Prion aggregation models 
Several mechanisms for prion protein aggregation have been proposed. For example, β­
oligomer structure can arise from a non-amyloid pathway, wherein the protein forms 
amorphous, β–structure rich aggregates which then arrange into spherical β-oligomers. 
Another model postulates that the pathway to amyloid fibrils involves a pre-amyloid 
intermediary which is a reversible mainly α-helical in structure and may exist in 
equilibrium with the native monomer (El Moustaine et al., 2008). This intermediate 
state then proceeds to a dimer stage. Dimerisation has been shown to be a crucial if not 
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an initiatory step in fibrillisation (Priola et al., 1995; Luhrs et al., 2006; Goggin et al., 
2007; Stohr et al., 2008). From the dimer formation, acquisition of β-sheet content 
leads to growth of proto-filaments to proto-fibrils, and finally to mature fibrils. The 
progression from proto-filaments to mature fibrils seems to be common to all amyloid-
forming proteins. The common structure of amyloid fibrils consists of a cross β spine 
containing a double sheet of stacked, parallel β-rich segments. These segments stack in 
a head to tail structure, and are bound to their neighbour via side chains which act like a 
zipper, using hydrogen binding and interactions between the backbones to form the 
structure (Makin et al., 2002; Torok et al., 2002; Margittai et al., 2004; Nelson et al., 
2005; Shewmaker et al., 2006; Chen et al., 2007). In mammalian prions, the cross β­
core correlates to amino acids 127-230 (Cobb, et al. 2007; Lu et al., 2007; Sun et al., 
2008) and the N-terminal tail, including the hydrophobic region of PrP, has been shown 
to be at the surface of fibrils as determined by antibody mapping (Novitskaya et al., 
2006b). 
1.5.3 Structural changes of conversion 
The C-terminal domain of the prion protein undergoes structural rearrangement during 
conversion of the disease-related isoform, and many suggestions have been proposed 
concerning the extent of structural rearrangement. At present, data are conflicting. It 
has been proposed that the C-terminal domain of PrP undergoes major structural 
rearrangement during conversion to an amyloid form, resulting in complete abolition of 
alpha helical structure (Lu et al., 2007). Alternatively, the C-terminal region retains α­
helical conformation, while either four regions spanning residues 116-119, 119-132, 
135-140, and 160-164 assemble into a β-sheet (DeMarco et al., 2004) or residues 89­
175 assemble into three left handed β-helices (Govaerts et al., 2004). 
It is thought that α-helix 1 of PrP may be important for aggregation (Dima and 
Thirumalai, 2002; Watzlawik et al., 2006; Yu et al., 2007; Bujdoso et al., 2005), 
although its role is unclear as it may not convert fully to a β-sheet form (Watzlawik et 
al., 2006) and it is stable over a range of pH values and solvent conditions (Liu et al., 
1999; Speare et al., 2003; Ziegler et al., 2003; Norstrom and Mastrianni, 2006). It has 
been theorised that the formation of asparagine-arginine salt bridges in α-helix 1 
stabilise PrP and form intermolecular bonds with other PrP molecules which could lead 
to aggregation (Morrissey et al., 1999). However the bridges appear to stabilise PrPC in 
vitro (Speare et al., 2003). It has therefore been suggested that the specific orientation 
of charged residues within α-helix 1, particularly the C-terminal end of α-helix 1, is 
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essential for conversion. This data corroborates the observation that interactions 
between glutamic acid 196, aspartic acid 202 and glycine 90 may be important for 
dimer formation (Kaimann et al., 2008). Further evidence that the C-terminus of the 
prion protein is rearranged during conversion was demonstrated by Fiztmaurice, et al 
who showed the ease of unwinding of α-helix 2 was correlated with modulation of the 
stability and aggregation of ovine PrP (Fiztmaurice et al., 2008). 
Additionally, the N-terminal region is capable of modifying PrP aggregation 
(Frankenfield et al., 2005), but is not strictly necessary for aggregation to occur as 
numerous studies use an N-terminally truncated PrP. 
1.5.4 Mutations to PrP and conversion 
Mutations of the prion protein are likely to affect PrP conversion. There are more than 
20 mutations of the Prnp gene, to human prion diseases has been attributed (Mead, 
2006). The most prevalent mutations are E200K, D178N, P102L and octapeptide repeat 
insertionsHuman PrP exists in two allelic forms with a polymorphism at amino acid 
position 129. This polymorphism has been linked to disease susceptibility in kuru, 
vCJD and iatrogenic CJD (Collinge et al., 1991; Collinge et al., 1996; Zeidler et al., 
1997; Hill et al., 1999; Collinge, 2001; Lee et al., 2001; Mead, 2006). Investigation of 
the different alleles on both the structure of PrPC and on aggregation indicate that the 
polymorphism at 129 of human PrPC has no effect on the globular structure or stability 
(Hosszu et al., 2004), or the ability of the protein to convert into a β-sheet rich form 
(Wong et al., 2000a; Lewis et al., 2006). However, it has been demonstrated that the 
initial folding state of the protein defines the kinetics of the conversion reaction (Tahiri-
Alaoui et al., 2004, 2005, 2006; Baskakov and Bocharova, 2005). While there are no 
differences between the allelic forms in conversion of α-monomeric human PrP to 
amyloid under non-denaturing conditions, (Liemann et al., 1999; Hosszu et al., 2004; 
Tahiri-Alaoui and James, 2005), under denaturing conditions there are differences. PrP 
with a methionine at 129 has a more exposed α-helix 1 and is more prone to form β­
rich oligomers and to aggregate (Tahiri-Alaoui et al., 2004; Pham et al., 2008). 
Aggregation of PrP with a valine at 129 gains β-sheet structure more rapidly than 
methionine at 129 and has a shorter lag period, although the rates of amyloid growth do 
not differ between the two (Baskakov and Bocharova, 2005). 
In addition, there are many other pathogenically-associated mutations whose effects on 
aggregation and amyloid formation have been described. Aggregation and disease 
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manifestation of the commonly found human PrP mutation D178N has been shown to 
be modulated by the allelic form of PrP at codon 129 (Apetri et al., 2005). 
Recombinant protein with another disease-associated mutation, F198S, also has a 
higher propensity for aggregation than wild type protein (Vanik et al., 2002). 
Furthermore, these pathological mutations appear to increase the propensity of 
monomeric folding intermediates and these folding intermediates again may be 
important in the pathway to amyloid formation. Finally, the polymorphism at 129 was 
also shown to affect the structure but not the aggregation of C-terminally truncated PrP 
containing N-terminal pathological mutations (Apetri and Surewicz, 2002; Apetri et al., 
2004). 
Another common pathological mutation associated with prion disease is the insertion of 
extra octapeptide repeats within the N-terminal region. PrP with these insertion 
mutations has an increased propensity to aggregate proportional to the number of 
insertions (Singh et al., 1997; Moore et al., 2007; Tank et al., 2007; Yu et al., 2007), A 
yeast model comparing similar insertions found the resulting fibrils are less stable 
(Kalastavadi and True, 2008). In cell culture, extra octapeptide repeats leads to 
increased aggregation and increased protease resistance (Priola et al., 1998). 
In addition to variations in human PrP aggregation, variations in conformation and 
aggregation of different sheep alleles of PrP have been shown (Bossers et al., 1997, 
2000; Rezaei et al., 2002; Thackray et al., 2004b; Bujdoso et al., 2005; Yang et al., 
2008). Cell-free conversion of different allelic forms of ovine PrP mimicked scrapie 
susceptibility in vivo. The most susceptible allelic form, V136R154Q177, had the highest 
rate of conversion to a protease resistant form of PrP, where the allelic form associated 
with scrapie resistance had a limited ability to form protease resistant PrP in the study 
(Bossers et al., 1997, 2000). Scrapie-resistant ovine PrP alleles have decreased β-sheet 
content in aggregation intermediates when compared to scrapie-susceptible allele 
(Rezaei et al., 2002; Yang et al., 2008). Furthermore copper-induced structural 
changes appear to be modulated by the ovine polymorphism M/T112, as M112 
A136R154Q177, a scrapie susceptible allele appears to be more thermostable but has a 
higher β-sheet content than T122 A136R154Q177 (Yang et al., 2008). Thus, studies of the 
structural characteristics induced by polymorphisms and pathological mutations 
provide insight not only into the mechanism of prion aggregation, but potentially 
explain the differences in pathogenicity seen between various diseases (Collinge and 
Clarke, 2007) as well as the susceptibility of specific polymorphisms to these diseases. 
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1.5.5 Additional factors affecting conversion 
Additional factors that have been theorised to affect prion protein conversion include 
metals, polyanionic compounds, glycosaminoglycans, and dendrimers. 
1.5.5.1 Metals 
Copper binding to PrP induces conformational change, as copper binding imposes 
structure on the unstructured N-terminal region (Stockel et al., 1998). This has been 
shown to increase β-sheet content of the protein as well as confer protease resistance, 
although the protease resistance is distinct from PrPSc protease resistance (McKenzie et 
al., 1998; Stockel et al., 1998; Wadsworth et al., 1999; Brown et al., 2000; Qin et al., 
2000; Quaglio et al., 2001; Wong et al., 2000b; Jones et al., 2004; Nishida et al., 2004; 
Liu et al., 2007). Polymorphisms can influence the degree to which copper can induce 
β-sheet structure, for instance, the scrapie-susceptible ovine allele V136R154Q177 has a 
greater increase in β-sheet structure when compared to the scrapie-resistant 
A136R154R177 allele (Rezaei et al., 2002; Wong et al., 2004). This copper-induced 
conformational change is mediated by the presence of the N-terminal region of PrP 
(Wong et al., 2004) and is thought to be due to the differences in α-helix 1 and residue 
171 (Thackray et al., 2004b). 
The actual effect of copper on prion protein aggregation is contradictory, as the 
addition of copper (II) ions has been shown to inhibit aggregation (Giese et al., 2004; 
Bocharova et al., 2005b; Ricchelli et al., 2006; Liu et al., 2008) and cell-free 
conversion (Orem et al., 2006) but can also initiate aggregation of recombinant protein 
(Requena et al., 2001; Rezaei et al., 2002, 2005; Shiraishi et al., 2005, 2006; 
Tsiroulnikov et al., 2006; Redecke et al., 2007; Fitzmaurice et al., 2008), suggesting a 
differential effect dependent on experimental conditions. 
In addition to copper, PrP is able to bind manganese as described in section 1.3.2.2. 
Upon binding to PrP, manganese induces conformation change and increased protease 
resistance (Brown et al., 2000; Abdelraheim et al., 2006; Kim et al., 2005; Treiber et 
al., 2006). Manganese-loaded PrP has been shown to initiate aggregation of PrP 
(Brown et al., 2000; Giese et al., 2004; Lekishvili et al., 2004; Kim et al., 2005). This 
initiation of aggregation is due to the structural change manganese confers on PrP once 
bound (Brown et al., 2000), similar to the manner that copper causes a conformational 
change. 
32 
1.5.5.2 Other factors effecting conversion 
RNA, polyanions and glycosaminoglycans (GAGs) stimulate cell-free conversion of 
synthetic peptides, recombinant and brain-derived PrP into a protease resistant form of 
PrP (Wong et al., 2001d; Gonzalez-Iglesias et al., 2002; Deleault et al., 2005; 
Boshuizen et al., 2007; Yin et al., 2007). This may be particularly relevant to disease 
pathogenesis, as it has been shown that GAGs can bind recombinant PrP (Pan et al., 
2002; Warner et al., 2002), and they are essential for prion replication (Hijazi et al., 
2005; Horonchik et al., 2005). The polyanion Congo Red (CR) has been shown to 
inhibit conversion of PrP in vitro at high molecular ratios by inducing PrP to adopt a 
more denatured state (Caughey et al., 1992, 1993; Caspi et al., 1998; Frid et al., 2007) 
and at low molecular ratios to promote aggregation (Rudyk et al., 2000). This 
differential effect is may be because CR does not act upon pre-existing PK-resistant 
PrP molecules (Caughey and Raymond, 1993). Finally, branched polymers called 
dendrimers have been shown to modulate aggregation of PrP peptides by inhibiting or 
slowing aggregation, modulating the amount of fibrils produced and rendering the 
resulting aggregations more protease-sensitive (Supattapone et al., 1999; Klajnert et al., 
2006, 2007). 
1.6 Transmissibility, neuroinvasion, and neurodegeneration 
As yet there is no definitive cause for the conversion of the prion protein, nor do we 
know why the conversion and subsequent accumulation of the prion protein leads to the 
disease state. It has been theorised that conversion of the protein leads to the 
accumulation of misfolded protein, possibly in oligomeric structures which then leads 
to neuronal loss and eventually patient death. One theory is that small oligomers are in 
fact the culprit in prion disease as it has been postulated that the infectious form of PrP 
was around 50-150 kDa in size (Alper et al., 1966; Gabizon et al., 1987; Bellinger-
Kawahara et al., 1988; Caughey et al., 2003) and later suggestions that a minimal 
infectious unit corresponded to a PrP molecule around 600 kDa in size (Tzaban et al., 
2002). As monomeric PrP is around 25-30 kDa, this suggests the infectious culprit 
would be an aggregated form of PrP. When PrPSc aggregates were dissociated, it was 
found that that the most infectious PrP aggregates were round spherical oligomers, 17­
27 nm in length and 300-600 kDa in size, corresponding to 14-28 PrP molecule units 
(Silveira et al., 2005). Further analysis of a PrP aggregation pathway, which produces 
well-ordered β-oligomers of PrP, has shown that oligomers consist of 25 monomeric 
equivalents of PrP. This evidence supports the idea of the oligomer as the minimal 
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infectious unit (Redecke et al., 2007). Recently it has been shown that small PrP 
oligomers are present in pre-clinical stages of prion disease and these oligomers 
increase in concentration as the disease progresses (Sasaki et al., 2009). Accordingly, 
these and other data indicate that prion protein oligomers are toxic to the cells and are 
responsible for disease development (Novitskoya et al., 2006a, 2007; Simoneau et al., 
2007; Dear et al., 2007). 
Considering the uncertainty surrounding the exact structure of infectious PrP, it is 
unsurprising that the mechanism of transmission is as yet unknown. In addition to the 
CNS, prion infectivity has been identified in several tissues of the body including 
blood, spleen, tonsil, fat, skin and muscle (Pattison and Millson, 1962; Hadlow et al., 
1982; Bosque et al., 2002; Thomzig et al., 2004, 2006, 2007; Castilla et al., 2005; 
Angers et al., 2006; Race et al., 2008, 2009; Cardone et al., 2009; Terry et al., 2009). 
Also, prion infectivity is found in bodily secretions including milk, saliva, urine, and 
faeces (Miller et al., 2004; Mathiason et al., 2006, 2009; Vascellari et al., 2007; 
Gregori et al., 2008; Safar et al., 2008; Krüger et al., 2009). Transmissibility to 
humans has been shown to occur via blood transfusions and dura matter grafts (Hunter 
et al., 2000; Llewelyn et al., 2004; Peden et al., 2004; Hunter, 2003; Mathiason et al., 
2009) as well as via consumption of prion-affected material as with kuru and vCJD 
(Gajdusek, 1977; Scott et al., 1999). Ovine and mouse-adapted scrapie as well as 
CWD has been shown to be transmitted via environmental exposure (such as housing 
uninfected animals in the same cages which previously held infected animals), Thus, 
while it can be argued that these diseases are contagious, it is not precisely clear how 
this transmission occurs (Pattison et al., 1971c; Miller et al., 2004; Ryder et al., 2004; 
Georgsson et al., 2006). 
Experimentally, prion diseases are traditionally transmitted via intracranial and 
intraperitoneal inoculation for the most consistent results. However, oral entry seems 
the most likely route of transmission for naturally acquired (not inherited) prion 
diseases such as scrapie, BSE, CWD and possibly kuru and vCJD (Pattison et al., 1974; 
Hadlow, et al., 1982; Andreoletti et al., 2000; van Keulen et al., 2000; Marsh and 
Bessen, 1993; Sigurdson, et al., 2001; Williams and Miller, 2003; Gajdusek, 1977; 
Cervenakova et al., 1998). Transmission via oral entry has been shown to result in 
subclinical disease even after a low dose of infectious innoculum and this subclinical 
presentation resulted in high levels of infectivity despite the lack of clinical signs 
(Thackray et al., 2002a, 2003a). This subclinical yet highly infectious disease resulting 
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from oral exposure to prions may represent a mechanism of environmental 
transmission, particularly as it has been recently shown that asymptomatic deer infected 
with CWD excrete infectious prions in faeces (Tamguney et al., 2009). 
The spread of prion infection throughout the body is not completely understood, but 
evidence suggests that upon oral entry, prion infectivity generally spreads from the 
alimentary canal to the lymphoid system, and from the lymphoid system to the 
peripheral nervous system and then to the CNS (Beekes and McBride, 2007; Kovacs 
and Budka, 2009). From the CNS prion infectivity may then spread back through the 
body to muscles via spinal or cranial motor neurons (Andrelotti et al., 2004; Thomzig 
et al., 2004). 
In experiments with animals fed infectious material, the first signs of prion infectivity 
are seen in the ileum and caudal jejunum (Krüger et al., 2009). From the gut, infection 
spreads to the gut-associated lymphoid tissues (GALT) including Peyer’s patches, 
tonsils, and GALT-draining lymph nodes (Maignien et al., 1999; Beekes and McBride, 
2000; van Keulen et al., 2000, 2002; Bruce et al., 2001; Wadsworth et al., 2001). From 
the GALT, infection spreads to other lymphatic tissue including the spleen (Kimberlin 
and Walker, 1989a,b; Beekes et al., 1996) except in BSE, where lymphatic 
involvement is restricted to GALT only (Terry et al., 2003; Epinosa et al., 2007; 
Hoffmann et al., 2007). The spread of prion infectivity in the lymphoid system could 
be due to several different types of cells that have been shown to harbour disease-
related PrP including follicular dendrite cells (FDC), follicle associated epithelial cells, 
dome and tangible macrophages, microfold cells, and dendritic cells (DCs) (Beekes and 
McBride, 2000; Huang et al., 2002; Koperek et al., 2002). It has been shown that 
interfering with FDC maturation delays TSE neuroinvasion (Muramoto et al., 1992; 
Klein et al., 1998; Mabbott et al., 2000 a, b) and ablating specific B cell receptors 
accelerates TSE neuroinvasion by altering the FDC network (van Poser-Klein et al, 
2008). This suggests that mature FDCs with specific intact B-cell signalling are 
required to spread prion infection. 
From the lymphatic tissue, prion neuroinvasion occurs via the peripheral nervous 
system involving the splanchnic and vagus nerves (which innervate the lymphatic 
tissue and gastrointestinal tract respectively) as well as the enteric nervous system 
(Goelher et al., 1999; McBride and Beekes, 1999). It is likely that neuroinvasion is 
facilitated by FDC and DC transportation of prion infectivity (Beekes and McBride, 
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2007). Once neuroinvasion occurs, prion infectivity spreads along enteric and cervical 
ganglia and is transported to the brain and spinal cord (Williams and Miller, 2003; 
Schultz-Schaeffer et al., 2000; Haik et al., 2003). The mechanism of prion propagation 
through the brain and spinal cord is unknown and may involve axonal transportation, 
spread through the neural interspaces, sequential infection of Schwann cells or even 
serial conversion via PrP-PrP contact along cell membranes (Kimberlin et al., 1983, 
1989a; Glatzel and Aguzzi, 2000; Follet et al., 2002; Kunzi et al., 2005; Kovacs et al., 
2005). 
Once the disease has entered the CNS (either by acquired or inherited modes) it is 
unclear how neuronal damage, loss and eventual patient death actually occurs; whether 
it is loss-of-function of PrP, whatever the function may be, or gain of toxic function 
(toxic aggregates or abnormal cellular forms) by PrP (Kovacs and Budka, 2009; 
Chakrabarti and Hegde, 2009). Several mechanisms have been proposed to explain 
how prion infection leads to neuronal loss, including apoptosis, endosomal or 
lysosomal dysfunction, endoplasmic reticulum stress, oxidative stress, and ubiquitin­
proteasome dysfunction (Forloni et al., 1996; Bence et al., 2001; Clarke et al., 2001; 
Guentchev et al., 2002; Wojcik, 2002; Hetz et al., 2003; Kovacs et al., 2004, 2007; 
Brown et al., 2005; Unterberger et al., 2005; Voigtländer et al., 2006; Kristiansen et 
al., 2007). It is possible that more than one mechanism contributes to the overall 
neurodegeneration seen in prion disease. 
A great deal of uncertainty plagues the field of prion disease research, despite intensive 
efforts by those working in the field. The normal function of PrPC is still debated, as is 
the mechanism behind the conversion to the disease state. Furthermore, there is no 
agreement as to what extent other molecules play in prion disease. There are several 
lines of evidence supporting a role for metals in prion disease, including the metal-
binding capabilities of PrP, altered metal levels associated with the disease, and the 
influence of metals on the structure of PrP. 
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1.7 Aims 
The aim of this work is to further identify the role metals and glycosaminoglycans play 
in prion diseases, and in particular the conversion from the normal PrPC to a disease 
related isoform. 
•	 Metals. 
o	 Firstly, a method for cellular prion infection will be developed using 
either infectious brain homogenate or chronically infected neuronal cells 
as an infectious source for uninfected neuronal cell. Whether the role of 
metals is either promotional or inhibitory in regards to the transfer of 
cellular prion infection will be assessed. 
o	 To determine whether the effect is due to metal-PrP interactions, a new 
method will be developed to study the conversion of PrP in an in vitro 
system using bacterially expressed recombinant protein. Experiments 
done using this system will assess whether metals have a stimulatory 
effect PrP aggregation under neutral pH and non-denaturing conditions. 
There is no precedent for this experimental approach, as most 
aggregation studies used extreme pH, temperature, or denaturants to 
study metal-PrP aggregation effects. Using a neutral system will 
provide us with information which may be more physiologically 
relevant and further our understanding of the role of metals in prion 
conversion. 
•	 Glycosaminoglycans. 
o	 To address the nature of the PrP-GAG interactions, ITC will be used as 
a novel technique to study PrP-GAG binding. 
o	 Subsequently, the role of heparin in PrP conversion, whether 
promotional or inhibitory, will be assessed by using the aforementioned 
cellular prion infection model. 
o	 Finally, to determine whether this affect is specific to a PrP-GAG 
interaction, the effect of heparin on the PrP aggregation system will be 
studied. If the effect is due to a PrP-GAG interaction, a similar 
(promotional or inhibitory) result will be obtained from these conversion 
methods. 
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In summary, this work aims to assess whether there is a promotional or inhibitory role 
of metals and glycosaminoglycans in conversion of the prion protein from a normal, 
cellular form to the disease-associated prion molecule, using recombinant protein 
aggregation and binding assays as well as a cellular prion infectivity culture model. 
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2. Materials and Methods 
2.1 Materials 
All reagents were purchased from Sigma (Poole, UK) unless otherwise noted. 
2.2 Molecular Biology Techniques 
Mammalian expression constructs pcDNA3.1+-mPrP(1-254), pcDNA3.1+-mPrP(1-254 
Δ67-90), and pcDNA3.1+-mPrP(1-254 Δ51-89) were created by Kate Edwards 
(University of Cambridge, Cambridge, UK). Constructs p3XFLAG-mCTR1, 
p3XFLAG-mCTR2, p3XFLAG-mCCS, and p3XFLAG-mATOX1 were created by 
Silvia Kralovicova (University of Bath, Bath, UK) (Table 1). Schematic representation 
of pcDNA3.1+-mPrP(1-254) is illustrated in Figure 2.1. 
Full Construct Name Denotation Created By 
pcDNA3.1+-mPrP 
Kate Edwards, Cambridge 
pcDNA3.1+-mPrP(1-254) 
University, UK 
pcDNA3.1+-mPrP(1­
254Δ51-89) 
pcDNA3.1+­
mPrP(Δ51-89) 
Kate Edwards, Cambridge 
University, UK 
pcDNA3.1+-mPrP(1­
254Δ67-90) 
pcDNA3.1+­
mPrP(Δ67-90) 
Kate Edwards, Cambridge 
University, UK 
p3XFLAG-mCTR1 p3XFLAG-CTR1 
Silvia Kralovicova, 
University of Bath, UK 
Silvia Kralovicova, 
p3XFLAG-mCTR2 p3XFLAG-CTR2 
University of Bath, UK 
p3XFLAG-mCCS p3XFLAG-CCS 
Silvia Kralovicova, 
University of Bath, UK 
Silvia Kralovicova, 
p3XFLAG-mATOX1 p3XFLAG-ATOX1 
University of Bath, UK 
Table 2.1 Mammalian protein expression constructs. All constructs were murine. 
1 23 51 90 110 146 231 254 
pcDNA3.1+-mPrP(1-254) 
Figure 2.1 Schematic representation of pcDNA3.1+-mPrP(1-254). 
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Bacterial expression constructs pET3a-mPrP(89-231), and pET3a-mPrP(23-231 Δ106­
126) were created by Jo Wright (University of Bath, Bath, UK). pET23a-mPrP(23­
231) was created by Salama R. Abdelraheim (University of Bath, Bath, UK). pET23a­
mPrP(23-231 H95A+H110A) were created by Andrew Thompsett (University of Bath, 
Bath, UK). Constructs pET23a-mPrP(23-231 H95A), pET23a-mPrP(23-231 H110A 
pET23a-mPrP(23-231H60A,H68A,H76A,H84A,H95A,H110A), and pET23a­
mPrP(23-231 H60A,H68A,H76A,H84A),were created by Paul Davies (University of 
Bath, Bath, UK) (Table 2). All proteins used in this thesis were expressed and purified 
personally. Schematic representation of mPrP mutations used for bacterial expression 
is shown in Figure 2.2. 
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Full Construct Name Denotation Created by 
pET3a-mPrP(23-231) 
Sarah Fontaine, University of 
pET3a-mPrP(23-231) 
Bath, UK 
pET3a-mPrP(Δ67-90) 
pET3a-mPrP(23-231 Δ51-
89) 
pET3a-mPrP(Δ51-89) 
Sarah Fontaine, University of 
Bath, UK 
pET3a-mPrP(23-231 Δ67­ Sarah Fontaine, University of 
90) Bath, UK 
pET3a-mPrP (89-231) pET3a-mPrP (89-231) 
Jo Wright, University of 
Bath, UK 
pET3a-mPrP(23-231 Δ106­
126) 
pET3a-mPrP(Δ106­
126) 
Jo Wright, University of 
Bath, UK 
pET23a-mPrP(23-231) pET23a-mPrP(23-231) 
Salama Abdelraheim 
University of Bath, UK 
pET23a-mPrP(23-231 
H95A) 
pET23a-mPrP(H95A) 
Paul Davies, University of 
Bath, UK 
pET23a-mPrP(23-231 
H110A) 
pET23a­
mPrP(H110A) 
Paul Davies, University of 
Bath, UK 
pET23a-mPrP(23-231 
H95A+H110A) 
pET23a­
mPrP(H95A+H110A) 
Andrew Thompsett, 
University of Bath, UK 
pET23a-mPrP(23-231 
H60A,H68A,H76A,H84A) 
pET23a­
mPrP(H95+H110A) 
Paul Davies, University of 
Bath, UK 
pET23a-mPrP(Null) 
Paul Davies, University of 
Bath, UK 
pET23a-mPrP(23-231 
H60A,H68A,H76A,H84A,H 
95A,H110A) 
Table 2.2. Bacterial mPrP constructs. 
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A 
mPrP(23-231) 
mPrP(Δ51-89) 
mPrP(Δ67-90) 
mPrP(Δ106-126) 
mPrP(89-231) 
B 
mPrP(23-231) 
mPrP(Null) 
mPrP(H95A, H110A) 
mPrP(Null+H95,H110) 
mPrP(Null+H95A) 
mPrP(Null+H110A) 
Octapeptide Repeat Hydrophobic Domain 
Region S S 
23 51 90 120 160 231 
23 51 90 120 160 231 
23 51 90 120 160 231 
23 
23 
23 
23 
23 
23 
23 
51 90 120 160 231 
90 120 160 231 
Octapeptide Repeat Hydrophobic S S 
51 Region 90 120 Domain 160 231 
H H H H H H 
51 90 120 160 231 
A A A A A A 
51 90 120 160 231 
H H H H A A 
51 90 120 160 231 
A A A A H H 
51 90 120 160 231 
A A A A A H 
51 90 120 160 231 
A A A A H A 
Figure 2.2. Schematic representation of mPrP constructs used for recombinant 
Deletion and truncation mutants. B) Mutations of copper-binding histidine residues. 
2.2.1 Purification of DNA 
2.2.1.1 Additional Materials 
Wizard SV Miniprep Kit (Promega) 
Luria-Bertani (LB) Broth (Melford, UK) 
Carbenicillin sodium salt (Melford, UK) 
2.2.1.2 Method 
protein expression. A) 
Single colonies were inoculated into 5 mL LB with 50 µg/mL carbenicillin. Cultures 
were grown overnight at 37°C with shaking at 200 r.p.m. The next day cultures were 
centrifuged for 5 min at 4000 r.p.m. to pellet cells. The supernatant was discarded and 
DNA extracted from cells per manufacturer’s instructions. 
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2.2.2 Polymerase chain reactions 
2.2.2.1 Additional Materials 
BamHI (Promega, UK)

NdeI (New England Biolabs, UK)

PWO DNA polymerase (Roche, UK)

Deoxyribonucleotides (dNTPs) (New England Biolabs, UK)

Sterile MillQ water, pH 7.4

25 µM primers (MWG, UK)

2.2.2.2 Method 
Custom primers were designed with restriction endonuclease sites NdeI and BamHI. 
The PCR reaction mixture consisted of 1 µg DNA (as extracted previously), 25 µM 
primers, sterile MilliQ water, 10x PWO Buffer with MgSO4, 25 µM dNTPs and 2.5 
Units PWO DNA polymerase per 50 µL reaction. PCR reaction conditions are as 
follows: 
mPrP 23-231 was amplified from pCDNA3.1+-mPrP(1-254). mPrP(Δ51-89) was 
amplified from pcDNA3.1+-mPrP(1-254Δ51-89), and mPrP(Δ67-90) was amplified 
from pcDNA3.1+-mPrP(1-254Δ67-90) using forward primer 
5’ GCGCATATGAAAAAGCGGCCAAAGCCT 3’ and reverse primer 
5’ TATGGATCCTTACTAGCTGGATCTTCTCCC 3’. 
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2.2.3 Agarose Gel Electrophoresis 
2.2.3.1 Additional Materials 
Agarose (Melford, Ipswich, UK) 
Tris-acetate (TAE) buffer (40 mM Tris acetate, 1 mM EDTA, pH 8.0) 
GeneRuler 1 kb DNA ladder (Fermentas, UK) 
2.2.3.1 Methods 
Agarose gels were prepared by dissolving agarose in TAE buffer to a final 
concentration of 1%. Typically, 1 g agarose was added to 100 mL TAE buffer and 
dissolved by heating in a 800 watt microwave at high power for 3 min. 10 µL 10 
mg/mL ethidium bromide was then added so DNA samples could be visualised with 
UV light. The agarose was poured into moulds (BioRad) and allowed to set. Once gel 
had solidified, it was transferred to the electrophoresis apparatus (BioRad) and DNA 
samples were mixed with 5X DNA loading dye before loading into wells. A 1 kb DNA 
ladder was run alongside samples to determine size. 
2.2.4 Gel Purification 
2.2.4.1 Additional Materials 
QIAquick Gel Extraction Kit (Qiagen, UK) 
2.2.4.2 Method 
DNA samples to be purified were run on a 1.5% agarose gel containing ethidium 
bromide for 1h at 100 volts. The gel was briefly exposed to UV light and correctly 
sized fragments were excised using razor blades and transferred to a sterile 1.5 mL 
eppendorf. Gel slices were then purified according to manufacturer’s directions using a 
QIAquick Gel Extraction kit. DNA was eluted from the column with the addition of 30 
µL nuclease free water and incubation for 60 s at room temperature. The columns were 
transferred to a sterile 1.5 mL eppendorf tube, and centrifuged for 60 s to elute the 
bound DNA. 
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2.2.5 Restriction Enzyme Digests 
2.2.5.1 Additional materials 
NdeI (New England Biolabs UK) 
BamHI (Promega, UK) 
Buffer 3 (New England Biolabs UK) 
10 mg/mL Bovine Serum Albumen (BSA) (Promega, UK) 
MilliQ sterile 
2.2.5.2 Method 
Restriction enzyme digests were typically performed on 1-10 µg DNA using restriction 
endonucleases at 10-20 Units. Double digests were performed utilising a suitable 
buffer for both enzymes (as determined from the manufacturer’s instructions). 
Digestions only included 0.25 µg/µL BSA if required by a specific enzyme. Digests 
were incubated at 37°C typically for 2 hours, or if the enzymes did not exhibit star 
activity (wherein the enzyme begins to bind within your DNA of interest to sequences 
similar to the recognition site) digests were allowed to incubate overnight. 
2.2.6 Vector preparation 
2.2.6.1 Additional Materials 
Shrimp Alkaline Phosphatase (SAP) (Promega, UK) 
pET3a (Novagen, UK) 
Buffer 3 (New England Biolabs, UK) 
10 mg/mL BSA (Promega, UK) 
2.2.6.2 Method 
5 µg pET3a DNA was digested for 4h with NdeI and BamHI in Buffer 3 with BSA as in 
2.2.6. Digested vectors were then gel-purified and eluted in 40 µL of nuclease-free 
water. 5 µL 10X SAP buffer and 5 µL SAP (1 Unit/µL) were added to the eluted DNA 
and incubated at 37°C for 15 min. The SAP was then inactivated by incubation at 70°C 
for 15 min 
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2.2.7 Phosphorylation of PCR products 
2.2.7.1 Additional materials 
T4 Polynucleotide Kinase (Promega, UK) 
10x Ligation buffer from T4 ligase (Promega, UK) 
2.2.7.2 Method 
PCR products that had been gel-purified were phosphorylated for blunt-ended ligations. 
8 µl each PCR product was mixed with 1 µl 10X T4 ligation buffer and 1 µl T4 
polynucleotide kinase. The reaction was incubated at 37°C for 30 min and then the T4 
polynucleotide kinase was inactivated by incubating at 70°C for 10 min. PCR products 
were then ligated into an intermediate vector. 
2.2.8 Preparation of intermediate vector for blunt-ended ligations 
2.2.8.1 Additional materials 
10 mg/mL Bovine Serum Albumen (BSA) (Promega, UK) 
EcoRV (Promega, UK) 
2.2.8.2 Method 
pcDNA3.1+ was used as an intermediate vector. 5 µg pcDNA3.1+ was digested with 
2.5 µL EcoRV with 0.5 µg BSA at 37°C overnight. The digested pcDNA3.1+ was then 
gel purified (2.2.5) and eluted in 40 µL nuclease free water, then SAP treated (2.2.7) 
and stored at -20°C until use. 
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2.2.9 Ligation Reactions 
2.2.9.1 Additional materials 
T4 DNA ligase (Promega, UK) 
Sterile MilliQ water 
2.2.9.2 Method 
Ligation reactions containing 100 ng vector DNA were typically performed in 20 µL 
volumes. A 3:1 ratio of insert DNA: vector DNA was typically used, following the 
manufacturer’s protocol. 1 µL T4 DNA ligase and 2 µL 10X T4 DNA ligase buffer 
was added to the DNA and sterile MilliQ water was used to bring the volume to 20 µL. 
Ligations were incubated overnight at 16°C and stored at -20°C until transformed into 
competent cells. 
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2.2.10 Preparation of calcium competent cells 
2.2.10.1 Additional Materials 
0.1 MgCl2 
0.1 M CaCl2 
0.1 M CaCl2 + 15% glycerol 
JM109 cells (Promega, UK) 
BL21-DE3 cells (Novagen, UK) 
2.2.10.2 Method 
Cells were streaked onto an LB plate and incubated overnight at 37°C. A single colony 
was inoculated into LB and incubated with shaking at 150 r.p.m. overnight at 37°C. 
The following day 10 mL of overnight culture was inoculated into 200 mL LB and 
grown at 37°C with shaking at 200 r.p.m. until the O.D.600 = 0.6. Cells were then 
pelleted by centrifuging for 10 min at 4000 r.p.m. at 4°C, and then resuspended by 
gently pipetting up and down in 200 mL ice cold 0.1 M MgCl2. Cells were pelleted by 
centrifuging for 10 min at 4000 r.p.m. at 4°C. Cells were gently resuspended in 200 
mL ice cold 0.1 M CaCl2 and incubated on ice for 20 min. The centrifugation and 
resuspension was repeated for final time in 10 mL ice cold 0.1 M CaCl2 + 15% 
glycerol. Cells were aliquotted quickly into pre-chilled sterile eppendorfs and stored 
immediately at -80°C. 
2.2.11 Transformation of DNA into Escherichia coli JM109 or BL21­
DE3 cells 
2.2.11.1 Additional materials 
SOC buffer (10 mM sodium chloride, 2.5 mM potassium chloride, 10 mM magnesium 
sulphate, 10 mM magnesium chloride, yeast extract, tryptone, 0.4% glucose) 
2.2.11.2 Method 
Calcium-competent JM109 or BL21-DE3 cells in 10% glycerol (v/v) were thawed on 
ice. 3 µL of the DNA to be transformed was added to a 1.5 mL sterile eppendorf tube 
and kept on ice whilst an aliquot of cells thawed. Once completely thawed, 100 µL of 
the competent cell suspension was transferred aseptically into the pre-chilled eppendorf 
tubes containing the DNA. This mixture was allowed to incubate on ice for 30 min. 
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After the incubation, a heat shock was performed at 42°C for exactly 45 s. Reactions 
were immediately placed back on ice for 2 min before 400 µL SOC buffer was added to 
each tube. Reactions were incubated at 37°C with shaking for no more than 1 h. 
Suspensions were then gently centrifuged to pellet the cells which were then 
resuspended in approximately 150 µL SOC and plated directly onto LB-agar plates 
containing 50 µg/mL carbenicillin. The plates were then incubated at 37°C overnight 
to allow successfully transformed colonies to grow. 
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2.3 Cell Culture Methods 
All tissue culture and prion infection work was performed under biosafety level 2 
standards. Prion contaminated material was thoroughly decontaminanted in 2 M NaOH 
as described by standard protocols for prion work by D.R.Brown. 
2.3.1 General cell culture: routine maintenance of cell lines 
2.3.1.1 Additional Materials 
Dulbecco’s Modified Eagle Medium (DMEM) with 4.5 g/L glucose, without L-
glutamine (Lonza, UK) 
Eagle’s Minimum Essential Medium (EMEM) (Lonza, UK) 
Medium 199 (Lonza, UK) 
Trypsin-EDTA (Gibco, UK) 
Newborn Calf Serum (NCS), heat-inactivated, USA origin 
Foetal Bovine Serum (FBS), heat-inactivated, origin (Lonza, UK) 
L-gluatmine (Gibco, UK) 
Non-essential amino acids (NEAA) 100X solution (Lonza, UK) 
Penicillin-streptomycin 
2.3.1.2 Method 
All cells were maintained at 37°C and 5% CO2 in a humidified incubator. 
2.3.1.2.1 N2a Cells 
Neuro2a (N2a) cells originate from a spontaneous tumour of an albino mouse (Klebe 
and Ruddle, 1969). N2a cells were maintained in EMEM supplemented with 10% 
FBS, 2.5 mM L-gluatmine, 1 X NEAA, and 1% penicillin-streptomycin. Cells were 
passaged at 1:10-1:15 for maintenance once confluent. 
2.3.1.2.2 SMB and SMB-PS Cells 
Scrapie mouse brain (SMB) cells originate from brains of mice infected with the 
Chandler strain of scrapie (Clarke and Haig, 1970). SMB-PS cells are SMB cells that 
were treated with pentosan sulphate to clear prion infection, as shown by the lack of 
detectable PK-resistant PrP in these cells. Cells were maintained in Medium 199 
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supplemented with 10% FBS, 5% NCS and 1% penicillin-streptomycin. SMB cells 
were passaged at 1:3 when 90% confluent and SMB-PS were passaged at 1:4-1:6 when 
confluent. 
2.3.1.2.3 Zpl and Zwl cells 
Zpl and Zwl cells are derived from Zurich mice (Kim et al., 2005) and were a kind gift 
from Professor Yong-Sun Kim, the New York State Institute for Basic Research in 
Developmental Disabilities. Cells were maintained in DMEM supplemented with 10% 
FBS and 1% penicillin-streptomycin and passaged 1:20 when confluent. 
2.3.2 Cryopreservation of cell lines 
2.3.2.1 Additional Materials 
Freezing medium (90% (v/v) FBS, 10% (v/v) DMSO 99.7% pure) 
2.3.2.2 Method 
Cells were grown to 70-90% confluency before dissociating with trypsin and re­
suspending in fresh medium. Cells were pelleted by centrifugation for 5 min at 1000 g. 
The medium was aspirated carefully away and cells were resuspended with 1-2mL 
freezing medium per 75 cm2 flask. Cell suspensions were immediately placed in a 
plastic freezing vessel filled with isopropanol and placed in the -80˚C freezer for 4h to 
overnight. Cells were stored long-term in liquid nitrogen. 
Cells were thawed by warming each vial in a 37˚C water bath until fully thawed. Then 
cells were diluted in pre-warmed complete culture medium. Cells were pelleted by 
centrifugation for 5 min at 1000 g. The medium was aspirated carefully away and cells 
resuspended with 6 mL of complete culture medium, then transferred to a 25 cm2 flask. 
Cells were placed in the incubator and allowed to adhere overnight. 
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2.3.3 Transfection 
2.3.3.1 Additional Materials 
Fugene HD (Roche, UK) 
DNA purified from QIAprep Spin Miniprep Kits (Qiagen, UK) 
EMEM, DMEM, M199 serum free (Lonza, UK) 
G418 Sulphate (PAA, UK) 
2.3.3.2 Method 
2.3.3.2.1 Creation of stably transfected cell lines 
Cells were plated into 6 well plates at a density of 1x105 cells per well and allowed to 
adhere overnight. In a sterile 1.5 mL eppendorf, 2 µg DNA was diluted in 100 µL 
serum free media. To this mixture 3 µL Fugene HD was added and the reaction was 
allowed to incubate at room temperature for 15 mins. The entire reaction was then 
added to each well, dropwise, and the cells were returned to the incubator for 48 h. 
Cells expressing the protein of interest were then selected for by adding the appropriate 
amount of G418 sulphate (PAA) to each well. G418 concentrations were determined 
by performing kill curves on each cell line wherein untransfected cells were treated 
with G418 and assessed twice a day to determine rate of death. The concentration 
which took one week to kill all the cells was chosen for use in the stable transfections. 
After one week all control cells were dead, and transfected cells were analysed by 
Western blot for successful expression of desired proteins. Cells were then maintained 
in normal culture media with G418 added. G418 concentrations for each cell line are 
listed in Table 2.3. 
2.3.3.2.2 Creation of transiently transfect cell lines 
Cells were plated into 6 or 12 well plates at a density of 1.09x104 cells per cm2 surface 
area and allowed to adhere overnight. In a sterile 1.5 mL eppendorf, 2 µg DNA was 
diluted in 100 µL serum free media. To this mixture 3 µL Fugene HD was added and 
the reaction was allowed to incubate at room temperature for 15 min. The entire 
reaction was added to each well, dropwise, and the cells were returned to the incubator 
for 48 h and protein expression levels were analysed by Western blot. 
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Cell line 
G418 concentraion (µg/mL culture 
media) 
N2a 700 
SMB-PS 150 
Zwl/Zpl 600 
Table 2.3 G418 concentrations required for stably transfected cell lines. Concentrations were determined by 
performing kill curves and assessing cells after one week of treatment with various G418 concentrations. 
2.3.4 MTT Assay for cell viability 
2.3.4.1 Additional Materials 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
Isopropanol (Fisher, UK) 
2.3.4.2 Method 
Cells were plated in a 96 well plate and treated accordingly. At the end of treatment, 
the media was removed and 50 µL 2.5mg/mL MTT in complete culture media was 
added to each well. Cells were then incubated at 37°C, 5% CO2 for 30 min. The MTT 
solution was removed and 100 µL isopropanol was added to each well. The plate was 
then incubated for a further 30 min at 37°C, 5% CO2. The reaction was pipetted up and 
down in the well to ensure an even reading and read at 562 nm on a FluroStar Omega 
reader (BMG). Data was analysed by comparing optical density (O.D.) values at 562 
as a percentage of the control as follows: 
(optical density of sample)/(mean optical density of control) x 100% 
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2.3.5 MTS Assay for cell viability 
2.3.5.1 Additional materials 
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H­
tetrazolium) (MTS) (Promega UK) 
Complete culture media (as in 2.3.1) 
Dulbecco’s PBS (Lonza UK) 
Phenazine methosulfate 
2.3.5.2 Method 
Cells were plated in 96 well plates typically 1 x 104 cell per well and treated as 
required. At the end of the treatment period, 2 mL prepared MTS solution (50 mg/mL 
in PBS, sterile filtered) was combined with 100 µL 0.92 mg/mL phenazine 
methosulfate solution and 20 µL of this solution was added per well. Plates were 
returned to the incubator for 1-4 h and read at 495 nm. Results were calculated as in 
2.3.4.2 using 495 nm values. 
2.3.6 Preparation of Chelex Treated Media 
2.3.6.1 Additional Materials 
Media preparations as described in 2.3.1 
Chelex-100 resin 
MgSO4 
CaCl2 
2.3.6.2 Method 
2.5 g Chelex-100 resin was added to 50 mL complete media and incubated typically 
overnight at 4°C with rocking, or for 1 h at room temperature with rocking. The media 
was then sterile-filtered using a 0.22 µm syringe filter (Millipore) and CaCl2 and 
MgSO4 was added back to basal levels (as published by the manufacturer). The media 
was allowed to equilibrate at 37°C, 5% CO2 before use. 
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2.3.7 Infectious inoculate preparation 
2.3.7.1 Additional materials 
Sterile PBS 
2.3.7.2 Method 
2.3.7.2.1 Preparation of brain homogenates 
Brains from mice infected with prion strains 79A and Me7 were suspended in 9 
volumes of PBS homogenised by serial passages through needles to create a 10% (w/v) 
homogenate. Presence of PK-resistant PrP was checked by digesting with PK as 
described in 2.3.10. Homogenates were stored at -80°C until use. 
2.3.7.2.2 Preparation of infected cell homogenates 
SMB or infected N2a cells over expressing mPrP were grown to confluence in 75 cm2 
or 175 cm2 flasks (Grenier BioOne) and trypsinised. Cells were counted, centrifuged, 
re-suspended in sterile PBS and subjected to five rapid freeze-thaw cycles. Rapid 
freezing and thawing was accomplished by immersing cells into liquid nitrogen until 
fully frozen and then transferring to a 37°C water bath. 
After freeze-thawing, cells were homogenised by repeatedly passing through a 30 G 
needle (at least 20 times per homogenate preparation). 20 µL of this homogenate was 
then plated in complete culture medium and observed for 48 h to ensure homogenate 
did not contain viable cells. Homogenates were stored at -80°C until use. 
2.3.8 Cell Infection 
2.3.8.1 Additional materials 
Complete culture media (as in 2.3.1) 
G418 sulphate (PAA, UK) 
Sterile PBS (135 mM NaCl, 26.5 mM KCl, 15 mM KH2PO4, 8 mM Na2HPO4) 
2.3.8.2 Method 
For infection experiments, ratios for cell infections were determined by continually 
plating and assessing confluency of N2a cells by eye over time periods corresponding 
to the infection experiments. The ideal densities would allow for the healthiest cell 
growth without cells becoming too over confident and allow enough cells that even if 
some cells succumbed (due to natural handling or any potential toxic effects of the 
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infectious innoculum) there would still be enough cells to take up and replicate prions. 
Cell density ratios were determined by seeding different ratios of target cells and 
choosing the ratio were cells were still viable but not over-confluent for the duration of 
the experiment. Ideal plating was determined to be 5.3 x 104 cells per cm2 of growth 
area. Growth area is determined from the culture vessel manufacturer’s specifications. 
Cell ratios of higher than this density resulted in over confluence and loss of cells. 
Lesser densities did not reliably show transfer of prion infectivity. Seeding densities 
for different culture vessels are listed in Table 2.4. 
Culture Vessel Growth area (cm2) Seeding Density 
24 well plate 1.9 1.01 x 105 cells per well 
12 well plate 3.8 2.02 x 105 cells per well 
6 well plate 9.4 4.98 x 105 cells per well 
Table 2.4 Starting seeding densities for infection assay experiments. 
2.3.8.2.1 Infection using scrapie brain homogenates 
Cells were plated in cell-culture treated 12 or 24 well plates (Nunc) as described in 
Table 2.3 and allowed to adhere in the incubator at least 6 h or preferably overnight. 
Once cells had adhered and determined to be of appropriate density (by eye), the media 
was aspirated and infectious homogenate was added to each well (no more than 10% 
total volume) and cells were incubated for 2 h, after which complete culture media was 
then added and cells incubated for a further 70 h. After this incubation, the media was 
removed by aspirating and cells were washed three times in sterile PBS before removal 
to a fresh plate. Cells were split after 4 days and passaged every 3-4 days thereafter at 
1:5-1:10. After 4 passages, cells were plated onto 13mm glass cover slips, grown to 
100% confluency and analysed as in Section 2.3.9.. 
2.3.8.2.2 Infection using infected cell homogenates 
Cells were plated and allowed to adhere as in 2.3.8.2.1. Homogenates were prepared to 
the required concentrations and diluted in 1 mL complete culture media. The media 
was aspirated from each well and replaced with the homogenate suspension as 
appropriate, and the plate was returned to the incubator for the desired length of time. 
After incubation for the appropriate time course, inoculate was aspirated and cells were 
washed twice with sterile PBS and then cultured in complete media until cells were 
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confluent. Once confluent, cells were trypsinised and plated onto cover slips for a cell 
blot, in a 24 well plate for Western blot analysis, and into a 12 well plate for continued 
culture. 
2.3.8.2.3 Infection by co-culturing with SMB cells 
This method is adapted from a published method (Kanu, 2002). Target cells were 
uninfected cells stably transfected to over-express mPrP. Both target and SMB cells 
(the infectious source) were trypsinised and counted. Cells were then combined at 
varying target: infected cell ratios and co-cultured in complete Medium 199, with no 
selection for 5 days. After 5 days, the medium was changed to favour the target cells 
and G418 was added to select for the target cells only. Cells were then cultured in 
G418 selection until all SMB cells were dead. Cells were then passaged and presence 
of PK resistant PrP confirmed by cell or Western blot. 
2.3.9 Cell Blot Assay for detection of proteinase K resistant PrP 
2.3.9.1 Additional materials 
13 mm glass cover slips (Best, Fisher, UK) 
24 well plate (Grenier BioOne, UK) 
Immobilon-P Polyvinylidene Fluoride (PVDF) membrane (Millipore, UK) 
Cell blot lysis buffer (50 mM Tris, 150 mM NaCl, 0.5% sodium deoxycholate (w/v), 
0.5% Triton-100 (v/v), pH 7.4) 
Guanidine thiocyanate (Acros Organics, UK) 
Proteinase K (PK) 
2.3.9.2 Method 
The method is adapted from Victoria Lewis, University of Melbourne and based on a 
previously published method (Bosque and Pruisner, 2000). Sterile 13 mm glass cover 
slips were coated with poly-L-lysine for 5 min, and then rinsed with sterile PBS. Cover 
slips were then placed inside wells of a 24-well plate using forceps. Cells to be 
analysed were plated onto the cover slips then grown to 100% confluency. Cells were 
then washed twice with PBS with the last wash being left on the cells so there is no 
surface tension between the cover slip and the bottom of the plate. An appropriately 
sized piece of PVDF membrane was then soaked in 100% methanol for 5 min. The 
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membrane was then washed in MilliQ water briefly and transferred to cell blot lysis 
buffer. An appropriately sized piece of cellulose blotting paper was soaked in lysis 
buffer and placed on top of a glass plate and using a 21G 1 ½” needle and tweezers, the 
cover slips were removed from the wells and placed face up on the blotting paper. 
Then the membrane was placed carefully on top of the coverslips and a dry piece of 
blotting paper placed on top. The sandwich was completed by another glass plate. 
Using the palms of both hands, pressure was then exerted on the sandwich for 2 min. 
Afterwards, the membrane was carefully removed, transferred to a dry container and 
dried for 1h at 37°C in a dry incubator. At this stage membranes were sometimes 
wrapped in cling film and frozen at -20°C. Frozen membranes were allowed to thaw 
for a few min before PK digesting. To PK digest, the dry membrane was first soaked in 
lysis buffer for 5 min at room temperature before incubation in a solution of lysis buffer 
containing 8 µg/mL PK at 37°C for 90 min. After the incubation, the PK solution was 
poured off and washed three times in MilliQ water. To inactivate any infectious 
material, the membrane was incubated 3M guanidine thiocyanate with 10 mM Tris pH 
7.4 for 10 min at room temperature. The blot was then washed three times with MilliQ 
water and then blocked and blotted as for Western blotting. 
2.3.10 Preparation of samples for SDS-PAGE analysis 
2.3.10.1 Additional Materials 
Lysis buffer (sterile PBS with 1% Igepal and 1% Triton X-100) 
4X loading dye (20% B-mercaptoethanol, 40% glycerol, 240 mM Tris-HCl pH 6.8, 8% 
SDS, 0.2% bromophenol blue) 
Sterile PBS (as 2.3.8) 
Proteinase K (PK) 
2.3.10.2 Method 
Samples were prepared for Western blot analysis by removing culture media cells and 
rinsingtwice with PBS. 150 µL lysis buffer was added per well in a 12 well plate, 74 
µL lysis buffer was added per well in a 24 well plate, and 20 µL lysis buffer was added 
per well in a 96-well plate. Cells were incubated with lysis buffer for 20 min at 37°C, 
then scraped and removed to appropriately labelled sterile eppendorfs. Protein 
concentration was determined using Bio-Rad assay (see 2.3.7) and all samples were 
normalised for protein concentration. PK digestion, when required, was performed at 
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this stage using 1 µg/µL PK at a PK to total protein ratio of 1:20. Samples were 
digested for 1 h at 37°C. 4X loading dye was added to each sample to a final 
concentration of 1X and either stored frozen or used immediately for a gel. Prior to 
loading on gel, all samples were boiled at 100°C for 5 min. 
2.3.11 Bio-Rad method for protein concentration determination 
2.3.11.1 Additional Materials 
BSA standards (0, 1, 2, 3, 4, 5 mg/mL) 
BioRad dye reagent concentrate (BioRad, UK) 
MilliQ water 
2.3.11.2 Method 
Samples and standards were all done in triplicate. 1 µl of each sample or standard was 
pipetted per well in a 96 well plate. A working reagent of the dye was prepared by 
combining 1 part dye reagent to 4 parts MilliQ and filtering through a 0.22 µm syringe 
to remove particles. 200 µL of the working reagent was added per well and mixed by 
pipetting up and down. The plate was incubated at room temperature for 5 min before 
being read on a plate reader at 595 nm. A standard curve was calculated and protein 
concentration was determined using the standard curve. 
2.3.12 Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
2.3.12.1 Additional Materials 
MilliQ water 
1 M Tris pH 8.8 
1 M Tris pH 6.8 
Amonium persulphate (20% w/v) 
Sodium dodecyl sulphate (SDS) (10% w/v) 
N,N,N',N'-Tetramethylethylenediamine (TEMED) 
Isopropanol (Fisher, UK) 
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Gel apparatus (ATTO Corporation, Japan) 
Running buffer (25 mM Tris, 200 mM glycine, 0.1% SDS) 
Prestained Protein Marker, 175-6 kDa (New England Biolabs, UK) 
Unstained Protein Marker, 212-6 kDa (New England Biolabs, UK) 
2.3.12.2 Method 
2.3.12.2.1 Separating gels 
Atto gel cassettes were assembled per manufacturer’s instructions. Briefly, a rubber 
grommet was laid around the grooves in the glass gel plate, which was then sandwiched 
between another glass plate. This was held in place with securing clips. For 15% 
separating gels, 4 Ml 30% acrylamide, 2.6 mL 1 M Tris pH 8.8, 1.3 mL MilliQ water, 
80 µL 10% SDS, 12 µL 20% APS and 10 µL TEMED were combined and poured 
into the glass plate cast. 1 mL isopropanol was then added on top of the gel mixture to 
ensure oxygen did not interfere with the polymerisation reaction and to ensure the 
resulting gel was level. Once the gel had set, the isoproanol was poured off and the gel 
rinsed with MilliQ water. Then the 5% stacking gel containing 625 µL 30% 
acyrlamide, 625 µL 1 M Tris pH 6.8, 3.6 mL MilliQ water, 50 µL 10% SDS, 20 µL 
20% ammonium persulphate and 10 µL TEMED was mixed and poured on top of the 
separating gel. A comb was carefully inserted to avoid air bubbles and this gel was 
allowed to set until firm. 
Once the gels had been set, the grommits, combs, and securing clips were removed and 
the gel cassettes were secured into the electrophoresis apparatus and the apparatus was 
filled with running buffer per manufacturer’s instructions. Samples were denatured by 
heating at 100°C in 4X loading dye before loading onto gel. Gels were electrophoresed 
at 260 volts, 35 milliamps per gel, 100 watts for 45 min or until the dye front had 
reached the bottom of the gel. Gels were then disassembled from cassettes and either 
stained with Coomassie blue stain or transferred as for Western Blot. 
2.3.12.2.2 Gradient gels 
Atto gel cassettes were assembled per manufacturer’s instructions. Briefly, a rubber 
grommet was laid around the grooves in the glass gel plate, which was then sandwiched 
between another glass plate. This was held in place with securing clips. 20% and 5% 
acrylamide mixtures were prepared as follows: for each 20% gel, 3.3 mL 30% 
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acrylamide, 1.625 mL 1 M Tris pH 8.8, 50 µL 10% SDS, and 8.75 µL 20% APS were 
mixed. For each 5% gel 833 µL 30% acrylamide, 1.625 mL 1 M Tris pH 8.8, 25 mL 
MilliQ water, 50 µL 10% SDS, and 8.75 µL 20% APS was mixed. 5 mL of each 
reaction was aliquoted into two separate falcon tubes, then 5 µL TEMED was added to 
each tube, rapidly mixed by inverting and immediately poured into gradient gel mixer. 
This reaction was allowed to fill a prepared gel cassette. A comb was carefully inserted 
to avoid air bubbles and the gel was allowed to set until firm. 
Once the gels had been set, the grommets, combs, and securing clips were removed and 
the gel cassettes were secured into the electrophoresis apparatus. Samples were 
denatured by heating at 100°C in 4X loading dye before loading onto gel. Gels were 
electrophoresed and further processed as described in 2.3.12.2.1 
2.3.13 Western blot 
2.3.13.1 Additional Materials 
Methanol 
Transfer Buffer (12.5 mM Tris, 100 mM glycine, 0.5% SDS (w/v), 20% methanol

(v/v))

Cellulose blotting paper extra thick

Immobilon-P PVDF membrane (Millipore, UK)

Ponceau S stain (0.2% w/v Ponceau S, 1% (v/v) acetic acid)

Marvel no fat milk powder (Sainsbury’s, Bath, UK)

BSA, cold ethanol precipitated fraction V (Fisher UK)

Tris buffered saline with 0.1% (v/v) Tween-20 (TBS-T) (40mM Tris, 150mM NaCl pH

7.8)

Immobilon horseradish peroxidise (HRP) Substrate (Millipore, UK)

Antibodies: 
ICSM-18 anti PrP antibody (D-Gen, UK) 
8B4 anti PrP antibody (Alicon, Switzerland) 
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Monoclonal Anti-α tubulin (Sigma, Poole, UK)

Anti-FLAG (Sigma, Poole, UK)

Goat anti-mouse immunoglobulins (Dako, Ely, UK)

Primary dilution Secondary dilution 
ICSM-18 1:15,000 1:20,000 
8B4 1:20,000 1:30,000 
Anti α-tubulin 1:30,000 1:30,000 
Table 2.5 Antibody dilutions used in Western blotting. 
2.3.13.2 Method 
SDS-PAGE gels were run as described. Immobilon-P membrane was cut to fit the gel 
and soaked in methanol for 5 min, before soaking in transfer buffer. Gels were soaked 
in transfer buffer for 15 min. Two appropriately sized pieces of cellulose blotting paper 
were wetted in transfer buffer before placing in a Trans-Blot semidry transfer cell 
(BioRad). Using forceps, the membrane was placed on top of the blotting paper and 
carefully smoothed to ensure no air bubbles would interfere with the transfer. The gel 
was then placed carefully on top of membrane before completing the sandwich with 
another two pieces of transfer buffer-soaked blotting paper. Transfers were done either 
at 100 watts, 20 volts, 100 milliamps per 6 x 9 cm membrane, for 2 h or 100 watts 6 
volts, 16 milliamps per 6 x 9 cm membrane, overnight. 
Once transfers were completed, the membrane was stained in Ponceau S, a reversible 
stain, for 2 min. After successful transfers were confirmed, membranes were rinsed in 
MilliQ water until all stain had been removed and then blocked in 5% BSA or 5% non 
fat milk powder in TBS-T for 1h at room temperature. Membranes were then 
incubated with primary antibody dilutions as indicated in Table 2.5,with rocking either 
for 2 h at room temperature or overnight at 4°C. After primary antibody incubation, 
membranes were rinsed twice in TBS-T then washed for three 5 min washes in TBS-T 
with rocking. Membranes were then incubated with secondary antibodies conjugated 
with horseradish peroxidase, in dilutions as indicated Table 2.5, for 1-2 h at room 
temperature with rocking before washing exactly as for the primary antibody. After the 
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last wash, membranes were laid face up on cling film and Immobulin HRP Western 
Reagent as applied evenly to the membrane. Membranes were incubated for five min, 
then the reagent was removed and membranes were wrapped in cling film and 
developed in a dark room by exposing Fujifilm X ray film to the membranes and 
developed. 
2.3.14 Coomassie Blue staining 
2.3.14.1 Additional Materials 
Coomassie stain (0.25 g Coomassie, 45% methanol (v/v), 10% glacial acetic acid (v/v)) 
Destaining buffer (7% glacial acetic acid (v/v), 8% methanol (v/v)) 
2.3.14.2 Method 
Gels were removed from the glass plate apparatus and carefully placed in a square 
plastic Petri dish filled with Coomassie stain. Gels were incubated in stain either 
overnight at room temperature with rocking or microwaved on high for 15 s then 
rocked at room temperature for 5 min. Stain was carefully poured away and gels were 
rinsed once with destain buffer to remove excess stain before incubating overnight in 
fresh destaining buffer. 
2.3.15 Densitometry analysis of Western blots 
2.3.15.1 Additional materials 
Computer scanner 
ImageJ software version 1.43n (http://rsbweb.nih.gov/ij/index.html) 
2.3.15.2 Method 
Western blot images to be quantified were scanned and analysis performed using 
ImageJ software. Relevant bands were measured using the same measuring area for 
each separate blot. Background values were subtracted from each sample and all 
samples normalised to their α-tubulin values to control for protein loading. Data are 
presented as normalised to the untreated control. 
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2.4 Recombinant Protein Techniques 
2.4.1 Expression of recombinant mPrP constructs 
2.4.1.1 Additional Materials 
LB (Melford, UK) 
Carbenicillin sodium salt (Melford, UK) 
Isopropyl β-D-1-thiogalactopyranoside (Apollo Scientific, UK) 
2.4.1.2 Method 
A single colony of the desired PrP construct, transformed into BL21 cells as above was 
inoculated into 100 mL LB containing 50 µg/mL carbenicillin and incubated with 
shaking at 160 r.p.m., overnight at 37°C. The next day, 15 mL of overnight culture was 
inoculated into each 1 L of LB media containing 50 µg /mL carbenicillin and incubated 
at 37°C with shaking at 200 r.p.m.. The optical density of the cells was monitored at 
600 nm and once the density reached 0.6, expression of the protein constructs was 
induced by the addition of 1 mM IPTG. Protein expression was carried out for a 
further five hours at 37°C with shaking at 200 r.p.m.. Cells were then pelleted by 
centrifugation at 4000 r.p.m. for 5 min. These pellets were stored at -20°C until lysis. 
2.4.2 Bacterial Cell Lysis 
2.4.2.1 Additional materials 
Bacterial lysis buffer (0.2 M NaCl, 0.5 M Tris, 1 mM EDTA pH 7.6) 
Lysozyme 
Deoxyribonuclease I 
Phenylmethanesulphonylfluoride 
Ribonuclease I 
2.4.2.2 Method 
Bacterial cells were re-suspended in 2 mL lysis buffer per gram of pellet. 15 mg 
lysozyme was added per 30 mL of solution to lyse the bacterial cells and 0.8 mM 
phenylmethanesulphonylfluoride was added to prevent degradation of recombinant 
protein. This reaction was incubated at 37°C for 30-45 min, and then 50 mg sodium 
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deoxycholate was added to solubilise membrane components and incubated for a 
further 45 min. Next, 1 mg each of deoxyribonuclease I and ribonuclease I was added 
to the 30 mL lysis solution and incubated for 1 hour to ensure all DNA and RNA had 
been degraded. The lysed solution was then centrifuged for 25 min at 12,500 r.p.m. 
and the supernatant was discarded. This pellet was then stored at -20°C or immediately 
processed for purification. 
2.4.3 Purification of recombinant PrP 
The preparation of PrP has been described previously (Thompsett et al., 2005). 
2.4.3.1 Additional Materials 
Bacterial lysis buffer (0.2 M NaCl, 0.5 M Tris, 1 mM EDTA pH 7.6) 
8 M urea buffer (8 M urea, 200 mM NaCl, 50 mM Tris pH 7.6) 
His-tag wash buffer (8 M urea buffer, 20 mM imidazole, pH 7.6) 
0.3 M CuSO4 
0.2 M EDTA

1 M sodium hydroxide (NaOH)

1 M sodium chloride (NaCl)

Elution buffer (8 M urea, 200 mM NaCl, 50 mM Tris, 300 mM imidazole, pH 7.6)

20% ethanol (EtOH)

Metal chelating sepharose, fast flow (GE Healthcare, UK)

2.4.3.2 Method 
2.4.3.2.1 Purification by immobilised metal affinity chromatography 
Immobilised metal affinity chromatography (IMAC) was used to purify PrP with 
copper binding regions intact. As PrP has a high affinity for copper, untagged 
recombinant proteins can be purified using copper-charged metal chelating sepharose. 
His-tagged proteins were purified using nickel-charged metal chelating sepharose. 
The pellet from the bacterial cell lysis was re-suspended by sonication at minimum 
power in 25 mL wash buffer A (bacterial lysis buffer, 1% Triton X-100, 0.5% Igepal) 
and centrifuged for 5 min at 12,500 r.p.m. and 4°C. The supernatant was discarded and 
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the wash step repeated once. Then the pellet was re-suspended by sonication at 
minimum power in 25 mL wash buffer B (lysis buffer, 1% Igepal) and centrifuged for 
five min at 12500 r.p.m., 4°C. The supernatant was discarded and the step repeated. 
The sonication/re-suspension/centrifugation step was then performed using lysis buffer 
only to clear any detergents from the preparation and the pellet retained. The pellet was 
solubilised in 8M urea buffer by sonicating at 75% maximum power 3 times in 30 s 
bursts. This re-suspended solution was then centrifuged for 25 min at 12500 r.p.m., 
4°C. The supernatant was then filtered through a 0.45 µm syringe filter and this protein 
solution used for IMAC purification. 
The IMAC column was prepared by packing an appropriate column with chelating 
sepharose and washing through with sterile MilliQ water. 6 column volumes (CVs) of 
0.2 M EDTA was then washed through, followed by MilliQ water, a further 6 CVs of 1 
M sodium hydroxide, then MilliQ water. Once an appropriate volume of MilliQ water 
had been washed through, the column was charged by pumping 6 CVs of 0.3 M CuSO4 
(non-tagged PrP) or 0.3 M NiSO4 (his-tagged PrP) through the column, followed by a 
MilliQ wash and 8 M urea buffer to prepare the column. The protein solution was then 
applied to the column and the column was washed with 8 M urea buffer without 
imidazole for non-tagged PrP or with his-tag wash buffer for his-tagged PrP. The flow 
through was monitored by UV absorbance readings at A280 until there was no protein in 
the flow through. The PrP was eluted from the column using elution buffer with the 
eluate collected in 3 mL fractions. These fractions were analysed by SDS-PAGE for 
purity and protein identity. The IMAC column was then regenerated by washing with 
0.2 M EDTA, 1 M NaCl, then 1 M NaOH, with each followed by MilliQ water. The 
column was stored in 20% EtOH at 4˚C when not in use. 
2.4.3.2.2 Purification using the wash method 
For PrP with reduced or without copper binding sites, a purification protocol using a 
wash method was developed. 
The pellet from the bacterial cell lysis was re-suspended by sonication at minimum 
power in 25 mL wash buffer A (bacterial lysis buffer, 1% Triton X-100, 0.5% Igepal) 
and centrifuged for 5 min at 12500 r.p.m., 4°C. The supernatant was discarded and the 
sonication /re-suspension/centrifugation step repeated for a total of six times. The 
pellet was then re-suspended by sonication at minimum power in 25 mL wash buffer B 
(lysis buffer, 1% Igepal) and centrifuged for five min at 12500 r.p.m. at 4°C. The 
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supernatant was discarded and the step repeated six times. The sonication/re­
suspension/centrifugation step was then performed four times using lysis buffer only to 
clear any detergents from the preparation and the pellet retained. The pellet was then 
solubilised in 8 M urea buffer by sonicating at 75% maximum power 3 times in 30 s 
bursts. This re-suspended solution was centrifuged for 25 min at 12500 r.p.m., 4°C. 
The supernatant was then filtered through a 0.45 µm syringe filter and analysed by 
SDS-PAGE. 
2.4.4 Refolding 
2.4.4.1 Additional Materials 
Glutathione (reduced form) 
Glutathione (oxidised form) 
Sodium phosphate buffer pH 5.8 
Sodium phosphate buffer pH 7.4 
2.4.4.2 Method 
2.4.4.2.1 Standard refolding 
PrP solubilised in 8 M urea is completely denatured. Re-naturation took place at room 
temperature. To re-nature the protein, the urea must be slowly diluted and dialysed so 
the protein folds into its native conformation. For use in Thioflavin T assays, 
glutathione in both oxidised and reduced forms was added to PrP in urea buffer at a 
final concentration of 6 mM each. This solution was then aliquoted into sets of three 1 
mL fractions. To the first 1 mL fraction, 10 mL sterile 10 mM sodium phosphate 
buffer, pH 5.5 was added very slowly with mixing. If any precipitate formed, it is 
assumed to be mis-folded (non-native) PrP and thus the solution was then centrifuged 
at 4000 r.p.m. until the solution cleared and misfolded protein was pelleted. This 
supernatant was then added very slowly to the second 1 mL fraction with stirring. The 
protein solution was again centrifuged until clear, and this supernatant was added 
slowly to the third 1 mL fraction with mixing. This solution was centrifuged until clear 
and transferred to fresh tube until dialysis. For ITC assays, PrP was refolded in sterile 
MilliQ water, pH 5.5. 
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2.4.4.2.2 Copper loaded refolding 
Re-naturation took place at room temperature. To load the PrP with CuS04, urea was 
sequentially diluted in 5 mM CuSO4, concentrating the solution between dilutions 
using a VivaSpin 10,000 MW cut-off concentrator. All solutions were centrifuged to 
remove precipitation before dialysis as in 2.4.4.2.1. 
Pre-refolding Post-refolding 
mPrP construct Purification (mg/L culture) (mg/L culture) 
mPrP(23-231) Cu-IMAC 10-15 6-8 
Wash 
mPrP(23-231) 20-35 2-5 
method 
mPrP(89-231) Wash 
method 15-20 2-4 
Wash 
mPrP(Δ51-90) 15-20 2-4 
method 
mPrP(Δ67-90) Wash 
method 15-20 2-4 
Wash 
mPrP(Δ06-126) 15-20 2-4 
method 
mPrP(Null) Wash 
method 20-25 2-5 
mPrP(H95A+H110A) Cu-IMAC 8-13 5-8

mPrP(H95A+H110A) Wash 
method 20-35 2-5 
mPrP(Null +H95, Wash 20-25 2-5 
H110) method 
mPrP(Null + H95) Wash 
method 20-25 2-5 
Wash 2-5 mPrP( Null +H110) 20-25 
method 
Table 2.6 Yeilds of mPrP protein preparations. All yields are calculated in mg per L of culture. 
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2.4.5 Dialysis 
2.4.5.1 Additional Materials 
12-14000 Dalton cut off tubing (Medicell, UK) 
7000 Dalton cut off tubing (Medicell, UK) 
MilliQ water 
Sodium phosphate pH 5.8 and pH 7.4 
Dialysis tubing preparation buffer (2% (w/v) sodium bicarbonate, 1 mM EDTA) 
2.4.5.2 Method 
Dialysis tubing was prepared by cutting appropriate sized lengths of tubing then rinsing 
with MilliQ water. The rinsed tubing was then immersed into dialysis tubing 
preparation buffer and heated to 80°C for 30 min. The tubing was then rinsed 
repeatedly in MilliQ and stored in 20% ethanol until use. 
Dialysis tubing was prepared for dialysis by rinsing tubing repeatedly in MilliQ water 
to remove all traces of ethanol. After double knotting the end of the dialysis tubing, 
protein was added to the tubing, sealed by double knotting and dialysed at 4°C against 
MilliQ water (GAG studies) or 10 mM sodium phosphate (ThT studies). Dialysis 
typically took place at pH 5.8 until the final round when the pH was adjusted to 7.4. 
The protein solution was dialysed at least 106 fold to ensure sufficient dilution of urea. 
Dialysed proteins were either stored at -80°C in aliquots until use to prevent freeze-
thawing or at 4°C for use within a week. 
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2.4.6 Concentration Determination 
2.4.6.1 Additional materials 
Quartz cuvettes (CaryBio) 
2.4.6.2 Method 
Recombinant protein concentration was determined by measuring the absorption of 1 
mL of protein solution at 280 nm in quartz cuvettes in a CaryBio UV-Vis 
spectrophotometer. Concentrations were calculated using an extinction coefficient 
obtained by entering the primary sequence into the ProtParam tool on the ExPASy 
database (Gasteiger et al., 2003). Extinction coefficients used are summarised in Table 
2.4. 
PrP Construct M-1 cm-1 A280 MW pI length 
(mg/mL) (aa) 
pET3a-mPrP(23-231) 63495 2.743 23150.5 9.56 210 
pET3a-mPrP(89-231) 27515 1.682 16360.2 8.84 143

pET3a-mPrP(Δ51-89) 35995 1.868 19268.4 9.56 171 
pET3a-mPrP(Δ67-90) 46996 2.264 20760 9.56 186

pET3a-mPrP(Δ106-126) 63495 2.97 21377.4 9.49 189 
pET23a-mPrP(H95A) 63495 2.761 22997.3 9.56 210

pET23a-mPrP(H110A) 63495 2.761 22997.3 9.56 210 
pET23a-mPrP(H95A+H110A) 63495 2.769 22931.3 9.56 210

pET23a-mPrP(Null) 63495 2.801 22535.8 9.56 210 
pET23a-mPrP (Null + H95, 63495 2.785 22799.1 9.56 210 
H110) 
Table 2.7 Recombinant PrP parameters calculated using primary amino acid sequences 
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2.4.7 Preparation of recombinant samples for SDS-PAGE analysis 
2.4.7.1 Additional Materials 
4X loading dye (20% B-mercaptoethanol, 40% glycerol, 240 mM Tris-HCl pH 6.8, 8% 
SDS, 0.2% bromophenol blue) 
2.4.7.2 Method 
Protein concentration was calculated as in 2.4.6. All samples were normalised for 
protein concentration and sample volume. 4X loading dye was added to each sample to 
a final concentration of 1X and samples were either stored at -20°C if not used 
immediately for a gel. Prior to loading on gel, all samples were boiled at 100°C for 5 
min. 
2.4.8 Aggregation Assays 
2.4.8.1 Additional Materials 
Sodium Phosphate Buffer pH 7.4 
CuS04 (Fisher, UK) 
MnS04 (Fisher, UK) 
ZnCl2 (Fisher, UK) 
Thioflavin T (ThT) 
3 mm glass beads 
2.4.8.2 Method 
2.4.8.2.1 Aggregation reactions 
Recombinant protein was refolded as described in 2.4.4 and dialysed against 10 mM 
sodium phosphate buffer. The final dialysis was performed in 10 mM sodium 
phosphate, pH 7.4 and protein concentrated to a final concentration of 20 µM. 100 µL 
of the protein was added to each well of a black 96-well plate and metals or heparin 
added as appropriate. 10 µL ThT dissolved in 10 mM sodium phosphate, pH 7.4 was 
added to each well for a final concentration of 10 µM and one sterile glass bead added 
per well. The plate was covered with a film, placed on a GrantBio plate shaker and 
incubated at 37°C whilst shaking at 600 r.p.m.. Measurements were taken at various 
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time intervals on a Fluoroskan (Thermofisher) using excitation wavelength 444 nm and 
emission wavelength 482 nm or on a FLUOstar Omega (BMG) using 445-5nm 
excitation and 480-10nm emission filters. 
2.4.8.2.2 Kinetic calculations. 
Rate calculations were done on normalised data on the linear increase of the 
aggregation curve. Any obvious outliers were excluded from calculations. All rate 
values were compared to an untreated control for comparative results. Rate is defined 
as in Equation 1: 
Equation 1 
Maximum fluorescence values were calculated by determining the highest fluorescence 
intensity reached during the reaction and comparing the value back to the untreated 
control. 
2.4.9 Transmission Electron Microscopy 
2.4.9.1 Additional materials 
Uranyl acetate 
2.4.9.2 Method 
Aggregation products were imaged using transmission electron microscopy (TEM) by 
Ms Ursula Potter of the Centre for Electron Optical Studies, University of Bath. mPrP 
aggregation reaction end products were coated onto copper grids, washed twice with 
MilliQ water and then negatively stained with 0.2% uranyl acetate. Microscopy 
imaging was performed on 80 kV Jeol-1200EX electron microscope and samples 
viewed at 100,000x magnification. 
2.4.10 Isothermal Titration Calorimetry 
2.4.10.1 Additional materials 
Heparin sodium sulphate, 3000 MW 
MilliQ water 
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Recombinant mPrP as prepared in sections 2.4.1-2.4.5 
2.4.10.2 Method 
2.4.10.2.1 ITC method 
Recombinant mPrP was refolded as described previously and dialysed against MilliQ 
water. During the final round of dialysis, the pH was adjusted to 7.4. Heparin sodium 
sulphate was then prepared in sterile MilliQ water pH 7.4. Measurements were 
performed using a VP-ITC (MicroCal). The heparin was loaded into the cell of the ITC 
machine and the temperature reference chamber was filled with MillQ water. mPrP 
was loaded into the syringe. Once assembled, the correct concentrations were entered 
into the VP-ITC control software and the injection parameters were 30x 4 µL injections 
with 120 s equilibration between injections, with constant stirring at 300 r.p.m.. Once 
the machine had equilibrated to 25°C, the reaction began. In between runs, the 
chamber and syringes were cleaned 10 times using MilliQ water. 
2.4.10.2.2 Data analysis of ITC data 
Data was analysed using Origin 5.0 software (MicroCal). It was determined by trial 
and error that sequential binding models best fit the data produced in these experiments, 
as determined by the χ2 value (the lowest value is a judgement for the validity of the 
binding model fit). For sequential binding, the binding constants K1, K2, .....Kn must 
be defined relative to the progress of saturation, so that 
[LM] [LM2] [LM 3] [LM n]K1 = K 2 = K 3 = Kn = (1) [L][M] [LM][M] [LM 2][M] [LM n − 1][M] 
In the sequential model only the total number of sites that are saturated are assessed. If 
the sites are identical, a statistical degeneracy associated with the sequential saturation 
since the first ligand to bind has more empty sites of the same kind to choose from than 
does the second ligand. For identical interacting sites the phenomenological binding 
constants Ki (defined by equation (1)) and the intrinsic binding constants Kio can be 
distinguished where the effect of degeneracies has been removed. The relationship 
between the two binding constants is given by the following equation: 
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n − i +1 0Ki = Ki (2) i 
All calculations given below, as well as parameters reported from curve-fitting, are in 
terms of Ki values but these can be manually converted to Kio values, if desired, using 
equation (2) (this is done within the program). As all concentrations of bound species 
[LMn] can be defined relative to unbound species [L] then the various fractions of L 
with n bound M can be defined by Fn in equations (3) 
1 F1 = K1[M] F 2 K1K 2[M]
2 
Fn = K1K 2..... Kn[M]
n 
(3) F 0 = 
X X X X 
Where 
X = 1+ K1[M] + K1K 2[M]2 + ....... + K1K 2... Kn[M]n (4)

n 
Xt = [X ] + Mt ∑ iF i (5) 
i−1 
The parameter n and K can now be assigned through trial and error, allowing equations 
3, 4 and 5 to be solved by the Bisection method. The total fractions can then be 
determined and related to the heat content Q after each titration of ligand by equation 
6. 
Q = LtVo(F1ΔH1 + F 2[ΔH1 +ΔH 2] + ........ + Fn[ΔH1 +ΔH 2 + ........ +ΔHn) (6)

Using the same definitions as before. The effect of each injection i, allowing for a 
correction for the displaced volume after i is then defined by 7 
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Q(i) + Q(i −1)
⎡
 ⎤
dV
i Q(i) Q(i)
 −
Q(i −1) (7)
Δ
 +
=
 ⎢
⎣

⎥
⎦
2
Vo 
Which is then submitted to the Levenburg-Marquardt minimization routine. This 
analysis is done through the Origin 5.0, where all these equations are built in and 
parameters are easily manipulated. 
2.4.11 Computational peptide analysis 
2.4.11.1 Additional materials 
TANGO (http://tango.crg.es/) 
WALTZ (http://switpc7.vub.ac.be/cgi-bin/submit.cgi) 
Mobyle (http://mobyle.pasteur.fr/cgi-bin/MobylePortal/portal.py?form=charge) 
2.4.11.2 Method 
2.4.11.2.1 TANGO 
Analysis of mouse PrP (NM_0011170) protein aggregation propensity was done using 
the on-line program TANGO ((http://tango.crg.es/), developed by L.Serrano, European 
Molecular Biology Laboratory. Analytical conditions were set at 310.15 K, pH 7.4, 
0.01M ionic strength, default stability (-10) and TFE concentration (0%). 
2.4.11.2.2 WALTZ 
Analysis of amyloidgenic regions in murine PrP (NM_0011170) was done using the 
on-line program WALTZ (http://switpc7.vub.ac.be/cgi-bin/submit.cgi), developed by 
the Switch Laboratory, Vrije Universiteit Brussel, Belgium. Analyses were performed 
using primary amino acid sequences of murine PrP. Analytical conditions were set at 
high specificity and at pH 7.0. 
2.4.11.2.3 Mobyle 
Analysis of protein charge distribution of PrP (NM_0011170) was performed using the 
Mobyle program 
(http://mobyle.pasteur.fr/cgibin/MobylePortal/portal.py?form=charge), developed by 
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The European Molecular Biology Open Software Suite (EMBOSS). Analyses were 
performed using primary amino acid sequences of murine PrP. 
2.5 Statistical Analyses 
Paired Student’s T-tests were performed on samples using Microsoft Excel Data 
Analysis Pak (2007) to determine significance at 95% confidence levels or above. 
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3. Metals and cellular prion infection 
3.1 Introduction 
Transmissible spongiform encephalopathies are often considered to be infectious 
diseases as studies have shown they are transmissible from animal to animal (Cuille 
and Cheille, 1936). The exact mechanism of transmission is unknown, as there is still 
very little insight into how the infection occurs. 
The infectious particle is generally thought to either consist solely of or include an 
abnormal version of the prion protein, called variously PrPSc, PrPres, or PrPTSE all of 
which refer to the disease-associated prion molecule. Standard identification of 
infectious material is identified by resistance to proteinase K and transmissibility in 
vitro cell culture or animal bio assays. TSE’s were first transmitted to laboratory 
animal models in the 1960’s and 1970’s (Chandler et al., 1961; Chandler and Turfry, 
1972; Zlotnik and Stamp, 1965). These rodent-adapted prion strains have been 
characterised in mouse and hamster models, and more recently in bank voles (Cartoni 
et al., 2005). The generation of transgenic mice expressing other mammalian PrP 
including hamster, bovine, ovine, cervid, and human PrP has allowed for 
characterisation of naturally occurring prion diseases such as scrapie, BSE and CWD 
(Hsiao et al., 1990; Browning et al., 2004; Buschmann et al., 2000; Telling, 2004; 
Kupfer et al., 2007). Study of prion disease in laboratory animal models is 
advantageous as they have a shorter incubation period than the host animal and 
laboratory animals are easier to maintain. However, while disease incubation periods 
are relatively reduced in laboratory animals, the experiments still take many months, 
and as with all animal experiments there is always a cost factor. 
Cell culture models of prion infectivity are an alternative to expensive animal 
bioassays. The advantages of cell culture models of prion infection are that the 
experiments are usually conducted in a much shorter length of time and are less 
expensive than maintaining animals for bioassay. Cell culture models are a useful 
method of obtaining more information regarding prion infectivity, although proof of 
principle is usually expected from animal bioassays. Only a handful of cell lines are 
permissive to prion infection, and both neuronal and non-neuronal cells have been 
shown to support prion infection. The first cell model of prion disease was the SMB 
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cell line, which was derived from the brain of a scrapie-infected mouse (Clarke and 
Haig, 1970). Further work identified neuronal cell types which support prion infection 
including neuroblastoma, hypothalamic, hippocampal, pheochromocytoma, septal 
neural cells and neural stem cells (Race et al., 1987; Schatzl et al., 1997; Rubenstein et 
al., 1984; Baron et al., 2006; Milhavet et al., 2006; Maas et al., 2007). In addition, 
primary neuronal cultures have also been shown to support prion infection (Cronier et 
al., 2004). As symptoms of prion disease are largely neuronal, neuronal cell cultures 
are widely used to investigate prion disease in vitro. However a number of non-
neuronal cells have been demonstrated to support prion infection, including epithelial 
cells, muscle cells, fibroblasts, and microglial cells (Vilette et al., 2001; Vorberg et al., 
2004; Dlakic et al., 2007; Iwamaru et al., 2007). Understanding prion infection in 
these cell models may provide more information regarding transmission of disease. 
Prion infection in cell culture models can be accomplished in several ways. The most 
common method is to expose uninfected cells to homogenates of brains from infected 
animals, or to use homogenised infectious cell preparations (Race et al., 1987; Butler et 
al., 1988; Bosque and Prusiner, 2000; Enari et al., 2001). Additionally infection can be 
accomplished by co-culturing infected and uninfected cells, or by applying partially 
purified prion preparations (e.g., prion rods) to cells (McKinley et al., 1991; Kanu et 
al., 2002; Hijazi et al., 2003). Once cells are exposed to the infectious material, they 
are analysed for the presence of PK-resistant PrP as a marker for infection. 
It has been well documented that PrP is capable of metal binding, as described in 1.3.2. 
The evidence suggests that metals may play a role not only in the normal function of 
the protein but potentially in disease pathogenesis as well. However, the precise role 
metals play in prion disease progression is unclear. 
Cell culture models have been used to identify PrPC interactions, anti-prion therapies, 
cellular changes in response to infection, PrP trafficking pathways, as well as 
identification of cellular components that may be involved in of the transfer of 
infectivity (Solassol et al., 2003; Hornchik et al., 2005; Morel et al., 2005; Vilette, 
2008). Despite this, relatively few studies have focused on the role of metals in prion 
infection in cell culture. This study aims to identify the role of metals, in particular 
copper, manganese, and zinc, in the transfer of prion infectivity (that is, conversion 
from PrPC to PK-resistant PrP associated with prion disease) using a cell culture model 
of prion infection. 
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Further to this investigation, there are many proteins which have specific functions 
controlling the movement and concentration of metal ions within the cell, including the 
copper associated proteins CTR1, CTR2, CCS and ATOX1. These proteins play an 
important role in copper movement through the cell. CTR1 is a copper transporter 
involved in regulating copper entry into the cell and CTR2, another transporter, is 
involved in mobilisation of copper from organelles to the aqueous cytoplasm (Prohaska 
and Gybina, 2004; Guo et al., 2004; van de Berghe et al., 2007). ATOX1 and CCS are 
copper chaperones. ATOX1 ferries copper to the trans-Golgi network, and CCS is 
responsible for distributing copper to copper/zinc superoxide dismutase (Prohaska and 
Gybina, 2004). The effect of these copper transporters on PrP expression and transfer 
of prion infectivity will be studied to determine if these proteins influence prion 
infection. 
3.2 Method Development 
To assess whether or not metals could influence the transfer of prion infectivity in cell 
culture, a model first had to be developed. 
3.2.1 Infected brain homogenates as infectious source 
Initial infection experiments were performed using homogenised infectious mouse 
brains. The mice were infected with the 79A or Me7 strain of mouse-adapted scrapie 
and inoculates prepared as described in 2.3.7.2.1.Only very limited quantities of the 
brains were available. 
Brain homogenates were assessed for PK-resistant PrP by Western blot (Figure 3.1). 
All cell blot and Western blot analysis throughout this chapter were performed using 
anti-PrP antibody ICSM-18. Western blot results show no PK-resistant PrP in the 
control (uninfected) homongenate samples, as expected. Samples of both Me7 and 79A 
brain homogenate contained detectable PK-resistant PrP. 
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Figure 3.1 Western blot of Proteinase K resistant PrP in infected brain homogenates. A) PK digested samples 
only of brain homogenates. Lane 1 is control brain homogenate and does not have any PK-resistant PrP 
present. Lane 2, brain homogenated from a mouse infected with the Me7 prion strain. Lane 3, brain 
homogenate from a mouse infected with the 79A prionstrain. Multiple bands can be seen in both the Me7 and 
79A prion strain samples, representing differently glycoyslated forms of PrP after PK digestion. All samples 
are 20 µg of 1% whole brain homogenate digested with 1 µg PK for 1 h at 37°C. B) Brain homogenates 
treated and not treated with PK to show PrP glycoprofiles.Lane 1 and 2 control, Lane 3 and 4 79A strain. 
Samples are 20 µg of 10% brain homogenate with and without PK digestion (1 µg PK for 1 h at 37°C). 
The target cells for the infection experiment with brain homogenate were N2a cells, 
which are a well characterised murine neuroblastoma cell line derived from a 
spontaneous tumour in albino mice (Klebe and Ruddle, 1969). N2a cells are routinely 
used for prion studies as they are susceptible to prion infection (Race et al., 1987). As 
over-expression of PrP in N2a cells increases susceptibility to prion infection (Nishida 
et al., 2000), all N2a cell used throughout this study were stably transfected to over 
express pcDNA3.1+mPrP(1-254) and denoted N2a(mPrP). PrP expression levels of in 
N2a and N2a(mPrP) cells are shown in Figure 3.2. Classic PrP banding patterns show 
di-, mono-, and unglycosylated forms of PrP at bands corresponding to approximately 
35, 24, and 18 kDa. 
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Figure 3.2 Western blot of PrPC expression in N2a cells. Lane 1, untransfected N2a cells. Lanes 2 and 3, 
N2a(mPrP). Lanes 2 and 3 represent two polyclonal stably over-expressing populations of N2a(mPrP) cells 
which were created at different times. Both populations express higher levels of PrP than un-transfected N2a 
cells. Markers are in kDa and the pattern of bands is characteristic of PrP blots and correspond to di-, mono-
and unglycosylated forms of PrP. 
Target N2a(mPrP) cells were plated as described in in Section 2.3.8. Cells were 
allowed to adhere overnight, and then the media was removed and fresh media 
containing 0.1% or 1% infectious brain homogenate was added to each well. 
Uninfected brain homogenate was used as a control. Cells were then analysed for PrPSc 
4 passages post infection to detect de novo prion infectivity. 
Prion infection of the brain homogenate infectivity assays is detected by cell blot. To 
ensure only prion infectivity (that is, PK-resisant PrP) and not residual cellular PrP 
signal was detected, the activity of PK was tested before each analysis to determine the 
appropriate concentration of PK to use. Tests were performed on SMB (scrapie mouse 
brain) cells, a chronically infected cell line (Clarke and Haig, 1970) and uninfected 
N2a(mPrP). The appropriate level of PK was judged to be where signal was present in 
SMB samples but no signal was detected in the N2a(mPrP) sample (Figure 3.3A). 
Figure 3.3B highlights that despite the high level of PrPC expression in N2a(mPrP) 
(lanes 1-2), only SMB cells express PK-resistant PrP (lanes 3 and 4), as shown by 
Western blot. 
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Figure 3.3 PK-resistant PrP in N2a(mPrP) and SMB cells. A) Cell blot showing example of PK digestion 
trial. Uninfected N2a(mPrP) and SMB cells were subjected to cell blot analysis with to increasing 
concentrations of PK (from left to right). B) Western blot of N2a(mPrP) and SMB. Lane 1 and 2, uninfected 
N2a(mPrP); Lane 3 and 4, SMB cells. PK-digested samples were subjected to 1 µg PK per 20 µg total protein 
and digested for 1 h at 37°C. Markers are in kDa. 
Results of infectivity assays using infected brain homogenates as the infectious source 
indicated PK-resistant PrP in target cells that were infected with 1% and 0.1% 79A 
homogenate but not with Me7 homogenate (Figure 3.4). These data support previously 
published observations asN2a cells are known to replicate Chandler, Fukokura, and 
RML prion strains, but do not replicate Me7 prions (Bosque et al., 2000; Klohn et al., 
2003). Further access to prion-infected brains was not possible, so an alternative 
infectivity assay was devised. 
Figure 3.4 Cell blot from brain homogenate infectivity assay, analysed 4 passages post infection. 1% and 
0.1% (w/v) brain homogenates were from Me7 and 79A infected mice, n=2. 
3.2.2 Infection by live cell co-culture 
Infection protocols were developed utilizing the co-culturing method described by 
Kanu et al (Kanu et al., 2002) and was first used by previous lab members who had 
adapted it from the original published results. 
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3.2.2.1 SMB-PS as target cell line 
SMB (scrapie mouse brain cells) were used as the infectious source, SMB cells are a 
line derived from the brain of a mouse clinically ill with scrapie (Clarke et al., 1970). 
These cells contain PK-resistant PrP as described in 3.2.1 and shown in Figure 3.3B. 
Target cells were stably transfected SMB-PS cells over-expressing mPrP (SMB­
PS(mPrP)). SMB-PS cells are SMB cells which have been treated with pentosan 
sulphate (PS) and no longer express detectable PK-resistant PrPSc (Birkett et al., 2001). 
For the infection assay, cells were cultured in the same flask at various ratios based on 
cell number (1:10, 1:50, 1:100 (SMB-PS(mPrP):SMB) for 5-7 days, and then G418 
sulphate was added to kill the susceptible SMB cells. The stably transfected SMB­
PS(mPrP) cells are resistant to G418 sulphate and therefore survive. Cells were then 
propagated for four passages and assessed for infection by detecting PK-resistant PrP 
by Western blotting. Results from the SMB-PS(mPrP) cells showed no PK-resistant 
PrP at any infectious dose tested despite expressing higher levels of PrPC than SMB 
cells(Figure 3.5). 
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Figure 3.5 Western blot of co-culturing assays with SMB-PS(mPrP) cells. Lanes 1 and 2, SMB control; 
Lanes 3 and 4, 1:10 (SMB-PS(mPrP):SMB) co-culture; Lanes 5 and 6, 1:50 (SMB-PS(mPrP):SMB) co­
culture; Lanes 7 and 8 1:100 (SMB-PS(mPrP):SMB) co-culture. Cells were co-cultured for one week before 
G418 selection. Markers are kDa. 
To kill the SMB cells, a high concentration of G418 sulphate is used initially followed 
by dropping the concentration to a maintenance level. This may also have killed any 
SMB-PS cells that were infected, as infected cells have been shown to have increased 
susceptibility to stress (Milhavet et al., 2000) and apoptiotic or necrotic death 
signalling could have adversely affected the robustness of the remaining cells. While 
no PK-resistant PrP can be detected with SMB-PS cells, the mechanism by which PS 
clears the infection in this cell line is unknown, and additional effects of PS on the cell 
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are not well understood. Therefore it was decided to use previously uninfected target 
cells, rather than the SMB-PS(mPrP) cell line. 
3.2.2.2 N2a(mPrP) as target cell line 
The next step was to use SMB cells as an infectious source but use N2a(mPrP) cells as 
the target. SMB medium, complete Medium 199 was used, as N2a(mPrP) cells 
tolerated the medium change much better than SMB cells tolerated N2a medium. No 
cell death, gross changes in morphology or cellular division rates were seen in 
N2a(mPrP) cells during the co-culture period. The protocol was altered during the 
killing stage. N2a(mPrP) cells have a higher LD90 for G418 than the SMB cells, and 
therefore only levels of G418 sulphate to maintain stably transfected cells (see 
2.3.3.2.1) were used. This meant that the N2a cells were not subjected to higher doses 
of G418, which may adversely affect the initially infected N2a(mPrP) cells. The SMB 
cells were still killed at an appropriate rate using this concentration of G418 sulphate. 
Additionally, the co-culture period was decreased from a week with the SMB-PS cells 
to days with the N2a(mPrP) cells. Once all SMB cells were dead, N2a(mPrP) cells 
were then passaged four times before analysis to ensure de novo prion detection. 
N2a(mPrP) cells were incubated SMB cells at either a 1:1, 1:100 or 1:1000 ratio of 
N2a(mPrP):SMB. Cell blot results show that transfer of infectivity in all ratios tested 
after 72 h (Figure 3.6A). Western blot analysis of infectivity assay cell lysates also 
showed PK-resistant PrP in 1:1, 1:100 or 1:1000 (N2a(mPrP):SMB) ratio (Figure 
3.6B). 
A range of incubation periods was tested with the co-culturing infectivity assay. 
N2a(mPrP) cells were incubated SMB cells at either a 10:1, 1:1 or 1:100 
(N2a(mPrP):SMB) ratio. PK-resistant PrP was present in 1:1 and 1:100 ratios in all 
incubation periods tested (Figure 3.6C). 
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Figure 3.6 Live cell co-culture infectivity assays. A) Cell blot analysis of N2a(mPrP) cells co-cultured with 
SMB cells for 72 h. PK-resistant PrP is present in 1:1 and 1:100 N2a(mPrP):SMB ratios. B) Western blot of 
PK-digested N2a(mPrP) cells co-cultured with SMB cells for 72 h. No PK-resistant PrP is detected in Lane 1 
which are uninfected N2a(mPrP). Lane 2 N2a(mPrP):SMB 1:1, Lane 3 N2a(mPrP):SMB 1:100, Lane 4 
N2a(mPrP):SMB 1:1000 all show PK resistant PrP bands. C) Cell blot analysis of N2a(mPrP) cells co­
cultured with SMB cells for 16, 24, 48 or 72 h. PK-resistant PrP is present in 1:1 and 1:100 N2a(mPrP):SMB 
ratios in all time points examined. All experiments were repeated at least three times. 
3.2.3 Infection by infected cell homogenates 
The difficulty in growing large amounts of SMB cells to use in experiments prompted 
development of the a cell homogenate method, based on the method described by 
Bosque and Prusiner wherein infectious cell cultures are homogenised by serial passage 
through needles and used as the infectious source (Bosque and Prusiner, 2000). This 
method allows for a reduction in the amount of infected cells required and the aim was 
to use ScN2a(mPrP) as sole infectious source in further experiments on these cells. To 
determine if the cell homogenate method would work in this system, SMB 
homogenates were tested. All experiments were repeated a minimum of three times. 
3.2.3.1 SMB homogenates 
SMB cells were harvested in PBS and rapidly frozen and thawed five times. 
Suspensions were then homogenised in PBS by serial passage from large to small 
gauged needles. Fifty µL of this homogenate was plated in complete media, returned to 
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the incubator and observed for 48 h but no cells survived. This homogenate was stored 
at -80°C until use and an as infectious sources for N2a(mPrP) target cells. 
Infectivity assays were performed by incubating target N2a cells with 1:100 and 1:10 
ratio (N2a:SMB, ratio based on cell number) of SMB homogenate for 48h. Both 
N2a(mPrP) and N2a(pcDNA3.1+) stably transfected cell lines were tested. Infectious 
homogenate was then removed and cells were washed three times in sterile PBS, and 
then propagated for four passages before analysis. Cell blot and Western blot results 
show transfer of prion infectivity to N2a(mPrP) cells in both 1:10 and 1:100 ratios as 
demonstrated by the presence of PK-resistant PrP in these samples. N2a(pcDNA3.1+) 
cells, which are transfected with the empty vector only, were also subjected to the 
infectivity assay to determine whether transfection alone was able to increase 
susceptibility to prion infection. No infection was seen in N2a(pcDNA3.1+) cells, 
confirming that over-expression of mPrP governs susceptibility to infection for N2a 
cells (Figure 3.7A). 
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Figure 3.7 Infection by SMB homogenate. A) Cell blot of N2a(mPrP) and N2a(pcDNA3.1+) cells incubated 
with 1:10 or 1:100 (N2a:SMB) dose of homogenate for 48 h. PK-resistant PrP was seen only in N2a(mPrP) 
cells at both the 1:10 and 1:100 ratio. No PK-resistant PrP was seen in the N2a(pcDNA3.1+) cells at either 
infectious dose. B) Cell blot of N2a(mPrP) cells infected by 1:100 dose of SMB homogenate. N2a(mPrP) cells 
were incubated in either complete EMEM or DMEM during the infection period. The transfer of infectivity 
was not affected by culture media differences as PK resistant PrP was detected in all samples tested. C) 
Western blot of N2a(mPrP) cells infected by 1:100 (N2a(mPrP):SMB. N2a(mPrP) cells were incubated in 
either complete EMEM or DMEM during the infection period. Lane 1, uninfected N2a(mPrP) control; Lane 
2, cell incubated win EMEM; Lane 3 cells incubated in DMEM. No differences in PK-resistant PrP were 
detected. 
Some studies suggest there is an effect of media on prion infectivity assays (Bosque 
and Prusiner, 2000). Therefore to identify whether media made a difference in these 
assays, N2a(mPrP) cells were infected by 1:100 (N2a(mPrP):SMB, cell number ratio) 
and incubated in either complete Eagle’s Minimum Essential Medium (EMEM, N2a 
normal medium) or high glucose Dulbecco’s Modified Eagle Medium (DMEM) during 
the infection period. PK-resistant PrP was detected in all N2a(mPrP) cells infected at 
this ratio, and both cell blot and Western blot show no detectable difference in transfer 
of infectivity with either medium (Figure 3.7B, C). Therefore all infectivity assays 
were performed in the normal medium for N2a cells, complete EMEM medium. 
3.2.3.2 ScN2a(mPrP) homogenates 
As the SMB homogenates successfully transferred prion infectivity to N2a(mPrP), the 
next step was to determine if homogenised infected N2a(mPrP) cells, referred to as 
ScN2a(mPrP), were also capable of transferring prion infectivity. 
ScN2a(mPrP) cells were homogenised as described in 2.3.7.2.2 and used as an 
infectious source for N2a(mPrP) target cells. 
Infectivity assays were initially performed by incubating target N2a(mPrP) with 1:100 
ratio (N2a(mPrP):ScN2a(mPrP)) of ScN2a(mPrP) homogenate for 48 h. Infectious 
homogenate was removed and cells were washed three times in sterile PBS, and then 
propagated for four passages before analysis. Cell blot results show transfer of prion 
infectivity occurred as demonstrated by the presence of PK-resistant PrP in target 
N2a(mPrP) cells (Figure 3.8A). 
Infectious ScN2a(mPrP) homogenates were then pooled to increase reproducibility in 
further experiments. To determine what infectious doses could transfer prion 
infectivity, assays were performed by incubating target N2a(mPrP) with 1:100, 1:50, 
1:25, 1:10, and 1:1 (N2a(mPrP):ScN2a(mPrP)) doses of ScN2a(mPrP) homogenate for 
48 h. Infectious homogenate was removed and cells were washed three times in sterile 
PBS, and then propagated for four passages before analysis. Cell blot results show 
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transfer of prion infectivity as demonstrated by the presence of PK-resistant PrP in the 
1:10, 1:25, 1:50, and 1:100 samples. No PK-resistant PrP was seen in the 1:1 or 
uninfected control samples (Figure 3.8B). 
Figure 3.8 Cell blot analysis of ScN2a(mPrP) infectivity assay. A) N2a(mPrP) incubated with 1:100 
(N2a(mPrP):ScN2a(mPrP)) dose of ScN2a(mPrP) homogenates for 48 h. Circles 1-5 are ScN2a(mPrP) cells 
originally infected by live cell co-culture and circles 6-8 are ScN2a(mPrP) cells originally infected by SMB 
homogenates. PK-resistant PrP is seen in all circle except the uninfected N2a(mPrP) negative control. B) 
N2a(mPrP) incubated with 1:100, 1:50, 1:25, 1:10, 1:1 (N2a(mPrP):ScN2a(mPrP)) doses of ScN2a(mPrP) 
homogenates for 48 h. PK-resistant PrP is detected in 1:10, 1:25, 1:50 and 1:100 N2a(mPrP):SMB samples 
but not in 1:1 or uninfected samples. 
Despite the success of ScN2a(mPrP) as an infectious source for N2a(mPrP), 
ScN2a(mPrP) homogenate was unable to infect N2a cells at any infectious dose tested 
from 1:77 to 1:300 (N2a:ScN2a(mPrP) (Figure 3.9). This confirms observations from 
other studies that over-expression of mPrP increases sensitivity of N2a cells to prion 
infection (Nishida et al., 2000). 
Uninfected N2a SMB control 
Figure 3.9 Cell blot of infectivity assay with un-transfected N2a cells as target cells and ScN2a(mPrP) 
homogenate. No infection was observed in any infectious dose. 
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3.2.4 PrP null cell line expressing mPrP 
Ideally, to study the effects of certain PrP domains on prion infectivity, a PrP-null cell 
line would be transfected with different PrP constructs and infectivity assays 
performed. This would eliminate endogenous PrP as a factor in the infectivity assay. 
However, not many PrP null cell lines exist, and those that do have poor susceptibility 
to prion infection (Solassol et al., 2003). 
To develop a system where PrP null cells could be used in a cellular prion infection 
system to study the different domains of the protein, the Zpl cell line was used which is 
derived from transgenic Zurich mice lacking Prnp (Kim et al., 2005). Figure 3.10A 
shows Zpl cells do not express PrPC whereas Zwl and N2a cells both express PrPC. 
Figure 3.10 Western blot of PrPC expression. A) PrPC expression in Zwl, Zpl and N2a cells. Lane 1, Zwl cells 
which express PrPC; Lane 2, Zpl cells which do not express PrP; Lane 3, N2a cells showing PrP expression. 
Tubulin blots confirm the absence of PrP in Lane 2. B) PrPC expression in Zpl cells and Zpl(mPrP) cells. 
Lane 1, untransfected Zpl cells which do not have detectable PrPC; Lanes 2 and 3, Zpl(mPrP) which show 
PrPC expression. Markers are in kDa.. 
In order to determine whether these cells were susceptible to prion infection, Zpl cells 
were first stably transfected to over-express mPrP(1-254), as shown by the Western 
blot in Figure 3.10B. 
Zpl(mPrP) cells were then used as the target line in infectivity assays. Infectivity 
assays were performed with SMB homogenate and ScN2a(mPrP) homogenate as the 
infectious source and Zpl(mPrP) as the target cells. Assays were performed as 
described in section 3.2.3, with target cells being incubated for 48 h with infectious 
homogenate. Results were assessed by cell blot (Figures 3.11A and B) and indicated 
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that Zpl(mPrP) cells were not able to be infected, determined by the lack of detectable 
PK-resistant PrP. Co-culturing infectivity assays were performed with Zpl(mPrP) and 
Zwl cells as target cells. No PK-resistant PrP was seen with either cell line (Figure 
3.11 B, C). 
This suggests the Zpl line is not susceptible to prion infection, even when transfected to 
over-expressing PrP. The parallel cell line Zwl, which does express PrP, was also not 
successful at propagating prion infection. This is not completely unexpected as many 
cell lines are unable to propagate prions (Solassol et al., 2003; Bedecs, 2008). An 
additional cause could be related to the fact both the Zpl and Zwl cell lines have a 
higher cellular division rate than N2a cells, and it has been suggested that cell division 
and prion propagation are related (Ghaemmaghami et al., 2007). Therefore Zwl and 
Zpl cell lines have no susceptibility for prion infection, and are not suitable for 
infectivity assays. 
Figure 3.11 Cell blots of Zpl(mPrP) and Zwl infectivity assays. A) Cell blot of Zpl(mPrP) incubated for 48 h 
with cell homogenates. Circle 1, 1:100 (Zpl(mPrP):ScN2a(mPrP). Circle 2 1:100 (Zpl(mPrP):SMB). Neither 
infectious source could transfer prion infectivity to the Zpl(mPrP) cells. B) Cell blot of Zpl(mPrP) co­
cultured with SMB cells for 48h. No PK-resistant PrP was seen in any sample. C) Cell blot of Zwl cells co­
cultured with SMB cells for 48 h. 
90 
3.3 Role of metals in transfer of prion infectivity in cell 
culture 
The role of metals in prion infectivity is poorly understood. While it is understood that 
metal levels alter during prion disease progression (Wong et al., 2001; Thackray et al., 
2002; Hesketh et al., 2007, 2008) the precise role metals play in prion disease is 
unclear. To assess the effect of metals in the transfer of prion infectivity, infectivity 
assays were performed in Chelex-treated media. Chelex-100 is commonly used to 
deplete metal ion concentrations in media (Rayner and Suzuki, 1995; White and 
Cappai, 2004; Du et al., 2008). Chelex treatment is described in 2.3.6. Copper, 
manganese and zinc were then added to the Chelex-treated medium to determine 
whether the metals affected transfer of prion infectivity. 
3.3.1 Viability of cells in Chelex media 
To confirm that the experimental conditions would not result in widespread cell death, 
viability assays were performed on N2a(mPrP) cells (the target cells used in the 
infectivity assay). Cells were treated in Chelex-treated media (with basal calcium and 
magnesium levels added back) for 48 h and viability was assessed using an MTS assay. 
Results indicate there is no statistically significant difference in cell viability in cells 
grown in Chelex-treated media compared to non treated control (Figure 3.12). 
Untreated Chelex 
Figure 3.12. Viability of N2a(mPrP) cells in Chelex-treated media determined by MTS assay. Cells were 
grown for 48 h in Chelex-treated media and viability was assessed. No significant effect on viability was seen 
in cells grown in Chelex-treated media compared to untreated cells. Error bars ± SEM, n=5. 
Next, the effect of metals on cell viability was tested. N2a(mPrP) cells were treated for 
48 h in Chelex-treated media with 100 µM CuSO4, MnSO4 or ZnCl2 added. Viability 
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was assessed using MTT assay. Results indicate there is no statistically significant loss 
of viability in cells treated with copper, manganese or zinc treated compared to no 
metal control but there is trend of decreasing viaibility seen across all experiments. 
(Figure 3.13). 
Figure 3.13. Viability of N2a(mPrP) cells in Chelex-treated media with 100 µM CuSO4, MnSO4 or ZnCl2 
added determined by MTT assay. Cells were grown for 48 h in Chelex-treated media with basal calcium and 
magnesium concentrations added back and viability was assessed. Error bars ± SEM, n=3. 
3.3.2 Cellular infectivity assay and metals 
3.3.2.1 Infectivity assays in Chelex-treated medium 
The effect of metals in prion infectivity was assessed by performing infectivity assays 
in Chelex-treated medium. In these experiments, the effect of metals on the infectivity 
assays cannot be due to a regulatory effect of metals on PrP expression, as the over-
expression of PrPC in the N2a(mPrP) cells is driven by the cytomegalovirus promoter 
and not the Prnp promoter. 
A minimum of four independent infectivity assays were performed. N2a(mPrP) cells 
were incubated with 1:100, 1:50, 1:25, 1:10 and 1:1 (N2a(mPrP):ScN2a(mPrP)) doses 
of ScN2a(mPrP) homogenate for 48 h. Cells were propagated four passages post 
infection and analysed by cell blot. 
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Cell blot results show PK-resistant PrP was seen in 1:100, 1:50, and 1:25 
(N2a(mPrP):ScN2a(mPrP)) infectious doses in cells infected in Chelex-treated 
medium. In contrast, infectivity assays performed in the normal medium showed PK-
resistant PrP in the 1:10 infectious dose (Figure 3.14). 
Figure 3.14 Effect of Chelex-treated media on transfer of prion infectivity. Representative cell blot of 
infectivity assay. N2a(mPrP) cells were incubated with 1:100, 1:50, 1:25, 1:10 and 1:1 
(N2a(mPrP):ScN2a(mPrP)) doses of ScN2a(mPrP) homogenate for 48 h in Chelex-treated medium and 
compared with cells incubated in normal medium. PK-resistant PrP was not seen at the 1:1 or 1:10 dose in 
cells cultured in Chelex-treated medium, in contrast to cells cultured in normal medium where PK resistant 
PrP was seen at the 1:10 dose. 
To assess the effect of metals on the transfer of prion infectivity, infectivity assays were 
performed in Chelex-treated medium and either 100 µM CuSO4, MnSO4, or ZnCl2 was 
added to the medium. A minimum of four independent infectivity assays were 
performed. N2a(mPrP) cells were incubated with 1:100, 1:50, 1:25, 1:10 and 1:1 
(N2a(mPrP):ScN2a(mPrP)) doses of ScN2a(mPrP) homogenate for 48 h. Cells were 
propagated four passages post infection and analysed by cell blot. 
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Figure 3.15 Representative cell blots of infectivity assays with metals. N2a(mPrP) cells were incubated for 48 
h with 1:100, 1:50, 1:25, 1:10 and 1:1 (N2a(mPrP):ScN2a(mPrP)) doses of ScN2a(mPrP) homogenate. A) 
Control (no metal and normal medium). PK-resistant PrP is seen in the cell samples treated with 1:10, 1:25, 
1:50, and 1:100 infective doses. B) Chelex treated medium. PK-resistant PrP is seen in the 1:25, 1:50, and 
1:100 infectious doses. C) Chelex-treated medium with 100 µM CuSO4. PK-resistant PrP is seen in the 1:10, 
1:25, 1:50, and 1:100 infective doses. D) Chelex-treated medium with 100 µM MnSO4. D) PK-resistant PrP is 
seen in cells treated with the 1:10, 1:25, 1:50, and 1:100 infective doses. Chelex-treated medium with 100 µM 
ZnCl2. PK-resistant PrP is seen cells treated with all infectious doses save 1:1 infective doses. 
As with Figure 3.14, results show infection with Chelex treated medium is only 
detected in 1:25 infectious dose that compared to the control (no metal and normal 
media) where PK-resistant PrP is present at the 1:10 infectious dose (Figure 3.15 A and 
B). 
Addition of 100 µM CuSO4, MnSO4, or ZnCl2 to Chelex-treated media resulted in PK-
resistant PrP detected in the 1:10, 1:25, 1:50 and 1:100 infectious doses, similar to the 
no-metal, no-Chelex control (Figure 3.15C-E). These results indicate that depletion of 
metal ions from the media lowers susceptibility of N2a(mPrP) cells to infection – as 
indicated by a higher infectious dose (1:25) required in order to detect PK-resistant PrP. 
The addition of copper, manganese, and zinc all restored the susceptibility of 
N2a(mPrP) cells to infection to control levels 
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3.4 Metal transporter proteins in prion disease 
As PrPC expression levels cannot be responsible for the metal-mediated effects seen in 
the infectivity assays, the next step was to determine whether altered metal transporter 
expression had any effect on transfer of prion infection. 
Plasmid constructs of copper transporting proteins were transfected into SMB and 
SMB-PS cells to determine whether these copper-transporting proteins affect PrP 
expression. PrP expression was analysed by Western blots quantified by densitometry. 
The results proved variable so data are treated as preliminary. Over-expression of 
ATOX1, CCS, CTR1 or CTR2 did not significantly affect the expression of PrPC in 
uninfected SMB-PS cells (Figure 3.16A) or N2a cells (Figure 3.16B). PrPSc expression 
in the infected SMB cells was also not significantly altered when ATOX1, CCS, CTR1 
or CTR2 was over-expressed (Figure 3.16A). 
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Figure 3.16 PrP expression is unaffected by over expression of copper transporting proteins. A) Over-
expression of copper transporting proteins did not affect PrPC (SMB-PS) or PrPSc (SMB) expression levels. 
n=3. B) PrPC expression in N2a cells over-expressing copper transporters. n=3. 
To determine if increased copper transporter expression would increase the 
susceptibility of N2a cells to prion infection, infectivity assays were performed using 
N2a cells over expressing ATOX1, CCS, CTR1 or CTR2. Cells were incubated with 
1:1, 1:100, 1:1000 (target:ScN2a(mPrP) for 48h and cells were propagated four 
passages post infection and analysed by cell blot. No infection was seen in any of the 
N2a cells over expressing copper transporting proteins with either ScN2a(mPrP) 
homogenate (Figure 3.17) or SMB homogenate (not shown). These data are consistent 
with previous findings that N2a cells are not susceptible to infection without over-
expression of PrP (Section 3.2.3.2). Therefore over expression of copper transporters 
did not render N2a cells more susceptible to infection. 
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Figure 3.17 Cell blot of infectivity assay of N2a cells over-expressing ATOX1, CCS, CTR1, and CTR2 in a 
FLAG-tagged vector. No PK-resistant PrP was detected at any infectious dose tested. 
3.5 Discussion 
Cell culture is comparatively a less expensive and time-consuming method than animal 
bioassay, and is used to study several aspects of prion biology including prion 
infection. This study used cell culture infectivity assays to assess the role of metals in 
the transfer of prion infectivity to previously uninfected cells. 
3.5.1 Development of prion infectivity assays 
The basic protocol to establish prion infection protocol in cell culture 
requiresincubation ofthe target cells with an infectious source and then propagation of 
the target cells for a number of passages to detect de-novo prion infection. Prion 
infection in cell culture can be accomplished using different sources of infectious 
material, albeit with varying success rates. Infectious sources used in the development 
of a suitable method for this study included infectious brain homogenate, live cells, and 
cell homogenates. 
The infectivity assays performed with brain homogenate yielded successful transfer of 
prion infection to the N2a(mPrP) cells, although this was strain-dependent, as the Me7 
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strain homogenate did not infect N2a(mPrP). Prion strains are classified in vivo by 
incubation period and neuropathological effects which are faithfully propagated. These 
strain characteristics are reproduced after secondary propagation in a different species. 
Biochemically, prion strains exhibit different glycosylation profiles, protease 
resistance, and electrophoretic mobility. Some prion strains in mice include RML, 
22L, Chandler, Fukurora, Me7, and 79A (Morales et al., 2007). The results of this 
study showed that infectious brain homogenate from the 79A strain, but not the Me7 
strain was able to infect N2a(mPrP) cells. These data are in agreement with previously 
published studies (Bosque and Prusiner, 2000; Klohn et al., 2003). 
The limited availability of infectious brain homogenate required development of an 
alternative infection assay, namely live cell co-culturing using a chronically infected 
cell line and infectious cell homogenates. These techniques were adapted from 
published methods for use in our laboratory (Bosque and Prusiner, 2000; Kanu et al., 
2002) and required SMB cells as the infectious source. 
The two cell lines utilised as target cells for live cell co-culturing were SMB-PS cells 
and N2a cells. It was necessary that both cell lines over-express mPrP, as selection of 
infected target cells is based on antibiotic resistance conferred by the mammalian 
expression plasmid pcDNA3.1+. In contrast to work published by Kanu et al, SMB­
PS(mPrP) cells were not able to be infected by live cell co-culture in this study perhaps 
on account of the pentosan sulphate used to clear the cell of detectable prion infection 
(Birkett et al., 2001). The exact mechanism by which pentosan sulphate clears prion 
infection is unknown as are any other effects pentosan may have on cellular processes. 
This and subtle differences in culture conditions could explain why some SMB­
PS(mPrP) cells were not susceptible to infection by co-culture. Further, the use of an 
antibiotic to select the SMB-PS(mPrP) cells after live cell co-culture may have affected 
cell survival. As prion infection is known to decrease the cellular response to oxidative 
stress (Brown and Bessinger et al., 1998), the increased stress on the cells from both 
antibiotic selection and SMB cell death may have been too strenuous for the newly 
infected SMB-PS(mPrP) cells. Finally, infected SMB-PS(mPrP) cells could have 
ejected the pcDNA3.1+-mPrP plasmid after the co-culture period as they were without 
constant selective pressure, thus rendering them susceptible to the antibiotic once they 
were added back. All things considered, further experiments were done using 
N2a(mPrP) cells. 
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In contrast to SMB(mPrP) cells, live cell co-culturing was very successful with 
N2a(mPrP) cells. This success could be attributed to fact that the shorter incubation 
period allowed cells to be with continuous antibiotic selection for a greater time period. 
Additionally SMB cells suffer death more quickly than N2a(mPrP) cells which require 
a higher dose of G418 selection. Finally, these data show that N2a(mPrP) cells were 
more susceptible to infection from SMB cells than infectious brain homogenate. 
Since it was impractical to use live cell co-culture as the sole method for infection, 
homogenates of infectious cells were used. This method was the most reproducible and 
economical method of infection for N2a(mPrP) cells, but did not successfully infect 
untransfected N2a cells or Zpl(mPrP) and Zwl(mPrP) cells. The lack of infection in the 
Zpl/Zwl cell lines is most likely due to an inability to support prion infection. The 
inability of several cell lines, including neuronal lines, to support prion infection has 
been previously documented but is poorly understood (Vilette, 2008). Qualitative 
estimates indicated this inability to support prion infection was not due to loss of 
viability or alteration to cell division or morphology. These results show Zpl(mPrP) 
and Zwl(mPrP) cells are not suitable for a model for prion infection. 
Once the infectious cell homogenate method stably produced results, the role of metals 
in transfer of infectivity was examined. 
3.5.2 Metals and prion infectivity 
The results here show that depleting the medium of metals results in a decreased 
susceptibility to lower prion doses; this suggests that metals may play a promotional 
role in infection. This decreased susceptibility was not due to a decreased viability, as 
shown by cell viability assays in 3.3.1. Adding copper, manganese, or zinc back 
restores susceptibility of the N2a(mPrP) cells back to those of the control, suggesting 
that adding metals to Chelex-treated media promotes prion infection. These results do 
not provide any insight as to how this occurs, but as these cells were over-expressing 
PrP under the control of the cytomegalovirus promoter it is unlikely this effect was due 
to an influence on protein expression. 
The restorative effect of metals on a Chelex-depleted background could be due to metal 
interactions with PrPC or with PrPSc which could induce conformational changes that in 
turn promote acquisition of infection. It has been well described that metal binding to 
PrP results in increased β-sheet content of the protein (McKenzie et al., 1998; Stockel 
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et al., 1998; Wadsworth et al., 1999; Brown et al., 2000; Qin et al., 2000; Quaglio et 
al., 2001; Wong et al., 2000b; Jones et al., 2004; Nishida et al., 2004; Liu et al., 2007). 
Manganese is also able to induce a conformation change in PrP (Brown et al., 2000; 
Abdelraheim et al., 2006; Kim et al., 2005; Treiber et al., 2006). Zinc and copper has 
also been shown to promote PrP-PrP interactions (Kenward et al., 2007). These metal-
induced conformation changes and increased PrP self-interaction could promote and/or 
permit conversion to occur and thereby infection to occur more readily. 
Another possibility for the restoration effect seen with manganese could be due to the 
requirement for manganese in glycosylation. It has been shown that specific 
unglycosylated PrP mutants are still able to convert to a protease resistant form, 
although altered PrP glycosylation has been shown to modulate response to different 
prion strains (Korth et al., 2000; Tuzi et al., 2008). Depletion of manganese in the cells 
leads to inhibition of N- and O-linked glycosylation (Suigiura et al., 1982; Elhammer 
and Kornfeld, 1986; Kaufman, et al., 1994) and this may be due to inactivation of 
SPCA1, the mammalian analogue of the yeast protein Pmr1 (Kaufman et al., 1994). 
This calcium(II)/manganese(II) transporter is responsible for supplying calcium and 
manganese to glycosylation, ER, and protein degradation pathways (Hu et al., 2000; 
Van Baelen et al., 2001). Therefore loss of manganese could alter N-linked 
glycosylation of the prion protein and result in a decreased response to prion infection, 
as seen in the Chelex-treated medium infectivity assays. This response would be 
ameliorated by resupplying manganese to the system, as was seen in section 3.3. 
On a broader level, while overall cell viability was not affected by the treatments in the 
experiments, it is probable that alterations in metal homeostasis occurred possibly 
including leaching of metal stores to ensure essential enzymes function properly in the 
case of reduced metal media treatments, or increase in metal transport, storage, and 
export. As the relationship between PrP and metals has yet to be fully defined, it is 
possible that alteration in the metal metabolism of the cell contributed to the increased 
susceptibility of these cells to infection. Indeed it has been shown that there are 
significant alterations to metal metabolism during disease pathogenesis, including 
altered metal levels in tissue and altered metal transporter expression levels (Wong et 
al., 2001b; Thackray et al., 2002b; Hesketh et al., 2007, 2008; Kralovicova et al., 2009; 
Mitteregger et al., 2009). 
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Proteins involved in copper homeostasis were examined in 3.4 by over-expressing 
copper transporters and chaperones in SMB, SMB-PS and N2a lines. There was no 
significant effect on prion protein expression. In particular the results of ATOX1 are in 
contrast to those by Wright et al., who showed that ATOX1 over expression resulted in 
increased PrPC expression (Wright et al., 2009a) and that ATOX1 was able to up-
regulate Prnp promoter activity. However, the mammalian expression vector used to 
express ATOX1 in the Wright et al. study was pCDNA3.1+ as opposed to the 
p3xFLAG vector used here. The FLAG tag was found to interfere with the DNA-
binding region of ATOX1 (J.A. Wright, personal communication) and therefore would 
not be able to affect the Prnp promoter and PrPC expression in the N2a cells. Given the 
results of Wright et al., and those showing that ATOX1 has copper-mediated 
transcriptional response (Itoh et al., 2008), it would be interesting to determine if (using 
an appropriate expression vector) ATOX1 over-expression in a copper-enriched 
environment was able to increase susceptibility of cells to prion infection by regulating 
Prnp expression. Increased Prnp promoter activity in response to metals could 
represent a mechanism by which increased metals promote transfer of prion infection. 
In summary, a successful cell culture model was established to study transfer of prion 
infectivity in culture. Successful transfer of prion infectivity was achieved using either 
co-culture with chronically infected cells as well as with infected cell homogenates. 
This method was used to determine whether metals affected the transfer of prion 
infectivity and results showed that depletion of environmental metals lowered 
susceptibility of N2a(mPrP) cells to infectivity transfer. This effect was ameliorated 
when copper, zinc, or manganese was added back to the system. The next step 
therefore is to identify how the metal-PrP interaction could influence conversion of the 
protein into a disease related form using a simplified in vitro aggregation system. 
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4. Metals and PrP Aggregation 
4.1 Introduction 
Evidence suggests that an aggregated form of PrPSc is in fact the key component in the 
disease (Prusiner et al., 1983; Pan et al., 1993; Nguyen et al., 1995) but the precise 
character of the infectious aggregates is unclear. In vivo, PrPSc exists in intracellular 
aggregate depositions (Prusiner et al., 1998). In humans, a proportion of these 
depositions are amyloid-like plaques, and these plaques differ in morphology between 
different types of prion disease (reviewed in Liberski and Ironside, 2004). It has been 
demonstrated that in vitro conversion ability is related to infectivity (Caughey et al., 
1997; Raymond et al., 1997). The study of in vitro aggregation of recombinant PrP is 
instrumental in providing insight into the mechanisms behind conversion from PrPC to 
PrPSc and aggregate accumulation. In addition it provides a means with which to study 
the conformation and species that is likely responsible for prion pathogenesis. 
Analysis of aggregated PrP is done using several methods. These include 
turbidometry, Fourier transform infrared spectroscopy (FTIR), circular dichromism 
spectroscopy (CD), electron microscopy, atomic force microscopy, and by the use of 
amyloid-binding dyes such as Congo red, 8-anilino-1-naphthalenesulfonic acid (ANS), 
Thioflavin T (ThT), and Thioflavin S (LeVine III, 1993; Ban et al., 2003). These dyes 
provide a useful method for monitoring the formation of amyloid structures as these 
dyes bind only to common β-sheet structures, allowing for distinction between β-sheet 
and non-β-sheet material. ThT in particular binds exclusively to β-rich 8-9Å diameter 
cavities which run along the length of the fibril axis (Groenning et al., 2007a,b). The 
emission wavelength of ThT upon binding to fibril-like structures (excitation 440 nm, 
emission 482 nm), is markedly different from that of the dye itself (excitation 350 nm, 
emission 438 nm) and also to the fluorescence pattern in water (excitation 440 nm, 
emission 493 nm) (Naikai et al., 1989; Maskevich et al., 2007). This makes the use of 
ThT a valuable method to study the conversion of α-helical PrP to β-sheet PrP, as the 
dye fluorescence pattern will increase as the β-sheet PrP proportion increases. PrPC has 
been shown to bind copper as well as other metals such as manganese, nickel, and zinc, 
both within the N-terminal octapeptide repeat region and within the hydrophobic region 
(Hornshaw et al., 1995a,b; Katamine et al., 1998; Viles et al., 1999; Brown et al., 
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2000; Collinge and Clarke et al., 2007; Yang et al., 2008). In addition, these metals are 
able to impart structural changes to PrP and it has been theorised that PrP may have a 
function in metal homeostasis as discussed in 1.3.2, which has led many investigators 
to look into the role of metals in PrP aggregation. 
It is important to understand the role metals play in PrP aggregation, it has been 
suggested that metals, in particular copper, play a role in the normal function of the 
prion protein (Brown et al., 1997). The interaction with metals, in particular 
manganese, in the aggregation process could be instrumental in understanding the 
disease pathogenesis. Previous studies on prion protein aggregation were performed 
under conditions such as low pH and/or denaturing reagents such as urea or guanidine 
hydrochloride (Jackson et al., 1999; Baskakov et al., 2001; Bocharova et al., 2005a,b). 
The site of PrPC-PrPSc conversion is unknown and two potential sites for conversion 
could be within lysosomes where the pH is low or on the cell surface, where the protein 
would be in a more pH neutral environment (Caughey et al., 1991; Caughey and 
Raymond 1991; Borchelt et al., 1992). As many groups have published work on PrP 
aggregation under low pH conditions, the aim of this work is assess the effect metals 
have on recombinant mPrP aggregation using neutral pH and buffer conditions the 
protein is more likely be exposed to either inside the cell (cytosol) or on the cell surface 
(extracellular space). 
4.2 Results of cloning, expression, and purification of PrP 
constructs 
The choice was made to clone several murine prion protein constructs, to produce 
constructs without a tag. Murine PrP pET3a-mPrP(23-231), pET3a-mPrP(Δ51-89), and 
pET3a-mPrp(Δ67-90) constructs were sub-cloned by PCR amplification of pcDNA3.1+ 
mPrP(1-254), a mammalian expression construct using primers with NdeI and BamHI 
restriction enzyme sites. The PCR amplified constructs were then ligated into an 
untagged bacterial expression vector, pET3a. Ligation into the appropriate vector was 
accomplished by either sticky- or blunt-ended ligation methods. All constructs were 
sequenced before use to confirm the gene product was correct.Once the mPrP 
constructs had been cloned and sequences were confirmed, constructs were transformed 
into competent Escherichia coli BL21-DE3 cells and expression trials were carried out 
to confirm the production of the correct protein. Figure 4.1 shows expression of 
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mPrP(23-231), mPrP(Δ51-89), and mPrP(Δ67-90). All mPrP constructs were tested for 
expression before use. 
Figure 4.1Expression trial showing induction of mPrP expression in BL21 E.coli. BL21 E.coli were 
transformed with pET3a-mPrP constructs and mini cultures were grown as in Section 2.4.1. Pre-and post-
induction samples were analyse to determine whether mPrP over-expression was present. Lanes 1, 3 and 5 
are pre-induction samples and lanes 2, 4, and 6 are 3h post induction samples. Lanes 1 & 2 are mPrP(23-231), 
lanes 3 & 4 are mPrP(Δ51-89) and lanes 5&6 are mPrP(Δ67-90). 
Purification of these mPrP proteins was either carried out using copper-IMAC or the 
wash purification method. Figure 4.2A and B show mPrP(23-231) purification and 
refolding. All mPrP mutants were compared to full length mPrP(23-231) purified by 
the same method as the mutant. Once purified, the proteins were refolded under 
oxidative methods as described in Section 2.4.4. Previous work has shown protein 
refolded using this method is mainly α-helical, similar to the structure of cellular PrP 
(Wong et al., 2000). Coomassie stained SDS-PAGE gels (performed as described in 
section 2.3.12 and 2.3.14) were analysed of each preparation to determine purity. 
Examples of refolded PrP proteins are shown in Figure 4.3. The main band of each 
lane corresponds to the predicted size of each constructs (see Table 2.4 for molecular 
weights). 
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Figure 4.2 Examples of mPrP(23-231) purification and refolding. A) SDS-PAGE gels stained with Coomassie 
of wash purification method. All samples taken from re-suspended pellets. Lane 1 is sample after initial cell 
lysis. Lanes 2-8 show successive samples after every 2nd wash cycle. Lanes 9-10 show successive samples 
during final, no detergent washes. Lane 11 is the final purified product in 8M urea buffer. B) SDS-PAGE 
gels stained with Coomassie of Cu-IMAC purification. Lanes 1&2 are samples from Cu-IMAC elution 
fractions. Lane 3 is re-natured protein before dialysis and lane 4 is re-natured protein after dialysis. 
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Figure 4.3 Coomassie staining of SDS-PAGE analysis of refolded mutant mPrP proteins. SDS-PAGE gels and 
staining was performed as indicated in Section 2.3.12 and 2.3.14. A) Lane 1 is mPrP(Δ67-90). Lane 2 is 
mPrP(Δ106-126). B) Lane 1 is mPrP(Δ51-90) and lane 2 is mPrP(23-231) from a different purification than 
Figure 4.2. C) Lanes 1 and 2 are two samples from the same mPrP(89-231) purification. E) Lane 1 is 
mPrP(Null +H95, H110), lane 2 is mPrP(Null), lanes 3 and 4 are mPrP(H95A+H110A) from the same wash 
purification. E) Lane 1 is mPrP(Null +H95) and lane 2 is mPrP(Null+H110). All markers are in kDa. 
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To further confirm the identity of the protein preparations, Western blot analysis 
(section 2.3.13) of the purified and refolded proteins was performed using the 
monoclonal ICSM-18 antibody on all constructs except for mPrP(Null), 
mPrP(Null+H95), mPrP(Null+H110), mPrP (H95A+H110A) and mPrP(Null + H95, 
H110). These constructs were blotted using the anti-PrP 8B4 antibody (Figure 4.4). 
These results show mPrP at the predicted sizes, although for the mPrP(Δ51-90) and 
mPrP(Δ67-90) the bands were rather blobby which could be due to protein overload of 
the gel. 
A B C D 
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Figure 4.4 Western blot analysis of post-refolded mPrP proteins. A) Western blot of mPrP(23-231) detected 
with anti-PrP antibody ICSM18. 
4.3 Method Development 
For the aggregation reactions, recombinant protein was prepared as described in 2.4.1­
2.4.6 and aliquoted into triplicate separate wells of a 96 well plate. Aggregation 
reaction method is described in 2.4.8 but the basic method is briefly reiterated here to 
illustrate how the buffer development occurred. Thioflavin T (ThT) dissolved in sterile 
pH 7.4 deionised water was prepared freshly every time. The reactions were incubated 
at 37°C, and agitated at 600 rpm as described by Bocharova et al (Bocharova et al., 
2005). Fluorescence measurements were taken at various time points using a BMG 
FLUOstar Omega multi-plate reader using filter sets 445-5 nm (excitation wavelength) 
and 480-10 nm (emission wavelength). Background fluorescence was subtracted from 
each sample before plotting the data versus time. In this system, aggregation is 
described as an increase in fluorescence intensity over time above that of the initial 
reading, as the ThT signal emitted at 482 nm will only increase if the amount of β-sheet 
increases in the reaction. 
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First, a range of solvent conditions were tested (Figure 4.5). All conditions were tested 
on mPrP(23-231) prepared exactly the same way, and all were agitated at the same 
time, with the same solution and concentration of ThT added to monitor the reaction. 
All reactions were incubated at 37°C and agitated at 600 r.p.m. Buffer conditions 
initially tested were from published studies (Bochorova et al., 2005; Baskakov and 
Bocharova, 2005) and were assessed both with and without denaturing components. 
As seen in Figure 4.5A, the aggregation reaction results were quite different under 
these solvent conditions compared to the published results. In many cases including 
using the 1M GdnHCl, 3M Urea, 50 mM HEPES, pH 6.0 buffer specified by 
Bocharova et al, and the buffer specified in Baskakov and Bocharova (1 M GdnHCl, 
2.4M urea, 20 mM sodium acetate at pH 5.0), very little aggregation was seen 
compared to reactions without denaturants (Bocharova et al., 2005; Baskakov and 
Bocharova, 2005). Other buffers tested included 1M GdnHCl, 3M Urea, 50 mM 
HEPES pH 6.0 (Bocharova et al., 2005); 1 M GdnHCl, 2,4M urea, 20 mM sodium 
acetate pH 5.0 (Baskakov and Bocharova, 2005); 10 mM PBS pH 7.3; 50 mM HEPES 
pH 6.8; 50 mM HEPES pH 7.2. Of these only reactions using PBS showed any 
aggregation (Figure 4.5B). 
The differences in the results of experiments presented here compared with previously 
published works may be due to the differences in protein preparation in this study 
compared to in previous studies. However, 3M urea or 1.5M guanidine are relatively 
high concentrations of denaturants and not likely to be encountered in vivo, and as this 
study is to assess PrP conversion under more physiological conditions a sodium 
phosphate buffer system was tested. 10 mM sodium phosphate buffers at pH 5.5, 6.8 
and 7.4 were tested (Figure 4.3C) with the pH 7.4 buffer producing the best aggregation 
reaction. 
After testing it was decided that 20 µM protein was an appropriate concentration to use, 
as it would allow for the greatest number of experiments to be done per preparation of 
protein and was a high enough concentration so the reaction was visible. Therefore all 
aggregation experiments described were performed at 37°C with agitation at 600 rpm. 
Each 100 µL reaction contained 20 µM protein and 10 µM ThT in 10 mM sodium 
phosphate, pH 7.4, with a sterile 3mm glass bead. At least two protein preparations 
were analysed for each PrP construct, with a minimum of three independent 
experiments performed (with each protein purified and refolded independently). 
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Figure 4.5 Optimisation of mPrP aggregation as assessed by ThT fluorescence. A) Aggregation reactions in 
same base buffer with increasing levels of denaturants. The addition of denaturants had a decreased response 
in this assay. B) Aggregation reaction with PBS. C) Aggregation of mPrP is dependent of pH. Aggregation 
reactions in 10 mM sodium phosphate at either pH 5.5, 6.8, or 7.4 using 50 µM protein were monitored by 
ThT fluorescnce. All experiments were performed a minimum of two times for preliminary studies. 
The drawback of this method was the variability seen in the maximal fluorescence 
calculations – that is, the extent of the reaction although the kinetic traces seen were 
similar. Figure 4.6 shows the maximum fluorescence values from mPrP(23-231) 
aggregation reactions. The variability made for more difficult statistical analysis so 
data were normalised to the no metal control to help account for this variability. 
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Figure 4.6 Variability in mPrP(23-231) maximum fluorescence values. Variety in protein preparation is 
evident from the variability seen in these values. While the kinetic curves are similar, the maxima are quite 
different. Each bar corresponds to an independently refolded aggregation reaction, and at least four separate 
protein purifications are represented. 
4.4 Aggregation of mPrP(23-231) 
The first step was to analyse the aggregation of full-length, recombinant mPrP(23-231), 
determine whether those aggregation products were capable of self-propagation, and 
finally investigate the effect the metals CuSO4, MnSO4 and ZnCl2 had on the 
aggregation. 
To assess the aggregation of recombinant mPrP(23-231), aggregation reactions were 
performed as described in section 2.4.8. Aggregation is described by a rate, which 
describes how quickly aggregation occurs, and overall maximum fluorescence 
intensity, calculated from the greatest fluorescence intensity measured to describe the 
amount of β-sheet content in the reaction. 
In other studies using mPrP(23-231), aggregation rates can be fitted to a sigmoidal 
curve (Baskakov and Bocharova, 2005); however this was not seen in this study. 
Aggregation increased in a linear fashion before reaching a plateau, after which no 
further aggregation was seen even in experiments continued past 24 h (Figure 4.7). 
Therefore only the linear rate was analysed by determining the linear increase for each 
reaction (from time zero to the start of the plateau). In this study, mPrP(23-231) 
aggregation had an average linear rate of 1273.8± 321.7, n=11. 
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A distinct maximal fluorescence value was calculated from each aggregation 
experiment. The average maximal fluorescence for mPrP(23-231) was 6282.7 ± 
1270.9, n=11 relative fluorescence units. 
Figure 4.7 Representative graph of recombinant mPrP(23-231) aggregation. The aggregation was monitored 
using ThT fluorescence and values are relative fluorescence units (excitation 445 nm, emission 482 nm) 
plotted over time. 
To assess what type of aggregates were formed by mPrP(23-231) aggregation, 
aggregate end products were subjected to transmission electron microscopy (TEM). 
Samples were negatively stained with uranyl acetate before imaging at 100,000 times 
magnification. TEM images showed that under these aggregation conditions aggregate 
end products were amorphous structures (see Figure 4.8). No discrete fibril or pre-
fibrillar products were observed. These results indicate that in neutral pH conditions, 
amorphous non-fibril aggregates are formed. 
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Figure 4.8 Negatively stained TEM image of mPrP(23-231) aggregate end products from aggregation 
reactions. The predominant structures are amorphous aggregates. No fibril structures were seen. 
4.4.1 Self-seeding capabilities of mPrP(23-231) 
A property of prion diseases is the capability to induce conformation change in natively 
folded PrP molecules. To test whether aggregates formed under these conditions were 
able to induce a conformation change or seed a reaction, mPrP(23-231) aggregation 
reactions were run for 6, 50, or 126h and then 20 µL of the end product was added to 
100 µl of 20 µM recombinant mPrP(23-231) containing 10 µM ThT. 
There was no significant effect on the rate of the reaction or on the maximum 
fluorescence achieved with the addition of any of the pre-formed seeds (Fig 4.9). 
Several other conditions including different concentrations of seed were tested and 
none were able to cause any significant increase in the rate or maximum fluorescence 
of any reaction (not shown). As the pre-formed material did not cause any significant 
seeding effect, these experiments were not pursued further. 
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Figure 4.9 Aggregation of seeded mPrP(23-231) reactions. Aggreation reactions were run for 6 or 50h before 
adding 20 µL of the end product to the start of a fresh aggregation reaction. A representative graph is shown 
comparing seeded(6h and 50h preformed product)reactions versus no seed control, n=3 
4.4.2 Effect of metals on mPrP(23-231) aggregation 
The effect of metals was then assessed by the addition of metals to the aggregation 
reaction. CuSO4, MnSO4 and ZnCl2 buffered in 10 mM sodium phosphate, pH 7.4 were 
added to 20 µM recombinant mPrP for a final metal concentration of 100 µM. 
Aggregation reactions were then performed as described in 2.4.8. As in the no metal 
experiments, after the linear increase in aggregation the reaction reached a plateau, and 
while the experiment was allowed to proceed for more than 20h, no further increases in 
aggregation were. Therefore the linear rate was determined for each reaction as well as 
maximum fluorescence. 
Results show mPrP(23-231) aggregation reactions with the addition of metals (Figure 
4.10A). Copper, manganese, and zinc addition did not affect the maximal fluorescence 
achieved in a statistically significant manner (Figure 10.8B). Linear rate calculations of 
aggregation also indicate a trend for metals to decrease the rate of the reaction when 
compared to the no metal control, although again this was not statistically significant 
(Figure 4.10C). 
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Figure 4.10 Aggregation of mPrP(23-231) with 100 µM metals as monitored by ThT fluorescence. A) 
Representative graph of linear aggregation with 100 µM metals. B) Average linear rate of aggregation with 
metals compared to no metal control. C) Average maximal fluorescence of each reaction with metals 
compared to no metal control. Error bars are n=8, ± SEM. 
Next, end products of aggregation reactions were run on 5-20% gradient SDS-PAGE 
gels and assessed by Western blot (as in section 2.3.12 and 2.3.13) to determine 
whether there was any difference in the end product between metal added reactions 
(Figure 4.11). No high molecular weight aggregates were seen in the Western blots, 
and there was no difference between the control and metal added reactions. Smaller 
PrP fragments were seen around 10-12 kDa, and even smaller fragments were present 
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at 6.5 kDa. Additionally, fragments were seen at around 16kDa, a size corresponding 
to N-terminal truncated PrP. To further determine what these smaller fragments were, 
the antibody 8B4 was used which recognises an epitope in the N-terminus only 
(residues 35-45). The results show the disappearance of some fragments, and a strong 
band at 6.5 kDa suggesting the fragments not were truncated up to residue 45. Smaller 
fragments were present which could correspond to cleaved N-terminal products. It is 
possible the bands present which are larger than the monomer (23kDa) could be 
aggregated fragments of the N-terminus. To further determine whether this may be 
true, imaging studies would need to be performed. 
Figure 4.11 Western blots of aggregate end products of mPrP(23-231). A) Western blot with anti-PrP 
antibody ICSM18. B) Western blot with anti-PrP antibody 8B4. In both blots, lane 1 is aggregate with no 
metal, lane 2 is with 100 µM CuS04, lane 3 is with 100 µM MnSO4, and lane 4 is with 100 µM ZnCl2. Markers 
are in kDa. 
4.5 Aggregation of truncated and deletion mutant mPrP 
The next set of mutant PrP used to examine which aspects of metal binding domains 
were responsible for metal-induced effects on aggregation were N-terminal truncation 
mutations and octapeptide repeat region deletion mutations (see Figure 2.2A).. A N-
terminally truncated mutation was used to determine whether in these conditions the N-
terminally truncated protein aggregation was affected by the presence of metals, as any 
effect seen would be solely due to the 5th site. 
The octameric repeat region is accepted as an important metal binding region of PrP. 
Therefore two deletion mutants were used to examine the effects of the octapeptide 
region on aggregation. PrP(Δ51-89) does not have any octapeptide repeats whereas 
mPrP(Δ67-90) has one repeat. mPrP(Δ106-126) was studied for several reasons: this 
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region has been thought to contain a sequence necessary for amyloid formation and has 
been found to cause neonatal lethality in mice (Li et al., 2007). In addition, this region 
has been shown to have neurotoxic properties as a peptide (Forloni et al., 1993; Brown 
et al., 1996). Previous peptide analysis has shown this region conformation can be 
influenced by metals (Jobling et al., 2001). 
4.5.1 Computational analysis of mPrP aggregation propensity 
Having determined that metals did not significantly affect the rate or amount of 
aggregation of mPrP(23-231), computer analysis was performed using WALTZ and 
TANGO online programs to help reason why this might be. Mutant PrP was also used 
to predict whether the N-terminal mutations used in this study would behave 
differently. WALTZ is a program which calculates the likely amyloidgenic regions of 
a protein sequence. Using this program, the primary amino acid sequences for all 
mutant PrP were inputted. Results indicate the main amyloidgenic regions of mPrP are 
situated within the C-terminus at residues 137-142; 149-154; 156-163; 204-210 (see 
Figure 4.12). As metal binding occurs at the N-terminus of the protein, the 
amyloidgenic sequences should not be directly affected by metal interactions. However 
this does not preclude metals from causing an effect on the aggregation by indirect 
means. 
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Figure 4.12 WALTZ-predicted amyloidgenic regions in mPrP. Predicted amyloidgenic regions encompassing 
residues 137-142, 149-154, 156-163, and 204-210 are highlighted in bold red. 
Next, the PrP mutants were analysed by TANGO, an on-line program which predicts 
the aggregation propensity of a peptide sequence. Analysis showed that mPrP(89-231) 
has a higher AGG value, which indicates an increased propensity to aggregate into β­
sheet structures, compared to mPrP(23-231) (Figure 4.13). In contrast, mPrP(Δ106­
126) had a lower AGG value, which indicated a decreased tendency to aggregate 
compared to mPrP(23-231). All mutants had a similar HELIX (a probability 
determinant for a-helix content) and HELAGG (a measure of helix-mediated 
aggregation) values when compared to mPrP(23-231), but all TURN values (which 
predict β-turn propensity) were decreased. 
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Figure 4.13 TANGO-predicted values for mPrP deletion and truncation mutant aggregation. All values are 
compared to the full length control. 
4.5.2 Aggregation of mPrP(23-231) versus truncated and deletion 
mutant mPrP 
The initial rate of aggregation of the mutant PrP compared to wild type (mPrP(23-231)) 
was assessed (Figure 4.14). As with mPrP(23-231), all mutant PrP showed initial 
linear increase in aggregation, and after 20h no further increases in aggregation were 
seen. Results indicated that deletion and truncation mutant mPrP had a higher linear 
rate than full length mPrP(23-231), although this was not statistically significant 
(Figure 4.14). Analysis of the maximum fluorescence showed mPrP(89-231) and 
mPrP(Δ67-90) were decreased in comparison to mPrP(23-231), although this was not 
statistically significant. Maximum fluorescence was increased very slightly with 
mPrP(Δ106-126) and mPrP(Δ51-89), although this was not significant. 
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Figure 4.14 Initial rate and maximum fluorescence of no-metal mPrP aggregation. A) Representative graph

of initial aggregation of full length, deletion and truncation mutant mPrP. B) Linear rate of aggregation of

truncation and deletion mutants compared to full length mPrP. Error bars are ± SEM, n=8 mPrP(23-231),

n=3 mPrP(89-231), n=4 mPrP(Δ51-89), n=4 mPrP(Δ67-90), and n= 5 mPrP(Δ106-126). C) Maximum

fluorescence of aggregation of truncation and deletion mutants compared to full length mPrP. Error bars are

± SEM, n=11 mPrP(23-231), n=3 mPrP(89-231), n=4 mPrP(Δ51-89), n=4 mPrP(Δ67-90), and n= 5

mPrP(Δ106-126).
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4.5.3 Aggregation of truncated mPrP(89-231) with metals 
First the effect of metals on an N-terminally truncated mPrP was assessed. mPrP(89­
231) lacks the octapeptide repeat region, which is important for metal binding. 
Therefore any effect seen would be due to the metals interacting with the so-called 5th 
site at His95 and His110. Aggregation reactions with mPrP(89-231) were performed as 
in 4.4.2 and linear rate of aggregation and maximum fluorescence was determined. 
mPrP(89-231) aggregation reactions with 100 µM CuSO4 and ZnCl2 showed addition 
of metals did not affect to the linear rate or the maximum fluorescence of the reaction 
compared to the no metal control (Figure 4.15 B, C). However, addition of 100 µM 
MnSO4 caused a significant (p<0.05) increase to the initial rate and maximum 
fluorescence compared to the no metal control (Figure 4.1 5B,C). This increase of the 
rate of the reaction may be due to the interaction of the manganese around the 5th site 
(His95, H110) which is the available metal binding region in this protein, and this 
stands to reason as this region has a higher affinity for manganese than the octameric 
repeat (Brazier et al., 2008). 
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Figure 4.15 Aggregation of mPrP(89-231) with 100 µM metals as monitored by ThT fluorescence. The 
schematic shows mPrP(89-231) compared to the to full length mPrP(23-231). A) Representative graph of 
aggregation of mPrP(89-231). B) Rate of aggregation with copper and zinc compared to no metal control 
shows no significant differences, whereas addition of manganese to the reaction caused a significant increase 
in rate. C) Maximum fluorescence of aggregation with copper and zinc compared to no metal control shows 
no significant differences. A significant increase in maximum fluorescence is seen with manganese addition. 
Error bars are SEM, n=3. * p<0.05 
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Next, end products of aggregation reactions were analysed by Western blots. Some bands 
were seen in the ICSM-18 blot (Figure 4.16A), particularly in the no metal control 
aggregation that are indicative of dimers (~32kDa). The banding pattern also suggests 
small oligomers were formed. There was no significant difference between the end 
products of the reactions with metals, although fewer bands were present in the metal-
added reactions. These results supports the idea that these reaction conditions caused 
β-sheet formation which does not lead to large aggregates but rather smaller, 
amorphous β-sheet-rich structures. 
Figure 4.16 Representative Western blot of aggregate end products of mPrP(89-231) aggregation with and 
without metal. Western blots were performed with anti-PrP antibody ICSM18 and at least one blot per 
aggregation experiment was performed (n=3). Lane 1 is aggregate with no metal, lane 2 is with 100 µM 
CuS04, lane 3 is with 100 µM MnSO4, and lane 4 is with 100 µM ZnCl2. Markers are in kDa. 
4.5.4 Aggregation of deletion mutants of PrP with metals 
4.5.4.1 Octameric repeat region deletion mutants 
To further assess the role of the octapeptide repeat region in metals an aggregation, 
aggregation assays were performed using two mutant constructs either lacking the 
octapeptide repeat region only (mPrP(Δ 51-89)) or with one repeat present (mPrP(Δ67­
90)). 
4.5.4.1.1 Aggregation of mPrP(Δ51-89) 
Aggregation reactions with metals were performed as in 4.4.2 and the rate of 
aggregation and maximum fluorescence of each reaction was determined. Linear 
aggregation of mPrP(Δ51-89) with the addition of 100 µM metals is shown in Figure 
4.17A. mPrP(Δ51-89), like mPrP(89-231) lacks the octameric repeat domain, so any 
effect of metals may be due to interactions with the 5th site at residues His95 and 
His110. Aggregation reactions with the addition of copper, manganese, or zinc all 
121 
showed a slight but statistically insignificant decrease in the initial rate of reaction 
when compared to no metal controls (Figure 4.17B). Addition of manganese, copper or 
zinc decreased the maximum fluorescence achieved compared to the no metal control 
but this was not statistically significant (Figure 4.17C). 
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Figure 4.17 Aggregation of mPrP(Δ51-89) aggregation with 100 µM metals as monitored by ThT 
fluorescence. Schematic shows mPrP(Δ51-89) mutation in relation to full length mPrP(23-231). A) 
Representative graph of mPrP(Δ51-89) aggregation with metals. B) Comparison of the rate of aggregation 
with metals to the no metal control show no significant differences. C) Maximal fluorescence reached during 
aggregation with metals compared to no metal control shows no significant differences. Error bars are SEM, 
n=4. 
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End products of aggregation reactions analysed by Western blot with two different anti-
PrP antibodies, ICSM-18 and 8B4 as described in 2.3.13 (Figure 4.18). No high 
molecular weight bands are present which would indicate large oligomeric structures. 
Bands corresponding to a dimer (~38kDa) could be seen in several samples. Overall, 
there was no significant difference between the metal added aggregate products and the 
no metal control. However, smaller PrP fragments were present at 10-12 kDa, as well at 
much smaller sized bands. These fragments may correspond to cleavage products of 
the protein which occurred during aggregation. Furthermore, bands which are larger 
than the monomer (19 kDa) yet smaller than the dimer (38 kDa) were present which 
could be aggregated N-terminal fragments. 
Figure 4.18 Western blots of aggregate end products of mPrP(Δ51-89). A) Western blot with anti-PrP 
antibody ICSM18. B) Western blot with anti-PrP antibody 8B4. Aggregates were analysed after each 
experiment (n=4). In both blots, lane 1 is aggregate with no metal, lane 2 is with 100 µM CuS04, lane 3 is with 
100 µM MnSO4, and lane 4 is with 100 µM ZnCl2. Markers are in kDa. 
4.5.4.1.2 Aggregation of mPrP(Δ67-90) 
mPrP(Δ67-90) aggregation reactions were performed with metals as described in 4.4.2. 
Linear aggregation of mPrP(Δ67-90) with the addition of 100 µM metals is shown in 
Figure 4.19A. Aggregation reactions with the addition of zinc produced data which 
was not able to be analysed and therefore were excluded. Addition of 100 µM copper 
significantly increased the initial rate and maximum fluorescence of the reaction 
(p<0.05). Addition manganese to mPrP(Δ67-90) aggregation reactions caused an 
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Representative graph of mPrP(Δ67-90) aggregation with metals. B) Rate of aggregation with metals 
compared to no metal control. Only the addition of copper caused a significant increase in the rate. C) 
Maximal fluorescence reached during aggregation with metals compared to no metal control. Addition of 
copper but not manganese caused a significant increase in the maximum fluorescence achieved. Error bars 
are SEM, n=4. *p<0.05 
Finally, Western blots with two different anti-PrP antibodies were performed as 
described in 2.3.13 to determine whether there was any difference in the end product 
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between metal added mPrP(Δ67-90) reactions (Figure 4.20). No significant difference 
was seen between the metal and no metal reactions. As with previous blots of mPrP 
aggregates formed with this method, no high molecular weight aggregates were present 
but the blots show smaller PrP fragments. These fragments may correspond to 
cleavage products of the protein which occurred during aggregation. Furthermore, 
bands which are larger than the monomer (20 kDa) yet smaller than dimer (40 kDa) 
were present. These bands may correspond to aggregated N-terminal fragments. 
Figure 4.20 Western blots of aggregate end products of mPrP(Δ67-90). A) Western blot with anti-PrP 
antibody ICSM18. B) Western blot with anti-PrP antibody 8B4. Aggregates were analysed after each 
aggregation experiment (n=4). In both A and B, lane 1 is aggregate with no metal, lane 2 is with 100 µM 
CuS04, lane 3 is with 100 µM MnSO4, and lane 4 is with 100 µM ZnCl2. Markers are in kDa. 
4.5.4.2 Aggregation of mPrP(Δ106-126) with metals 
Aggregation of mPrP(Δ106-126) reactions with metals were performed as previously 
described in 4.4.2. 
Linear aggregation of mPrP(Δ106-126) with the addition of 100 µM metals is shown in 
Figure 4.21A. Aggregation reactions with the addition of CuSO4, MnSO4 and ZnCl2 
tended to increase the initial linear rate compared to the no metal added control (Figure 
4.21B). Although this was statistically insignificant, this trend was seen in every 
experiment. The statistics may not have stacked up as reactions this mPrP construct 
were highly variable in terms of maximum fluorescence. Addition of copper, 
manganese and zinc all caused an increase in the maximum fluorescence reached by the 
aggregation reaction, compared to no metal control, although this trend was not 
statistically significant (Figure 4.21C). 
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Figure 4.21 Aggregation of mPrP(Δ106-126) with the addition of 100 µM metals as monitored by ThT 
fluorescence. The schematic representation of the mutation compared to full length mPrP(23-231) is 
illustrated above. A) Representative graph of aggregation of mPrP(Δ106-126) with the addition of metals. 
Kinetic data: B) Rate of aggregation with metals compared to no metal control shows no significant 
difference. C) Maximal fluorescence reached during aggregation with metals compared to no metal control. 
No significant difference is seen. Error bars are SEM, n=5. 
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Next, end products of aggregation reactions were assessed by Western blots with two 
different anti-PrP antibodies (Figure 4.22). No high molecular weight aggregates were 
present, and there was no difference between the metal added aggregate products and 
the no metal control. The Westerns show PrP fragments at 10-12 kDa, as well as some 
6.5 kDa fragments. These fragments may correspond to cleavage products of the 
protein which occur as the protein is agitated during aggregation. Bands were present 
that correspond to a size that is larger than the monomer (21 kDa) yet smaller than a 
dimer. These could be aggregated N-terminal fragments (Figure 4.223A). This is 
supported by the Westerns with the N-terminal specific antibody, as those bands are not 
present (Figure 4.22B). 
Figure 4.22 Western blots of aggregate end products of mPrP(Δ106-126). A) Western blot with anti-PrP 
antibody ICSM18. B) Western blot with anti-PrP antibody 8B4. In both blots, lane 1 is aggregate with no 
metal, lane 2 is with 100 µM CuS04, lane 3 is with 100 µM MnSO4, and lane 4 is with 100 µM ZnCl2. Markers 
are in kDa. 
4.6 Aggregation of metal binding point mutations of mPrP 
In order to dissect which domain of the protein was responsible for the effect of the 
metals on PrP aggregation several point mutation forms of PrP were used. PrP has 
been shown to bind metals such as copper, manganese, zinc, and nickel, as described in 
1.3.2, and it is through histidine coordination this binding occurs. Therefore site-
directed mutagenesis was used to develop PrP mutant with histidine�alanine 
mutations (Figure 2.2 B). These mutations could therefore be used to determine 
whether the histidines within the octapeptide repeat region or the so-called 5th site 
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region were responsible for the effects seen with metals. Aggregation of each mutant 
mPrP was monitored by ThT fluorescence as described in 2.4.8. 
4.6.1 Computational analysis of metal-binding point mutations 
As determined in section 4.5.1, the WALTZ-predicted amyloidogenic sequences are 
located within the C-terminus of the protein. Next, the PrP mutants were analysed by 
TANGO, an on-line program which predicts the aggregation propensity of a peptide 
sequence. TANGO values predicted the TURN (β-turn propensity) values for 
mPrP(Null) and mPrP(Null+H95, H110) were decreased compared to other PrP (Figure 
4.23). However, there was no difference in the AGG (propensity to aggregate), HELIX 
and HELAGG (helical aggregation propensity). This suggests there should be no 
difference in the propensity of these metal-binding point mutant mPrP aggregation 
reactions. 
Figure 4.23 TANGO-predicted values for metal-binding point mutation mPrP aggregation, compared to wild 
type mPrP(23-231). 
4.6.2 Aggregation of mPrP(Null+H95), mPrP(Null+H110), 
mPrP(Null+H95, H110) and mPrP(Null) 
In order to determine whether the histidine residues involved in metal binding are 
essential for metal-mediated effects on aggregation, the mutant mPrP(Null), which has 
all histidine within the octameric repeat region and the 5th site binding region mutated 
to alanines, was used. In mPrP(Null), mPrP(Null+H110A), mPrP(Null+H95A) and 
mPrP(Null+H95, H110) reactions, no fluorescence signal was detected beyond that of 
the blank which indicates this protein did not aggregate in any reaction, Raw 
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fluorescence data for mPrP(Null) aggregation reaction is shown in Figure 4.24 and no 
signal above the blank is detected. 
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Figure 4.24 Representative aggregation reaction of mPrP(Null) monitored by ThT fluoresescence. The 
schematic shows the point mutations relative to wild type mPrP(23-231). No fluorescence is dectected at levels 
above that of the dye alone blank. 
4.6.3 Aggregation of mPrP(H95A+H110) 
Next, the aggregation of the metal-binding mutant mPrP(H95A+H110A) was examined 
to determine whether this mutant protein could aggregate and whether absence of the 
5th site produced any metal-induced effect on aggregation of mPrP. Aggregation 
reactions were performed as described in 2.4.8. First, the linear rate of aggregation and 
maximum fluorescence achieved was determined without metals added, and compared 
to the full length mPrP (Figure 4.25A). Both the initial rate and maximum fluorescence 
were decreased compared to full length mPrP although this was not statistically 
significant (Figure 4.25 B,C). Data from mPrP(H95A+H110A) reactions was very 
variable and difficult to analyse. This protein is more difficult to prepare and has a 
tendency to precipitate during purification. 
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Figure 4.25 Rate and maximum fluorescence of no-metal mPrP(H95A+H110A) aggregation as monitored by 
ThT fluorescence. A) Rate of aggregation of point mutation mPrP(H95A+H110A) compared to full length 
mPrP(23-231) shows no significant differences. B) Maximum fluorescence of point mutation 
mPrP(H95A+H110A) compared to full length mPrP(23-231) is not significantly different. Error bars are ± 
SEM, n=4. 
Next, to assess the effect of metals on mPrP(H95A+H110A) aggregation, CuSO4 and 
MnSO4 buffered in 10 mM sodium phosphate at pH 7.4 were added for a final metal 
concentration of 50 µM. Aggregation reactions were performed as described in 2.4.8. 
Results from aggregation reactions with 50 µM metals were highly variable and were 
not able to be analysed and are not included. 
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End products of mPrP(23-231) and mPrP(H95A+H110) aggregation reactions were 
analysed by Western blot as in 2.3.13 to determine whether there was any difference in 
the end product between mutants (Figure 4.25). Neither aggregation reaction showed 
high molecular weight aggregates which would indicate fibrils and/or amorphous 
aggregates, although 10-12 kDa PrP fragments were present. This suggests that 
aggregation of these mutants under these reaction conditions form β-sheet-rich PrP 
structures which do not lead to large ordered aggregates. 
Figure 4.26 Western blot analysis of aggregation end products without metals. All blots were probed with 
anti-PrP antibody ICSM18. A) mPrP(23-231) and B) mPrP(H95A+H110A). 
4.7 Conclusion and Discussion 
In this study a method was developed to assess the aggregation of mPrP under 
conditions more representative of physiological conditions than previously published 
aggregation studies (Baskakov et al., 2001, Baskakov and Bocharova, 2005; Bocharova 
et al., 2005a,b) and determine whether the addition of copper, manganese, or zinc 
played any role in the aggregation. 
Aggregation of mPrP mutant protein showed no significant differences when compared 
to full length mPrP under the conditions developed for this assay. Specifically, shorter 
mPrP constructs did not differ in rate of aggregation or the extent of β-sheet content 
compared to full length mPrP. These results do not completely align with the predicted 
aggregation propensity obtained from the online program TANGO as mPrP(Δ106-126) 
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was predicted to have a decreased aggregation propensity compared to full length 
mPrP(23-231). 
Aggregation of mPrP with metal binding point mutations, in contrast to full length 
mPrP control, yeilded unexpected results. The online program WALTZ predicted 
amyloidogenic sequences of PrP were all C-terminal, suggesting that there would be no 
direct effect with N-terminal alterations. Additionally, the TANGO-predicted 
aggregation propensity was the same between wild type and point mutation mPrP. 
However under the conditions used here, mPrP(Null), mPrP(Null+H95A), 
mPrP(Null+H110A) and mPrP(Null+H95, H110) did not aggregate. Disagreement 
between predicted and observed aggregation propensities may be explained by the fact 
that online computations consider only amino acid sequence, and therefore any 
structural instability of the folded protein would not be taken into account. 
Furthermore, online prediction programs assume 100% protein purity which is difficult 
to achieve when working with a highly insoluble protein like PrP. mPrP(Null), in 
particular, was found to be quite unstable and degraded quickly. Additionally 
mPrP(H95A+H110A) is very difficult to purify and solubilise and tends to precipitate 
quickly. Data obtained from this mPrP was highly variable. These factors could have 
contributed to the differences between predicted and experimental results. 
Under neutral aggregation conditions, the addition of metals to full length mPrP and 
various mutants did not show any significant alterations to how quickly the aggregation 
occurred (linear rate), or to the accumulation of β-sheet content (maximum 
fluorescence, a parameter to measure extent of aggregation) during the reaction 
compared to a no metal control. No significant effect of metals was seen with the 
mutant lacking the octameric repeat region, mPrP(Δ51-89) and while the trend of 
metals increasing mPrP(Δ106-126) aggregation was seen in all experiments, it was not 
statistically significant. 
However addition of manganese to mPrP(89-231) caused a statistically significant 
increase in the initial rate and maximum fluorescence achieved by the reaction. No 
significant effect was seen with either copper or zinc. According to recently published 
data, mPrP(89-231) has only one high affinity binding site for manganese, residue 
His95 (Brazier et al., 2008). Metal binding sites are influenced by fragment length 
(Klewpatinond and Viles, 2007) and it may be that manganese interacts with this 
binding differently to the full length protein. This would also explain the differences 
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seen between the full length protein and with the mutant mPrP(Δ51-89), which also 
lacks any octameric repeat binding regions for manganese. It is possible that the 
additional residues 23-50 influence the manner in which manganese would interact 
with the high affinity binding site centred on residue His95. 
Copper addition to mPrP(Δ67-90) significantly increased the initial rate of aggregation 
as well as the maximum fluorescence achieved by the reaction relative to the no metal 
control. No effect was seen with manganese addition. mPrP(Δ67-90) lacks all but one 
of the octameric repeats and in theory would be able to bind 2-3 coppers – one within 
the octameric repeat and 1-2 copper ions within the “5th site” region involving 
histidines 95 and 110. This protein alone showed a promotional effect with copper. 
These data may suggest that a different metal-protein interaction will be observed when 
the 5th site region is alone (as in mPrP(Δ51-90)) and when it is present with the full 
complement of octameric repeats. It may be that the 5th site acts in concert with the 
octameric repeats to maintain normal interactions with respect to metals (as with wild 
type protein) but alterations to the 5th site –octameric repeat partnership result in 
variable metal-induced effects. Also, it may be that a completely different binding 
geometry and therefore N-terminal structure is generated upon copper interacting with 
mPrP(Δ67-90) and is responsible for the promotional effect seen on aggregation. 
Several factors may have contributed to the differences in results for metals and PrP 
aggregation observed here and in comparison to those seen in previously published 
work. Many methods used to study PrP aggregation require low pH and denaturing 
materials (Jackson et al., 1999a,b; Baskakov et al., 2001; Martins et al., 2006). Low 
pH conditions mimic those of the lysosome/early endosome, which are proposed sites 
for prion conversion (Caughey, 1991). The concentration of the denaturant guanidine 
hydrochloride, which is a common reagent in recombinant PrP aggregation assays, 
influences not only the kinetics of PrP aggregation but also has profound effects on the 
structure of PrP both in solution and as aggregated products (Polano et al., 2009). It is 
known from PrP trafficking studies that the protein it is naturally exposed to neutral pH 
as well. Not only is it unlikely denaturing reagents would be present at those 
concentrations in vivo, it is important to consider the interaction between metals and 
denatured PrP is very different from the interaction of metals and re-natured PrP in a 
native-like state at neutral pH. It has not been demonstrated how PrP associates with 
metals under conditions presented by Baskakov et al., whereas the association between 
metals and PrP at neutral conditions has been well described (Jackson et al., 2001; 
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Davies et al., 2009). The discrepancy between the results presented here to those seen 
in previously published work can be attributed to differences in protein preparation , 
purification, and different reaction conditions.It is thought ThT binds within cavities 
between β-sheets (Groenning et al., 2007a, b), however there is no evidence indicating 
whether it only binds to fibril structures and not amorphous β-sheet-rich oligomers. 
The results in this chapter suggest the aggregates formed under these conditions contain 
β-sheet structures but are not fibrils. This is evidenced by the TEM data for mPrP(23­
231) which did not show any fibril structures and the Western blot analysis which does 
not show any high molecular weight aggregates. Recently it has been shown that 
decreasing concentrations of denaturant cause more globular aggregate structures to 
form, in contrast to the mature amyloid fibrils formed with high (2M) concentrations of 
denaturant (Polano et al., 2009). Therefore these aggregates produced in the absence of 
denaturants may be predisposed to form amorphous structures. 
PrP is thought to have self-catalytic properties and it has previously been demonstrated 
that aggregates formed in vitro are capable of conferring conformational change onto 
monomeric proteins, or “seeding” (Colby et al., 2007; Baskakov, 2004; Bocharova et al 
2005a). In this study since the end products of aggregation reactions were unable to 
influence initial rate of aggregation, it suggests that the products formed under these 
specific conditions have very little, if any, self-propagation propensity. 
In all mPrP constructs Western blot analysis did not show significant amounts of higher 
molecular weight aggregates, although some dimers were seen in the N-terminally 
truncated mutant mPrP(89-231) and in the deletion mutants mPrP(Δ51-90) and 
mPrP(Δ67-90). Bands which were larger than the monomer yet smaller than the 
predicted dimer size were seen in Westerns using a C-terminal antibody. With both 
this antibody and an N-terminal specific antibody, smaller fragments were seen which 
likely correspond to cleaved N-terminal products. Cleavage of the prion protein has 
been shown to occur in vivo (Pan et al., 1992; Shyng et al., 1993; Jimenez-Huete et al., 
1998; Nieznanski et al., 2005). The results therefore suggest one of two possibilities. 
The first is that PrP forms β-sheet-rich structures which are smaller, possibly 
amorphous structures which may not be stable and do not survive SDS-PAGE analysis. 
The second possibility is that these results show the products of a PrP cleavage event 
acquire β-sheet structure over time but do not necessarily aggregate. TEM images of 
mPrP(23-231) in this work confirmed the absence of large fibril structures that have 
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been reported by other groups (Baskakov and Bocharova, 2005; Bocharova et al., 
2005a). 
To fully determine the role of metals in PrP aggregation, further experiments are 
necessary. As previously mentioned, differences and variability seen in this assay 
could be attributed to protein purification. PrP is highly insoluble and difficult to 
further purify. It does not respond well to futher purification treatments such as FPLC. 
Alternatively, circular dichromism could be utilised to determine the starting structure 
for each batch of protein used, which would provide insight into which starting 
conformations form more highly β-sheet end products. Attempts to further optimise the 
system by using different controls could lead to the generation of more consistent data. 
For example, performing the experiments with a known pro-aggregation peptide such 
as PrP106-126 as well as a proper negative control (e.g., a protein similar in size to 
PrP) could have helped to optimise the system more fully. Furthermore, overloading 
the system (using much higher concentration of protein and/or metals) could have more 
substantially confirmed the effects seen. Separation of the fragments via size exclusion 
techniques would allow for imaging studies (TEM, FTIR) to be performed on each 
fragment to determine the structure and the effect metals may have on this aggregation. 
Another alternative is that the main influence on PrP conversion is not metals but 
glycosaminoglycans. To determine whether this is the case, the next step would require 
investigating the role of GAGs in cellular prion infection (as in Chapter 3) and the 
aggregation method developed in this chapter. 
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5. Glycosaminoglycans	 in PrP aggregation and 
cellular infection 
5.1 Introduction 
Glycosaminoglycans (GAGs) are a group of compounds which are produced by most 
cells and include heparan sulphates, keratin sulphates, dextran sulphates, and 
chondroitin sulphates. The structure of these compounds consists of long chains of 
repeating disaccharide units, and they are divided into classes based on these 
disaccharide chain units and degree of sulphation. The molecules can vary 
significantly in size, charge distribution, and fine structure (Lander, 1994). Heparin, a 
highly sulphated version of heparan sulphate, is a well known protein binding partner 
which has been shown to bind to a variety of proteins that participate in 
anticoagulation, cell adhesion, and cell proliferation. In addition, heparin and heparan 
sulphate binding have been implicated in disease-associated processes, including aiding 
viral entry into cells and amyloid P plaque assembly (Capila and Linhardt, 2002). 
There is evidence that GAGs play a role in prion disease, as detailed in 1.5.5.2. 
Furthermore, it has been shown that recombinant, brain-derived, and mammalian cell-
derived PrPC have each been shown to bind to GAGs, particularly heparin and heparan 
sulphate (Brimacombe et al., 1999; Pan et al., 2002; Warner et al., 2002; Gonzalez-
Iglesias et al., 2002). The biological relevance for PrP binding heparin is unclear. It 
has been demonstrated that endogenous GAG expression is required for disease 
progression (Horonchik et al., 2005) and GAGs can stimulate the conversion of PrP to 
a resistant form of PrP (Wong et al., 2001; Deleault et al., 2005; Kajnert et al., 2006); 
in contrast, however, it has also been shown that the addition of exogenous GAGs can 
delay onset of disease in animal models and clear PrPSc from cell culture models 
(Caughey and Raymond, 1993; Gabizon et al., 1993; Ehlers and Diringer, 1984; 
Kimberlin and Walker, 1986). The most potent of these compounds are chemically 
modified high molecular weight dextran sulphate or heparin mimetics. In cells, these 
anti-prion compounds prevented uptake of infectivity and limited endocytosis of PrPC 
(Schonberger et al., 2003; Horonchik et al., 2005). 
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Heparin binding studies with recombinant hamster, human and bovine PrP all indicate 
the main binding regions are located in the N-terminal region of the protein. This 
region of the protein is flexible and lacks definitive structure, and has a number of basic 
residues. Previously studies using molecular modelling have shown the motif 
XBBBXXBX (where X denotes a non-basic residues and B a basic residue) on the face 
of α-helix and a second motif XBBXBX on β-strand were common motifs in heparin 
binding (Cardin and Weintraub, 1989). Specific spatial orientation of basic residues is 
required for heparin binding, with high affinity binding occurring when basic residues 
are 20 Ǻ apart from opposite faces of a β-strand and a α-helix (Margalit et al., 1993). 
Further study of the spacing of basic residues in relation to binding affinity in known 
heparin-binding proteins showed the most common spacing pattern found included a 
single non-basic residue between clusters of basic residues (BXB/BXB), and a second 
pattern of two non-basic residues between each basic residue cluster (BXXB). Clusters 
containing up to three residues is common, and spacing patterns of up to five but no 
more than seven non-basic residues between basic residues has been seen (Fromm et 
al., 1997). Previous studies examining the binding of GAGs to PrP have used primarily 
biosensor or ELISA techniques to measure the binding to either peptides or his-tagged 
protein. 
Previous heparin-PrP binding studies have been done using ELISA, biosensor, and 
fluorescent polarisation techniques and using either histidine tagged recombinant 
protein or peptides. As heparin binding is known to involve basic residues, the use of 
histidine tagged protein is not ideal. Furthermore, binding effects seen with short 
peptides may not occur with full length protein. Therefore heparin binding to mPrP 
was studied using isothermal titration calorimetry (ITC), a method which measures the 
changes in enthalpy caused by the interaction of two molecules in solution. This work 
will study the effects of heparin and mPrP binding, aggregation, and cellular infection 
to determine whether heparin is a promotional or inhibitory molecule in prion 
pathogenesis. 
5.2 Heparin binding to mPrP 
Binding studies were performed on deletion and truncation mutant PrP to determine 
which parts of N-terminal domain of PrP is essential to heparin binding. mPrP(Δ51-89) 
and mPrP(89-231) were used to determine what difference in binding the presence of a 
single heparin binding motif in the N-terminal region, at residues 23-27 (KKRPK). 
The full length mPrP(23-231) construct was used as a control. Figure 5.1 illustrates 
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previously published heparin binding regions on PrP overlaid on the mPrP constructs 
used in this work. 
A 
23-231

89-231

Δ51-89

---------------------MKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQGGTWGQPH 
------------------------------------------------------------
---------------------MKKRPKPGGWNTGGSRYPGQGSPGGNR-----------­
23-231 GGGWGQPHGGSWGQPHGGSWGQPHGGGWGQGGGTHNQWNKPSKPKTNLKHVAGAAAAGAV 
89-231 ----------------------------MQGGGTHNQWNKPSKPKTNLKHVAGAAAAGAV 
Δ51-89 ---------------------------YPPGGGTHNQWNKPSKPKTNLKHVAGAAAAGAV 
23-231

89-231

Δ51-89

VGGLGGYMLGSAMSRPMIHFGNDWEDRYYRENMYRYPNQVYYRPVDQYSNQNNFVHDCVN 
VGGLGGYMLGSAMSRPMIHFGNDWEDRYYRENMYRYPNQVYYRPVDQYSNQNNFVHDCVN 
VGGLGGYMLGSAMSRPMIHFGNDWEDRYYRENMYRYPNQVYYRPVDQYSNQNNFVHDCVN 
23-231 ITIKQHTVTTTTKGENFTETDVKMMERVVEQMCVTQYQKESQAYYDGRRSS-­
89-231 ITIKQHTVTTTTKGENFTETDVKMMERVVEQMCVTQYQKESQAYYDGRRSS-­
Δ51-89 ITIKQHTVTTTTKGENFTETDVKMMERVVEQMCVTQYQKESQAYYDGRRSS-­
B 
23-231 ---------------------XBBBXBXXXXXXXXXBXXXXXXXXXXBXXXXXXXXXXXB 
89-231 ------------------------------------------------------------
Δ51-89 ---------------------XBBBXBXXXXXXXXXBXXXXXXXXXXB-----------­
23-231 XXXXXXXBXXXXXXXBXXXXXXXBXXXXXXXXXXBXXXXBXXBXBXXXBBXXXXXXXXXX 
89-231 ----------------------------XXXXXXBXXXXBXXBXBXXXBBXXXXXXXXXX 
Δ51-89 ---------------------------XXXXXXXBXXXXBXXBXBXXXBBXXXXXXXXXX 
23-231

89-231

Δ51-89

XXXXXXXXXXXXXXBXXXBXXXXXXXBXXBXXXXBXXXXXXXBXXXXXXXXXXXXBXXXX 
XXXXXXXXXXXXXXBXXXBXXXXXXXBXXBXXXXBXXXXXXXBXXXXXXXXXXXXBXXXX 
XXXXXXXXXXXXXXBXXXBXXXXXXXBXXBXXXXBXXXXXXXBXXXXXXXXXXXXBXXXX 
23-231 XXXBXBXXXXXXBXXXXXXXXXBXXXBXXXXXXXXXXXBXXXXXXXXBBXX-­

89-231 XXXBXBXXXXXXBXXXXXXXXXBXXXBXXXXXXXXXXXBXXXXXXXXBBXX-­

Δ51-89 XXXBXBXXXXXXBXXXXXXXXXBXXXBXXXXXXXXXXXBXXXXXXXXBBXX-­

Figure 5.1 Heparin binding of mPrP deletion and truncation mutations overlaid with previously published 
heparin binding regions. Red box = binding sites from Warner et al 2002, blue underline= binding sites from 
Pan et al 2002. A) Basic residues are highlighted in light blue. B) All residues are labelled basic (B) or non-
basic (X). Heparin binding motifs are highlighted in light blue. 
5.2.1 ITC binding results for mPrP(23-231) 
Experiments were performed in at least triplicate with a MicroCal VP-ITC as described 
in 2.4.10. Briefly, as the protein molecules bound heparin molecules, energy of 
binding is measured as a temperature change relative to reference cell. The energy 
change is then plotted against the concentration of the system (calculated from the 
initial input into the program) and a binding isotherm is produced. Each experiment is 
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repeated with a minimum of three independently refolded protein preparations. By 
experimentally fitting binding models to the isotherm within the MicroCal Origin 5.0 
software, the number of binding sites and relative binding affinities can be calculated. 
Trial and error (judging best fit as the lowest χ2 value) determined that a sequential 
binding model was the best fit. Details of the binding model are found in 2.4.10.2.2. 
Briefly, in the sequential model, there is no distinction as to which sites are saturated, 
but only the total number of sites that are saturated. If the sites are identical in terms of 
affinity, then there is a statistical degeneracy associated with the sequential saturation 
since the first ligand to bind has more empty sites of the same kind to choose from than 
does the second ligand and the second ligand has more sites to choose from than does 
the third, and so forth. For identical interacting sites then, the phenomenological 
binding constants Ki and the intrinsic binding constants Kio can be distinguished where 
the effect of the statistical degeneracy has been removed. The data is then presented (in 
the program) as molar stability constants (log Ka) and useful information extrapolated. 
Therefore each isotherm obtained was fitted to a sequential binding model, and the 
model which had the lowest χ2 value was taken as the best fit. Isotherms obtained from 
mPrP(23-231) binding heparin over a 1:20 molar ratio best fit a four-site sequential 
binding model. The percentage difference χ2 value in binding models was 17% and 
39% between a three- and five-site binding model and the four-site model. A 
representative binding isotherm is shown in Figure 5.2. All binding isotherms are 
representations of the energy change of the system, where the top graph represents the 
energy change as a function of time and the bottom graph plots the energy change 
relative to the molarity of the system. 
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Figure 5.2 Representative ITC binding isotherm for mPrP(23-231) and heparin. mPrP(23-231) was injected 
into the cell containing a molar excess amount of heparin. All experiments (n=8) were performed at pH 7.4 
and 25°C, and data are presented as blank subtracted and fit to a four-site binding model. The top graph 
represents energy change as a function of time, and the bottom graph represents energy change as a function 
of molarity. 
The log Ka for each site was calculated and the log Ka values for each site from each 
independent experiment were averaged. All stability constants (K values) were within 
8% of the mean, and are summarised in Table 5.1. Affinity values are calculated from 
the log Ka values by inversion (e.g. 1/log Ka = M). For the first three binding sites range 
from 10 to 100 nanomolar, with the fourth site is lower affinity and has a range of 1-10 
micromolar. The only previously published heparin binding affinity for PrP was also in 
the 10-100 nanomolar range, which is in agreement with these data (Andrievskaia et 
al., 2007 
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Log K1 Log K2 Log K3 Log K4 % Error between 
M-1 M-1 M-1 M-1 
K values 
mPrP(23-231) 7.48 7.43 7.01 5.90 8 
mPrP(Δ51-89) 11.7 6.53 6.03 N/A 1

mPrP(89-231) 6.89 6.97 N/A N/A 24 
mPrP(Null) 6.25 5.78 4.28 2.07 7

Cu-loaded mPrP(23-231) 4.85 4.91 5.02 5.01 21 
Table 5.1 Log Ka and number of binding sites for mPrP binding to heparin. All values are averaged from 
each independent experiment and are in M-1 . Wild type (mPrP(23-231)) data are averaged across all 
experiments performed and used for comparative purposes. 
5.2.2 ITC binding results for mPrP(Δ51-89). 
Experiments were performed and analysed as in 5.2.1. Heparin binding isotherms 
obtained from mPrP(Δ51-89) did not fit a four site sequential binding model. The best 
fit was obtained with a three-site model and a representative isotherm is shown in 
Figure 5.3. The percentage difference between the three site model and either a two- or 
four-site sequential binding models was 69% and 2% respectively. However, the three 
site binding model had a lower relative error within the data and therefore was chosen 
as the best fit. The reduced binding capacity is further demonstrated by the different 
shape of the curve of the binding isotherm compared to the isotherm produced with 
mPrP(23-231) (Figure 5.5). The log Ka was calculated for each of the three binding 
sites and the values averaged (n=4). All K values were within 1% of the mean and are 
listed in Table 5.1. 
In addition to have one less binding site than mPrP(23-231), the affinity values for 
heparin binding to mPrP(Δ51-89) were altered, with one high (1-10 femtomolar range) 
affinity site, and the second and third site having affinity values in the 100 nanomolar 
and 1-10 micromolar range respectively. These data suggests that without the 
octameric repeat, the number and nature of heparin binding sites are altered. 
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Figure 5.3 Representative ITC binding isotherm for heparin binding to mPrP(Δ51-89). Recombinant 
mPrP(Δ51-89) was injected into the cell containing a molar excess amount of heparin. All experiments (n=4) 
were performed at pH 7.4 and 25°C, and data are presented as an energy value. Data presented as blank 
subtracted and fitted to a three site binding model. The top graph represents energy change as a function of 
time, and the bottom graph represents energy change as a function of molarity. 
5.2.3 ITC binding results for mPrP(89-231) 
ITC binding experiments were performed and analysed as in 5.2.1. In contrast to 
mPrP(23-231) and mPrP(Δ51-89), heparin binding isotherms obtained from mPrP(89­
231) did not fit a four site sequential binding model, nor did it fit a three site model. 
The best fit was obtained with a two-site sequential binding model, shown in Figure 
5.4. The percentage difference between two- or four-site sequential binding models was 
30% and 8% respectively. 
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Figure 5.4 Representative heparin binding isotherm for mPrP(89-231). Data are shown as blank subtracted 
and fit to the appropriate binding model. As with the previous isotherms, the data are presented as energy 
values as a function of time (top graph) or as a function of molarity of the system (bottom graph). 
Experiments were performed at pH 7.4 and 25°C, n=3. 
The log Ka was calculated for each site (error between K values did not exceed 24%) 
and averaged from three independent experiments. Values are summarised in Table 5.1. 
Truncation of the N-terminal region to residue 90 results in reduced heparin binding, as 
binding affinities for each site were within the 100 nanomolar and 1-10 micromolar 
range respectively. Reduced binding is further evidenced by the very different shape of 
the isotherm produced with mPrP(89-231) binding heparin. The curve was very 
different to those produced from both mPrP(23-231) and mPrP(Δ51-89). A comparison 
of each of the binding curves produced from these proteins is shown in Figure 5.5. 
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Figure 5.5 Comparison of binding isotherms of mPrP(23-231), mPrP(Δ51-89) and mPrP(89-231). Red = 
mPrP(23-231), green = mPrP(Δ51-89) and blue = mPrP(89-231). Each isotherm shows a binding experiment, 
with the background subtracted, at 1:20 molar ratio mPrP:heparin and is plotted as energy change as a 
function of the molarity of the system. All experiments were performed at 25C and pH 7.4 and all protein 
purified using the exact same method. 
Taken together, these data suggest that wild type mPrP(23-231) has four heparin 
binding sites, and the N-terminal region (to residue 89) is responsible for at least two 
heparin binding regions, one of which is located between residues 23 and 51. This 
binding region is likely to be centred on the heparin binding motif KKRPK at residues 
23-27, as loss of the octameric repeat region resulted in a reduced number of heparin-
binding sites but a higher affinity for one of the remaining sites whereas truncation of 
the N-terminus to residue 89 results in loss of the higher affinity site. In addition the 
binding models, the isotherms produced by mPrP(Δ51-89) and mPrP(89-231) are 
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different to mPrP(23-231) even though all constructs were tested under the same PrP: 
heparin molar ratio (Figure 5.6). 
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5.2.4 Heparin binding to mPrP(H95A+H110A) and mPrP(Null) 
The effect of basic to non-basic single amino acids substitutions in the N-terminus of 
PrP on binding of heparin to mPrP was studied to determine whether alteration of the 
histidine residues would affect heparin binding. Experiments were performed with 
mPrP(H95A+H110A) to assess the role of the “5th site” histidine residues. mPrP(Null) 
was used to determine whether the loss of histidine residues of the N-terminus has any 
effect on the binding of heparin to mPrP. All binding experiments were compared to 
the relative control mPrP(23-231). Figure 5.6 shows previously published heparin 
binding regions on PrP overlaid on the mPrP constructs used in this work. 
A 
23-231 MKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQGGTWGQPHGGGWGQPHGGSWGQPHGGSWG 
H95A+H110A MKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQGGTWGQPHGGGWGQPHGGSWGQPHGGSWG 
Null MKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQGGTWGQPAGGGWGQPAGGSWGQPAGGSWG 
23-231 QPHGGGWGQGGGTHNQWNKPSKPKTNLKHVAGAAAAGAVVGGLGGYMLGSAMSRPMIHFG 
H95A+H110A QPHGGGWGQGGGTANQWNKPSKPKTNLKAVAGAAAAGAVVGGLGGYMLGSAMSRPMIHFG 
Null QPAGGGWGQGGGTANQWNKPSKPKTNLKAVAGAAAAGAVVGGLGGYMLGSAMSRPMIHFG 
23-231 
H95A+H110A 
Null 
NDWEDRYYRENMYRYPNQVYYRPVDQYSNQNNFVHDCVNITIKQHTVTTTTKGENFTETD 
NDWEDRYYRENMYRYPNQVYYRPVDQYSNQNNFVHDCVNITIKQHTVTTTTKGENFTETD 
NDWEDRYYRENMYRYPNQVYYRPVDQYSNQNNFVHDCVNITIKQHTVTTTTKGENFTETD 
23-231 
H95A+H110A 
Null 
VKMMERVVEQMCVTQYQKESQAYYDGRRS 
VKMMERVVEQMCVTQYQKESQAYYDGRRS 
VKMMERVVEQMCVTQYQKESQAYYDGRRS 
B 
23-231 XBBBXBXXXXXXXXXBXXXXXXXXXXBXXXXXXXXXXXBXXXXXXXBXXXXXXXBXXXXX 
H95A+H110A XBBBXBXXXXXXXXXBXXXXXXXXXXBXXXXXXXXXXXBXXXXXXXBXXXXXXXBXXXXX 
Null XBBBXBXXXXXXXXXBXXXXXXXXXXBXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX 
23-231 XXBXXXXXXXXXXBXXXXBXXBXBXXXBBXXXXXXXXXXXXXXXXXXXXXXXXBXXXBXX 
H95A+H110A XXBXXXXXXXXXXXXXXXBXXBXBXXXBXXXXXXXXXXXXXXXXXXXXXXXXXBXXXBXX 
Null XXXXXXXXXXXXXXXXXXBXXBXBXXXBXXXXXXXXXXXXXXXXXXXXXXXXXBXXXBXX 
23-231 XXXXXBXXBXXXXBXXXXXXXBXXXXXXXXXXXXBXXXXXXXBXBXXXXXXBXXXXXXXX 
H95A+H110A XXXXXBXXBXXXXBXXXXXXXBXXXXXXXXXXXXBXXXXXXXBXBXXXXXXBXXXXXXXX 
Null XXXXXBXXBXXXXBXXXXXXXBXXXXXXXXXXXXBXXXXXXXBXBXXXXXXBXXXXXXXX 
23-231 XBXXXBXXXXXXXXXXXBXXXXXXXXBBX

H95A+H110A XBXXXBXXXXXXXXXXXBXXXXXXXXBBX

Null XBXXXBXXXXXXXXXXXBXXXXXXXXBBX

Figure 5.6. Heparin binding of mPrP histidine to alanine mutations overlaid with previously published 
heparin binding regions. Red box = binding sites from Warner et al 2002, blue underline = binding sites from 
Pan et al 2002. A) Basic residues are highlighted in light blue. B) All residues are labelled basic (B) or non-
basic (X). Heparin binding motifs are highlighted in light blue. 
The binding of heparin to mPrP(H95A+H110A) was analysed as in 5.2.1.1. The results 
showed a very different binding curve when compared to mPrP(23-231). The best 
binding isotherms were produced with a 1:4 molar ratio of PrP: heparin. These results 
fitted poorly to single or sequential binding site models, but the lowest chi-squared 
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value was obtained by fitting a sequential 2-site binding model, which had 17% and 
22% difference between one- and three- site sequential binding models respectively. 
However, the experiments proved more variable than the mPrP(23-231), and despite 
repeating the experiments several (n=4) times only limited data was produced and can 
be considered preliminary at best. There was evidence of precipitation of the protein 
during the experiments, which affected the reproducibility of the data and 
thermodynamic calculations, and resulted in affinity values which ranged over nine 
orders of magnitude. An example isotherm is shown in Figure 5.7. 
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Figure 5.7 ITC isotherm of heparin binding to mPrP(H95A+H110A). All experiments were performed at 
25°C and pH 7.4; however limited data was produced due to variability in protein stability and repeated 
precipitation during the experiments. All values are presented as energy change over time (top) and energy 
change as a function of molarity (bottom). 
Next, the binding of heparin to mPrP(Null) was analysed as in 5.2.1.1. . The results 
showed a very different binding curve was produced (Figure 5.8) when compared to 
mPrP(23-231) and mPrP(H95A+H110A). Although this data fit best to a sequential 
four-site binding model, similar to mPrP(23-231), with a difference of 6.7% and 2.2% 
between three- and five-binding site models. Error between K values did not exceed 
7%, and log Ka data (mean values from n=4) are summarised in Table 5.1. 
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As with mPrP(23-231), three of the binding sites had affinity values within the 100 
nanomolar range, and the fourth site was of a lower 1-10 micromolar range. These 
values are not significantly different to those of mPrP(23-231) despite the fact 
mPrP(Null) has six N-terminal histidine residues replaced by alanines. 
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Figure 5.8 Representative ITC isotherm of mPrP(Null) binding to heparin sodium sulphate. Data are blank 
subtracted and fitted to a four-site sequential binding model. All experiments (n=4) were performed at 25°C 
and pH 7.4. Data are expressed as energy change as a function of time (top) or molarity of the system 
(bottom). 
Analysis of the charge distribution of these proteins was performed using the online 
program Mobyle and is shown in Figure 5.9, with areas of interest in the N-terminus 
circled in red and green. These ITC results therefore show that altering the charge 
pattern of the N-terminus due to replacement of histidine residues with alanine residues 
is not sufficient to abolish heparin binding altogether. 
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mPrP(23-231) mPrP(H95A+H110A) 
mPrP(Null) 
Figure 5.9 Charge distribution of mPrP(23-231), mPrP(H95A+H110A) and mPrP(null). Sequences were 
analysed by the online program Mobyle and are represented graphically as charge per amino acid residue. 
Red and green circles show areas where charge distribution is altered compared to the wild type. 
5.2.5 Effect of copper on heparin binding to mPrP 
Previously published studies indicate metals can modulate or effect the interaction of 
PrP with GAG, either by formation of stabilising bridges with copper ions, or by 
directly affecting the nature of binding (Brimacombe et al., 1999; Gonzalez-Iglesias et 
al., 2002; Pan et al., 2002; Warner et al., 2002). Copper and GAGs bind in the same 
region of PrP, which suggests metals and GAGs may interact with each other as well as 
with PrP. Therefore, experiments were performed using protein which had been loaded 
with copper. Previously published work has shown copper-loaded PrP prepared in this 
manner has an increased β-sheet content compared to PrP prepared in the absence of 
metals (Wong et al., 2000). 
Experiments were performed and analysed as in 5.2.1.1.copper-loaded mPrP(23-231) 
showed a similarity in the curve of the isotherm (Figure 5.10), as well as the number of 
heparin binding sites when compared to the no metal mPrP(23-231). As with the wild 
type, Copper-loaded mPrP(23-231) data fit best to a sequential four-site binding model, 
with a difference of 8.9% and 25% between three- and five-binding site models 
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respectively. All data were within 21% error, with log Ka data for copper-loaded 
mPrP(23-231) compared to the averaged wild type data are summarised in Table 5.1. 
Figure 5.10 Effect of copper on heparin binding to mPrP(23-231). A) mPrP(23-231) without copper (n=8). 
B) mPrP(23-231) loaded with copper (n=3). All data are presented as blank subtracted energy values plotted 
against time (top graph) or as a function of the molarity of the system (bottom graph). All experiments were 
performed at 25°C and pH 7.4. 
The affinity values for the first and second binding site in copper-loaded mPrP(23-231) 
are within the 10-100 micromolar range, and the last site has an affinity in the 1-10 
micromolar range. The affinity values are less than those of mPrP(23-231) with no 
metal bound, which has affinity values within the 10-100 nanomolar range for the 
higher affinity sites and 1-10 micromolar range for the lower affinity site. These data 
suggest that when copper is bound to PrP, the protein is still able to interact with GAGs 
but the interaction is weakened. This is in agreement with previously published studies 
which show copper does not abolish GAG-PrP binding (Pan et al., 2002; Warner et al., 
2002) and with data that indicates copper weakens the heparin-PrP complex 
(Andreivskaia et al., 2007). 
151 
5.2.6 Binding of other glycosaminoglycans to mPrP 
PrP has been shown to bind other GAGs as well (Brimacombe et al., 1999; Pan et al., 
2002; Warner et al., 2002). Dextran sulphate and in particular high MW dextran 
sulphate, has been shown to delay the onset of disease symptoms in animals infected 
with prion disease (Kimberlin and Walker, 1986). It may be that a difference in 
dextran sulphate and heparin binding to PrP could provide insight as to the 
contradictory effects of GAGs in prion disease. 
ITC binding experiments were performed in at least triplicate as described in 5.2.1.1 
except low molecular weight dextran sulphate was used as the ligand. 
Unfortunately ITC binding analyses of low-molecular weight dextran sulphate and 
mPrP(23-231) produced data which proved even more difficult to analyse than that for 
heparin binding. None of the sequential site binding models would fit the data, so 
binding models commonly used for pharmaceutical interactions were tested. These 
more complex models did not fit the data. The same was true with the isotherms from 
mPrP(H95A+H110A) binding experiments. Representative binding isotherms are 
shown in Figure 5.13 where, as previously, energy change is plotted as a function of 
time or system molarity. These data indicate the nature of the interaction of these 
compounds and mPrP is too complex to be measured by ITC and other methods would 
need to be used to fully understand these interactions. 
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Figure 5.11 Representative ITC isotherms of dextran sulphate binding to mPrP. A) mPrP(23-231). B) 
mPrP(H95A+H110A). All experiments were performed at 25°C and pH 7.4 and are representative of at least 
four indepenedent experiments. All data are presented as blank-subtracted energy change as a function of 
time (top graph) or molarity (bottom graph). 
5.3 Heparin and PrP aggregation 
Heparin and other GAGs have been shown to stimulate the aggregation of prion 
proteins (Wong et al., 2001; Deleault et al., 2005; Kajnert et al., 2006; Boshuzien et al., 
2007). Therefore the effect heparin had on the aggregation of mPrP constructs with 
and without specific heparin binding regions was assessed using the aggregation system 
developed in Chapter 3. 
To assess the effect of heparin aggregation of recombinant mPrP(23-231), aggregation 
reactions were performed as described in 2.4.8 with either 25 µg/mL, 50 µg/mL, 500 
µg/mL or 1000 µg/mL heparin sodium sulphate buffered in 10 mM sodium phosphate, 
pH 7.4. mPrP(23-231) aggregation results show that addition of heparin sulphate to 
mPrP(23-231) did not significantly affect the linear rate of the aggregation reaction 
compared to no heparin control (Figure 5.12 B) although there was a trend of increased 
rate in each experiment. All concentrations of heparin caused an increased trend in the 
maximum fluorescence achieved during the reaction compared to the no heparin 
control (Figure 5.12C). Due to variability between the experiments (as discussed 
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C 
previously in Chapter 4 and probably a result of purification and refolding), statistical 
analysis was not possible and no significant differences were seen in any reaction with 
heparin.. 
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Figure 5.12 Aggregation of mPrP(23-231) with heparin. A) Representative graph showing aggregation of 
mPrP(23-231) with the addition of various concentrations of heparin. B) Rate of aggregation with heparin 
compared to no heparin control show no significant differences. C) Maximum fluorescence reached during 
aggregation reaction with any concentration of heparin is not significant when compared to the no heparin 
control reactions. Error bars are ±SEM, n=5. 
To further assess the effect of heparin on mPrP aggregation, aggregate end products 
were analysed by Western blots (as in 2.3.13) to determine whether there was any 
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6 
difference in the end product between heparin added reactions (Figure 5.13). Two anti-
PrP antibodies with distinct epitopes (ICSM18, residues 145-154 or 8B4, residues 35­
45) were used to help obtain structural information. 
Figure 5.13 Western blots of aggregate end products of mPrP((23-231). A) Western blot with anti-PrP 
antibody ICSM18. B) Western blot with anti-PrP antibody 8B4. In both blots, lane 1 is aggregate with no 
heparin added, lane 2 is with 25 µg/mL heparin, lane 3 is with 50 µg/mL heparin, lane 4 is with 500 µg/mL 
heparin, and lane 5 is with 1000 µg/mL heparin. Markers are in kDa. 
Results show there were no very high molecular weight aggregates that would indicate 
the presence of fibrils. There was no great difference between the heparin and the no 
heparin control. Some samples with higher concentrations of heparin showed more 
bands corresponding to higher molecular weight aggregates at ~46kDa, particularly in 
the Western blots with the C-terminal monoclonal antibody ICSM18. The apparent 
size makes it likely these fragments correspond to dimers. Smaller PrP fragments (10­
12 kDa, as well as, 6.5 kDa) were present. 
5.3.1 Deletion and truncation mutations of PrP 
Both this work and studies by others shown that heparin binding sites are located 
within the N-terminus of PrP (Warner et al., 2002; Pan et al., 2002). Therefore the 
effect of reduced heparin binding sites on mPrP aggregation with heparin was assessed 
using N-terminal mutations. 
As with mPrP(23-231) aggregation, recombinant mPrP(89-231) or mPrP(Δ51-89) was 
incubated with either 25 µg/mL, 50 µg/mL, 500 µg/mL or 1000 µg/mL heparin sodium 
sulphate buffered in 10 mM sodium phosphate, pH 7.4. Aggregation reactions were 
performed and analysed as described in 2.4.8. 
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Heparin addition did not affect the initial rate of or maximum fluorescence reached of 
either mPrP(89-231) or mPrP(Δ51-89) aggregation. Unlike mPrP(23-231), no clear 
trends were seen. mPrP(Δ51-89) rate and maximum fluorescence data is shown as an 
example (Figure 5.14). 
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Figure 5.14 Initial rate and maximum fluorescence of mPrP(Δ51-89) aggregation in the presence of varying 
concentrations of heparin. No significant differences are seen in either protein at any concentration of 
heparin assessed. All values are compared to the no heparin added control. Error bars are ±SEM, n=3. 
5.4 Heparin and cellular prion infection 
Experiments have shown endogenous GAGs are required for propagation of prion 
infection (Horonchik et al., 2005). Experiments wherein cells are treated either with 
sodium chlorate, an inhibitor of sulphation, or with specific GAG-degrading enzymes 
fail to become infected when challenged with infection (Horonchik et al., 2005; Ben-
Zaken et al., 2003). Reconstitution of infection did not occur when exogenous GAGs 
were added to these treated cells, indicating the role of GAGs in prion biology is 
specific to the cells’ endogenous population. Additionally, there is evidence that the 
metabolism of GAGs is in fact disrupted in prion disease (Halimi et al., 2006; Mayer-
Sonnenfield et al., 2005) and in cellular infection models ablation of GAG biosynthesis 
genes reduce the capability of PrPSc bind to cells (Hijazi et al., 2005). Exogenous 
heparin sulphate has been shown to enhance infectivity of solubilised PrP27-30, which 
otherwise showed quite low infectivity (Shaked et al., 2001) further adding evidence to 
the involvement of GAGs in disease. 
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The role of heparin sulphate in cellular prion infectivity was examined using the 
infectivity assay using infectious cell homogenate as devloped in Chapter 3. N2a cells 
over-expressing pCDNA3.1+-mPrP(1-254), N2a(mPrP), were treated were treated for 
24 h with 30 mM sodium chlorate to deplete endogenous GAGs as previously 
described by Horonchik et al. Then, these cells were infected using ScN2aM 
homogenate at various doses from 1:100, 1:50, 1:25, 1:10 and 1:1 
(N2a(mPrP):ScN2a(mPrP)). 25 µg/mL or 100 µg/mL heparin sulphate was added to 
the cells at the start of the infection incubation periods. Cells were incubated with the 
exogenous heparin and infectious material for 48 h before being washed three times 
with PBS. Infection was analysed after 4 passages by cell blot. At least four 
independent infection experiments were performed. 
Uninfected 
1:100 1:50 1:25 1:10 1:1 N2a(mPrP) 
Untreated control 
100 µg/mL heparin sulphate 
Sodium Chlorate 
25 µg/mL heparin sulphate 
SMB Control 
Figure 5.15 Cell blot of infectivity assay of N2a(mPrP) with heparin. Cells were treated with 30 mM sodium 
chlorate for 24 h to deplete endogenous GAGs and then treated with 25 or 100 µg/mL heparin sulphate for 48 
h concurrent with incubation of infectious cell homogenate. The infectious treatment was then removed and 
cells were washed and propagated for 4 passages before analysis by cell blot. 
Results show that sodium chlorate treatment did not inhibit prion infection, as infection 
was seen at similar infectious doses as the untreated control. However, addition of 
heparin sulphate increased the susceptibility of N2a(mPrP) to infection by 
ScN2a(mPrP) cell homogenates, as determined by the presence of PK-resistant material 
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at a lower infection dose (1:1) than the control (1:10) (Figure 5.15). These results 
suggest that a low amount of heparin can promote infectivity, in agreement with 
previously published observations (Shaked et al., 2001). 
In order to confirm that the effect on infectivity was not merely due to an effect on 
heparin on the level of expression in the cells, N2a(mPrP) cells were treated with 30 
mM sodium chlorate for 24 h to deplete the endogenous GAGs. Then cells were 
treated with varying concentrations of heparin sulphate for 48 h and Western blots were 
performed. PrPC was quantified by densitometry and normalised to α-tubulin. Results 
from four independent experiments show there was no significant change in mPrP 
expression levels in treated cells compared to the non-treated control, although these 
data are highly variable (Figure 5.16A). 
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Figure 5.16 Effect of heparin sulphate on PrPC expression. A) PrPC expression in N2a(mPrP) cells treated 
for 24 h with sodium chlorate then 48 h with heparin sulphate. B) N2a cells treated for 24 h with sodium 
chlorate then 48 h with heparin sulphate. All are ± SEM, n=4. C) Representative Western blots of N2a cells. 
Lane 1, untreated control; Lane 2, sodium chlorate; Lane 3, 25 µg/mL heparin sulphate; Lane 4, 100 µg/mL 
heparin sulphate; Lane 5, 500 µg/mL; and Lane 6, 1000 µg/mL heparin sulphate. Markers are in kDa. 
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These results are in agreement with previously published observations that heparin does 
not increase PrPC expression in cells, whereas heparin sulphate (the less sulphated 
GAG) does (Gabizon et al., 1993). Also, N2a(mPrP) cells over-express PrPC but the 
high level PrP expression is under the control of the CMV promoter. The CMV 
promoter constitutively expresses protein at very high levels in cells, and therefore 
subtle changes to endogenous PrPC expression (under the control of the PRNP 
promoter) would not be detected. To confirm PrPC expression was unchanged by 
heparin treatment due to the high level of PrPC expression in N2a(mPrP) cells, 
expression was also quantified in N2a cells (Figure 5.16 B,C). However, no significant 
difference was seen. 
5.5 Discussion 
The presence of GAGs are required for prion infection to occur (Horonchik et al., 2005; 
Ben-Zaken et al., 2003), thus understanding their role in prion biology is essential. 
5.5.1 GAGs and PrP binding 
The first way to assess the role of heparin in prion biology is to analyse heparin 
binding. Heparin binding studies using ITC indicate that mPrP(23-231) binds four 
heparin molecules. Data from binding studies with mPrP(Δ51-89) and mPrP(89-231) 
showed three and two binding sites respectively, indicating that at least 2 of those 
binding sites are located in the N-terminal region encompassing residues 23-90. These 
data agree with previously published studies indicating the main heparin binding region 
of PrP is located in the N-terminus of the protein (Warner et al., 2002, Pan et al, 2002). 
Mutation of N-terminal histidines to alanines did not completely abolish heparin 
binding at pH 7.4. mPrP(Null) heparin binding data best fit a four site model, as with 
mPrP(23-231), but the results had very different isotherms. This suggests that the 
ablation of six histidine residues from mPrP affects the nature but not necessarily the 
number of heparin binding sites. While the overall charge structure has been altered 
with mPrP(Null), it is probable that other binding regions compensate for the loss of the 
histidines in the N-terminal region. It has been demonstrated that hydrophobic 
interactions and hydrogen bonding can also participate in GAG-protein binding. 
mPrP(Null) still contains the heparin binding motif KKRPK at residues 23-27, as well 
as arginine and lysine residues prior to the octameric repeat region which may account 
for some heparin binding sites. Data from mPrP(Δ51-89) showed that when the 
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octameric repeats were deleted PrP was still able to bind heparin at three sites, and one 
of these was a high (1-10 femtomolar range) affinity site. This site is likely to be 
centred around residues 23-51, which are rich in heparin binding motifs. Truncation of 
the N-terminus of the protein to residue 89 results in loss of a further heparin binding 
site, suggesting there are two binding sites located further along the protein. These data 
indicate that within residues 23-89, the octameric repeat region (residues 51-89) is 
responsible for one binding site and residues 23-51 comprise the other binding site. 
As for the other two binding sites on the protein, they may be located further along the 
C-terminus(Warner et al., 2002). To determine whether the region around residues 95­
110 is involved in heparin binding, experiments were performed with 
mPrP(H95A+H110A). However this data was problematic and highly variable 
compared to wild type data. As mentioned in 4.7, this protein proved difficult to purify 
and also had a high tendency to precipitate prior to and during the experiments. Only 
limited conclusions can be drawn regarding the data gleaned from these data as the 
analysis software does not compensate for the thermodynamics of precipitation. Work 
from this laboratory has shown that mPrP(H95A+H110A) ITC experiments with metals 
are also highly variable and precipitation is rampant (P. Davies, personal 
communication and unpublished results). Possibly, different mutants would need to be 
used to definitely determine where the other heparin binding sites are located on mPrP. 
Finally, it has been suggested that there is a heparin binding region at residues 185-208 
(Klajnert et al., 2006). It is unknown whether this is a major binding site in the wild 
type protein but it may participate if there is significant alteration to the charge pattern 
of the N-terminus. 
Copper has been reported on different occasions to enhance PrP-GAG binding as well 
as to weaken it (Gonzalez-Iglesias et al., 2002; Warner et al., 2002; Pan et al., 2002; 
Andreivskaia et al., 2007). The results obtained with ITC in this chapter demonstrate 
that PrP with copper already bound has lower binding affinities for heparin than metal-
free mPrP. This is in agreement with the results by Andreivskaia et al. Copper-loaded 
mPrP has increased structure within the N-terminal region compared to no metal mPrP 
(Wong et al., 2000b). This structural difference would affect the nature of the PrP-GAG 
interaction. There are also possible steric complications due to the presence of copper 
which could weaken the interaction between mPrP and heparin. To further clarify the 
relationship between copper and heparin, binding experiments could be performed 
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where copper is added directly into the binding assay, instead of saturating the copper 
binding sites as in the ITC experiments. 
Overall, the results presented here are a novel method of studying PrP-heparin 
interactions and the data support previously published data identifying the N-terminal 
region of the protein as the heparin-binding region (Warner et al., 2002; Pan et al., 
2002). These results also confirm the previously published binding affinity for heparin 
and PrP which is also within the 10-100 nanomolar range (Adreivskaia et al, 2007). 
5.5.2 GAGs and PrP aggregation 
Several studies show that GAGs can stimulate the aggregation of PrP (Gonzalez-
Iglesias et al., 2002; Yin et al., 2007; Wong et al., 2001; Bozhuezin et al., 2007; 
Deleault et al., 2005). The results of this study show that addition of heparin to mPrP 
aggregation caused a trend of increased initial rate of aggregation and maximum 
fluorescence compared to the no heparin reaction. Variability, perhaps due to 
methodology, made statistical analysis difficult. In Chapter 4 it was shown this method 
produces amorphous β-sheet structures, not fibrils (Figure 5.15). These overall trends 
suggested by the data also agree with previously published data indicating at neutral pH 
GAGs stimulate PrP aggregation, although the experiments described were performed 
with different protein concentrations and at different temperatures (Yu et al., 2008). 
The lack of aggregation stimulation by heparin on mPrP(89-231) and mPrP(Δ51-89) 
could be explained by the reduced number of binding sites available. It is possible that 
the octameric repeat region is responsible for any stimulatory effect of heparin. This is 
supported by a study by Yu et al., showing that aggregation of PrP without the 
octameric repeat region was not stimulated by GAGs, which is in agreement with the 
data seen in this work. 
5.5.3 GAGs and prion infectivity 
The interaction between GAGs and prion infectivity is complex. PrPSc has been shown 
to bind heparin (Hijazi et al., 2005) and several reports have shown that long-term 
inhibition of GAG biosynthesis can reduce the amount of PrPSc in chronically infected 
cell cultures (Gabizon et al., 1993; Ben-Zaken et al., 2003; Horonchik et al., 2005). It 
has been shown that heparin sulphate participates in initial PrPSc binding to cells and a 
heparinase III-sensitive heparin sulphate compound is required for transfer of prion 
infectivity (Ben-Zaken et al., 2003; Hijazi et al., 2005; Horonchik et al., 2005). The 
162 
infectivity assay results in this study show that sodium chlorate treatment for 24 h does 
not abolish transfer of prion infectivity. Sodium chlorate is an inhibitor of sulphation 
and long term treatment has been shown to decrease PrPSc in infected cells (Gabizon et 
al., 1993). Despite identical chlorate treatments (30mM for 24 h) the results here are in 
contrast to observations by Horonchik et al., who saw significant reduction of PrPSc 
uptake in chlorate-treated cells (Horonchik et al., 2005). However, there are several 
methodology differences between the two studies including the cell type, source of 
prion infection and the length of incubation with the infectious source. 
Further results of the infectivity assays showed that addition of exogenous heparin to 
chlorate-treated cells increases susceptibility of N2a(mPrP) cells to prion infection, and 
renders cells more susceptible to lower doses of infectivity. Soluble heparan sulphate 
and chondroitin sulphate (another GAG) have also been shown to increase detectable 
PrPSc after chlorate treatment (Ben-Zaken et al., 2003). It has been suggested that cell 
surface GAGs are required for prion infection to occur, and chlorate treatment inhibits 
sulphation but does not degrade endogenous GAGs. Therefore there are likely some 
GAGs still present at the cell surface that act as receptors for PrPSc . Additionally, 
heparin can bind PrPSc which may make the infectious PrP more attractive to 
internalisation by the cell, as GAGs have also been shown to stimulate internalisation 
of PrPC (Shyng et al., 1995a; Hijazi et al., 2005). 
5.5.4 Future directions 
Future work should be undertaken to further identify where heparin binding sites are 
located on PrP. The precise identification of GAG binding sites on PrP and more 
profound understanding of their biological relevance may be useful in further 
development of therapeutics for prion diseases. To fully compare the results presented 
here, binding experiments with a known heparin-binding protein could be performed to 
provide a control for these experiments. Many chemically modified GAGs and 
naturally occurring GAGs are known to decrease PrPSc and delay disease on set in vivo 
(Ehlers and Diringer, 1984; Kimberlin and Walker, 1986; Ladogana et al., 1992; 
Gabizon et al., 1993; Caughey and Raymond, 1993; Horonchik et al., 2005; 
Schonberger et al., 2003; Adjou et al., 2003; Ouidja et al., 2007) and therefore precise 
binding information and activity of those binding sites in prion infectivity would be 
instrumental in developing more targeted molecules for possible treatments. 
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6. Discussion 
6.1 Summary of results 
In this study the role of metals in scrapie infectivity was assessed by developing a cell 
culture model using mouse-adapted scrapie as the prion source. The successful model 
used N2a(mPrP) cells which had been infected by SMB cells (e.g. Sc(N2a(mPrP) cells) 
as an infectious source and uninfected N2a(mPrP) cells as the target cell line. The role 
of metals was assessed by using chelated medium to reduce the metal concentrations in 
the extracellular environment and resulted in cells having a reduced susceptibility to the 
transfer of prion infectivity. The addition of copper, zinc or manganese to the chelated 
medium resulted in restoration of infectivity to the control level of prion susceptibility. 
These results suggest that while metals may play a regulatory role in prion infectivity; 
the exact role cannot be discerned by these results. 
The conversion assay and cell culture infectivity methods were utilised to determine the 
effect of the glycosaminoglycan heparin in prion protein conversion. First, the nature 
of PrP and heparin binding was studied using isothermal titration calorimetry, a method 
which is novel to PrP-heparin interaction study. Results from the ITC experiments 
confirmed previous reports that PrP binds heparin within the N-terminus of the protein, 
and that residues 23-90 account for at least two of the binding sites. One of the binding 
sites comprises residues 23-51 and the other involves the octameric repeat region 
(resiudes 51-89). Next, the role of heparin in modulating PrP aggregation was studied 
although the data did showed heparin did not have either a significant inhibitory or 
promotional effect on mPrP aggregation. In a cellular infection model, addition of 
exogenous heparin was found to increase the susceptibility of target cells to prion 
infection. 
The results presented in this thesis demonstrate that both metals and GAGs play a role 
in prion protein conversion. However, further work in this area is needed in order to 
fully understand how metals and GAGs are involved in aggregation and infection. 
Possible mechanisms related to aggregated PrP, infection and cell death are discussed 
in the following sections, along with some suggested future work to help further define 
the role of metals and GAGs in prion disease. 
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6.3 PrP aggregates, metals, and glycosaminoglycans 
The results of this work show non-fibril aggregates are the products of aggregation 
assays both with metals and GAG under neutral conditions. Several other groups have 
studied PrP aggregation under various conditions, and have reported different resulting 
structures as well as different effects of metal and GAGs on PrP aggregation 
(Bocharova et al., 2005b; Gonzales-Iglesias et al., 2002; Wong et al., 2004; Thackray 
et al., 2004; Giese et Qin et al., 2000; Rezaei et al., 2002, 2005; Morrissey and 
Shakhnovich, 1999; Redecke et al., 2007; Ricchelli et al., 2006). The aggregates 
shown in this work may represent a normal form of aggregation which under normal 
cellular circumstances is cleared by protein quality control mechanisms. 
Conformational change and oligomerisation of the prion protein have been shown to be 
produced in response to copper and GAGs (Tsiroulnikov, 2006; Rekecke, 2007; 
Gonzales-Iglesias et al., 2002; Yang et al., 2008; Wong et al, 2004). Metals have also 
been shown to modulate aggregation of and toxic effects of other neurodegenerative 
disease-related proteins such as tau and α-synuclein (Zhou et al., 2007; Wright et al., 
2009). Furthermore, heparin has been shown to bind metals in particular copper and 
manganese (Parmar et al., 2003) and GAGs are associated with prion plaques (Snow et 
al., 1989, 1990). Divalent cations have previously been reported to promote GAG-
protein complexes (Björk et al., 1989; Renne et al., 2000). Zinc and to a lesser extent 
copper have been shown to promote heparin binding of amyloid precursor protein 
(Multhaup et al., 1995; Borza and Morgan, 1998). Possible mechanisms by which 
metals associate with PrPSc may include metals binding PrP thereby changing its 
conformation to a more aggregation-prone structure or heparin binding PrP and 
similarly affecting aggregation. The metal- or GAG-PrP aggregates could then 
associate, possibly strengthening the structure, as it has been shown that PrP-GAG 
complexes are stabilised by the presence of copper (Gonzales-Iglesias et al., 2002). 
Further work would need to be done in order to determine which scenario is the most 
likely, and whether the effect metals and/or GAGs have non-fibril aggregates 
modulates the toxicity or infectious nature of these oligomers. 
6.2 Oligomeric PrP, toxicity and infection 
The infectious form of PrP has been theorised to be around 50-600 kDa in size (Alper 
et al, 1966; Gabizon et al, 1987; Bellinger-Kawahara et al., 1988; Tzaban, 2002; 
Caughey and Lansbury, 2003). Disassociation of PrPSc aggregates suggested the most 
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infectious PrP aggregates were spherical oligomers, 17-27 nm in length and 300-600 
kDa in size, corresponding to 14-28 PrP molecule units (Silveira et al., 2005). This has 
been supported by reports that a pathway producing well-ordered β-oligomers of PrP 
consist of the equivalent of 25 monomers of PrP (Redecke et al., 2007). Although the 
size of oligomers can vary depending on the experimental conditions under which they 
were produced, roughly spherical and globular oligomers are common products of 
prion misfolding pathways (Lu and Chang, 2002; Rezaei et al., 2005; Vendrely et al., 
2005; Redecke et al., 2007). It has been suggested that the formation of smaller 
oligomeric structures in misfolding pathways are the key components to prion diseases 
and that these intermediates are in fact the molecule responsible for infection (Morillas 
et al., 2001; Baskakov et al., 2002; Sokolowski et al., 2003; Govaerts et al., 2004; 
Weissmann, 1991). 
Current research now supports the idea that β-oligomers are not formed on the amyloid 
fibril pathway but exist in a dynamic state with α-helical monomers (Baskakov et al., 
2002; Bocharova et al., 2005a; Teplow et al., 2006; Haass and Selkoe, 2007; El 
Moustaine et al., 2008; Soto and Estrada, 2008). If this is true, it is important to 
understand what structures aggregates form under non-denaturing conditions, and how 
these structures might participate in prion disease. It may be that these aggregates are 
able to transfer prion infectivity and/or are neurotoxic depending on the stage of the 
disease. 
It has been established that PrPSc is toxic to cells and that synthetic and recombinant 
prion protein peptides exhibit neurotoxicity (Forloni et al., 1993; Brown, 2000; 
Daniels, et al., 2001). More recent evidence indicates that prion oligomers and fibrils, 
which are both rich in β-sheet content, have been shown to be toxic in vivo and in vitro 
(Kazlauskaite et al., 2005; Novitskaya et al., 2006a, 2007; Corsaro et al., 2006; Villa et 
al., 2006; Chiovitti et al., 2007; Simoneau et al., 2007). The controversy as to whether 
β-oligomers are more toxic than amyloid fibrils may stem from the fact cells have 
varied responses to alternative protein conformations. It was shown that β-oligomers 
induced apoptosis, whereas amyloid fibrils first induce cell aggregation around the 
fibrils prior to apoptosis (Novitskaya et al., 2006a). 
PrP-induced toxicity and prion infection may or may not be mutually exclusive 
(Chesebro et al, 2005; Fioriti et al., 2005). Cells that are persistently prion-infected 
undergo apoptosis (Schatzl et al., 1997). Evidence suggesting that aggregated PrP 
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induces apoptosis includes experiements where covalently cross-linked PrP (Solforosi 
et al., 2004) and β-oligomeric forms of PrP triggered apoptotic cell death (Watzlawik et 
al., 2006; Demuro et al., 2005). Whether or not aggregated PrP is the sole toxic 
reagent is unknown. It has been demonstrated that PrP oligomer toxicity may not 
require PrPC expression, as both ovine and murine PrP β-oligomers cause apoptosis­
mediated death even on PrP-/- mice and cell cultures (Simoneau et al., 2007). 
Additionally, PrPC expression is not required for toxicity of cytosolic PrP, another 
candidate for the toxic form of PrP (Mironov et al., 2003). In contrast, the use of small 
interfering RNA for knock-down expression of PrP in cells was shown to reduce the 
toxicity of both fibrils and oligomers in those cells (Novitskaya et al., 2006). This 
observation by Novitakaya et al. is in agreement with published work that shows 
endogenous PrPC is necessary for the effect of PrPSc (Brandner et al., 1996; Blattler et 
al., 1997). This suggests that oligomer toxicity independent of high levels of PrPC 
expression could be a mechanism by which widespread neurotoxicity and degeneration 
occurs, regardless of whether or not PrP oligomers are the transmissible agent. 
6.3 Mechanisms of oligomer toxicity and neurodegeneration 
Many lines of evidence suggest there is a common toxic mechanism with oligomeric 
proteins due to shared structural features (Bucciantini et al, 2002; Reixach et al, 2004). 
The ability to fold into a β-rich structure is a general property of proteins and is not 
exclusive to proteins associated with neurodegeneration (Guijarro et al., 1998). 
Oligomers derived from many different neurodegenerative conditions including 
Alzheimer’s, Parkinson’s and Huntington’s diseases react to the same oligomer-specific 
antibody (Hernandez and Avila, 2008; Kayed et al., 2003, 2006, 2007; Lafaye, 2009; 
Moore et al., 2009). It has also been shown that oligomers of non-disease related or 
non-mammalian proteins can cause cell death (Pieri et al., 2006) and even induce 
neurodegeneration (Vieira et al., 2007). These data suggest that oligomer structure 
may bestow toxicity that is not in and of itself inherent to the specific protein 
composition of these oligomers. This commonality regarding oligomer structure and 
associated toxicity may manifest through similar mechanisms. Several proposed 
mechanisms are discussed below. 
One favoured mechanism suggested for oligomeric mediated toxicity is increased 
oxidative stress and free radicals within the cell. Oxidative stress may be caused by 
protein accumulation itself (Behl et al., 1994; Hsu et al., 2000), and there is evidence 
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that oxidative damage to RNA occurs at the very early stages of neurodegenerative 
disease (Nunomura et al., 2007; Breusing and Grune, 2008). 
Generation of reactive oxygen species can mediate protein folding (Nakomura and 
Lipton, 2009). Further, gross oxidative stress associated with the presence of oligomers 
has been demonstrated in several other neurodegenerative disorders and may in fact 
represent a common pathway of neurodegeneration (Halliwell, 2006; Calabrese et al., 
2007; Nunomura et al., 2009; Petrozzi et al., 2007). Oxidative damage has been 
demonstrated at early stages of Alzheimer’s, Parkinson’s, and Huntington’s disease 
(Browne and Beal, 2006; Nunomura et al., 2001; Wang et al., 2006) and it has been 
shown that oxidative stress increases with ageing (Pratico and Sung, 2004). As many 
neurodegenerative conditions occur later in life, the corresponding increase in oxidative 
stress during ageing may be due to increased oligomeric protein load within the cells. 
In terms of prion disease, markers of and susceptibility to oxidative stress are increased 
in prion-afflicted cells and mice (Yun et al, 2006; Brazier et al., 2006; Freixes et al., 
2006; Brown and Bessinger, 1998; Milhavet, 2000). In addition, PrPC and in particular 
the octameric repeat region can protect against reactive oxygen species-mediated 
cellular damage (Zeng et al., 2003; Watt et al, 2007; Malaisé et al., 2008; Haigh et al., 
2009). This suggests that the conformational change which occurs during prion 
conversion may obliterate the protective effect of PrPC in regards to oxidative stress in 
prion disease. Thus, it can be argued that oxidative stress may be a mechanism through 
which aggregated abnormal forms of PrP enhance cell death. 
All things considered, elucidating how metals might contribute to oxidative cell death 
will provide insight into potential mechanisms of disease progression. Disruptions in 
brain metal homeostasis, like those observed in prion disease (Wong et al., 2001b; 
Thackray et al., 2002; Hesketh et al., 2007, 2008) have been shown to increase reactive 
oxygen species production, possibly through Fenton chemistry-dependent or 
independent means (Linert, 2006). Aberrant metal homeostasis also may contribute to 
oxidative damage and toxicity of Aβ oligomers (Maynard et al., 2005). It is interesting 
therefore that aggregates produced from metal-catalysed oxidation have been shown to 
consist of small stable oligomers (Redecke et al., 2007). This suggests that oxidative 
reactions are permissive to stable oligomer species. Whether high levels of oxidative 
stress cause the oligomers or oligomers cause oxidative stress has not been proven 
conclusively. In addition, exposure of recombinant PrP to conditions mimicking those 
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of oxidative stress resulted in an increase in β-sheet structure, PK resistance, and the 
ability to act as a seed in aggregation reactions, suggesting oxidative damage could 
enhance the progression of prion disease (Requena et al., 2001, 2004; Dear et al., 2008) 
which would then contribute to activation of apoptosis signalling cascades. 
Apart from the well documented phenomenon that the function of the proteasome is 
impaired during the natural ageing process, an associated hallmark of 
neurodegenerative disease is proteasome dysfunction due to the presence of aggregated 
proteins (Carrard et al., 2002; Bennett et al., 2005; Dahlmann 2007) partially due to the 
fact that the proteasome cannot effectively degrade large amounts of aggregated protein 
(Verhoef et al., 2002). This suggests that a possible mechanism of oligomer-induced 
cell death is intracellular accumulation of oligomers saturates the proteasome system 
thereby initiating apoptosis. 
Perhaps the most compelling evidence for the impairment of the ubiquitin-proteasome 
system as a mechanism of oligomer toxicity comes from the finding that PrP β­
oligomers, but not amyloid fibrils, inhibit the activity of the 26S proteasome 
(Kristiansen et al., 2007). The UPS is involved in turnover of wild type PrP (Yedidia et 
al., 2001) and it was initially proposed that altered PrPC trafficking impairs the function 
of the UPS, leading to accumulation of PrP aggregates and apoptosis (Ma and 
Lindquist, 2001). The function of the UPS is impaired in prion-infected cells, resulting 
in the accumulation of cytosolic aggresomes containing PrPSc, ubiquitin, heat shock 
protein 70, proteasome subunits and other components (Kristiansen et al., 2005). 
These aggresomes appeared to be neurotoxic and activate caspase 3- and 8-dependent 
apoptosis (Kristiansen et al., 2005), in agreement with previous demonstrations that 
caspase 8 is activated in response to aggregates in Huntington’s and Alzheimer’s 
diseases (Gervais et al., 2002; Lu et al., 2003). This inhibition was specific only to β­
oligomers, as use of oligomer-directed antibodies resulted in an abrogation of the 
inhibition effect (Kristiansen et al., 2007). Inhibition of UPS activity in response to 
prion infection was demonstrated using a GFP-reporter system in transgenic mice, 
thereby demonstrating the impairment of the UPS during prion infection in vivo 
(Kristiansen et al., 2007). 
An alternative theory argues that the accumulation of oligomers and aggregates alters 
endoplasmic reticulum (ER) homeostasis triggering apoptosis by the alteration of ER 
signalling pathways (Hetz et al., 2007; Hetz and Soto 2006). ER stress has shown to be 
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caused by changes to structure or function of proteins as well as accumulation of 
misfolded proteins (Wojda et al., 2008). The resulting aggregation of disease-related 
proteins can disrupt calcium homeostasis leading to synaptic dysfunction, oxidative 
stress, and impaired energy metabolism (Marambaud, 2009; Mattson, 2007). ER stress 
has also been shown to compromise UPS function (Menedez-Benito et al., 2005). 
Interestingly, oxidative stress has also been shown to cause damage to the 26S 
proteasome, making it less effective at degrading misfolded or damaged cytosolic 
protein (Breusing and Grune, 2008). It is very probable that a combination of ER 
stress, oxidative stress and UPS dysfunction all contribute as mechanisms oligomer-
mediated toxicity. 
6.4 Future directions and conclusions 
Future work could be carried out in order to confirm whether the products from the 
conversion experiments have any associated toxicity in a cell culture system. Such 
work should be informed by more detailed structural analysis both for structures 
formed in the presence and in the absence of metals and heparin. Different structures 
of oligomers would need to be purified perhaps by size exclusion chromatography or 
gel filtration. It is likely that conformation of the aggregates formed in the presence of 
metals is different from those formed in the absence of metals, and the same might be 
true of heparin. It has been shown that copper binding to the N-terminus of the prion 
protein can increase the β-sheet content of PrP (Viles et al., 1999; Stockel et al., 1998; 
Qin et al., 2000). This is also true for manganese binding to PrP (Brown et al., 2000; 
Abdelraheim et al., 2006; Kim et al., 2005; Brazier et al., 2008). Therefore any effect 
of metals or heparin seen in PrP aggregation could be due to a binding induced-
conformational change within the N-terminus which influences the conformational 
stability of the C-terminus. This theory is supported by previously published work 
which has shown that interactions in the N-terminal region of the protein can alter the 
conformation of the C-terminal region (Thackray et al., 2003; Li, 2000) and that N-
terminally PrP aggregation does not undergo as many different pre-amyloid states as 
full length PrP (Frakenfield et al., 2005). To clarify the role of metals in PrP-GAG 
interactions, it would be prudent to determine the key region where copper/heparin 
interaction occurs, whether this is centred around the region 95-110 or whether this 
interaction occurs within the OR region. 
Next, the structure of the sorted oligomers would need to be analysed with EM and 
potentially more powerful imaging techniques in order to obtain as much information 
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as possible regarding oligomer structure and toxicity. Once the structure of the 
aggregates had been thoroughly investigated, the next step would be to expose the 
products to mammalian cells expressing PrP and also cells which do not express PrP to 
determine whether the aggregates have any toxic or infectious effect. The toxic effect 
may or may not be PrPC dependent, as conflicting studies have shown (Novitskoya et 
al., 2006; Simoneau et al., 2007; Shiraishi et al., 2009). After determining which 
structure was responsible for the toxic effect, it would then be interesting to determine 
whether metals could render the aggregates more toxic, as has been shown in other 
forms of neurodegenerative disease such as Parkinson’s disease (Wright et al., 2009b). 
It would then follow to determine if heparin or any other GAGs could enhance or 
ameliorate the toxic effect. This could provide further insight into the normal function 
of PrP, especially given that both GAG and copper can stimulate internalisation of PrP 
(Shyng et al., 1995; Pauly and Harris, 1998). Detailed study of the nature of the 
toxicity elucidating whether it occurs by proteasome dysfunction, increased oxidative 
stress, increased ER stress, or indeed all three would be necessary to better our 
understanding neurodegeneration. 
Once the structure responsible for toxicity had been identified, further work could be 
undertaken to determine whether the structures that were toxic also had any 
transmissibility, i.e. if the structures are able to propagate prion infection. Through the 
utilization of a cell culture model system, the dependence of prion infection on GAG 
and metals could be assessed. This could be tested using cells treated with the 
oligomer structures in assays similar to the one presented in this study, and further 
confirmed using animal models. This could be extended to include studies looking at 
the different domains that are required for the effect as well, by using transgenic 
animals or cells expressing various mutants of mPrP. For clinical applications, it is 
necessary to understand what part of the protein is required for the potential toxic 
and/or transmissible effect of oligomeric structures and what role other compounds 
play in this effect. 
Previously published studies showing that metal-bound PrP is able to be extracted from 
brains of patients with sporadic CJD (Wong et al., 2001b) and that heparan sulphate is 
found in prion amyloid plaques (Snow et al, 1989) dictate the importance of identifying 
if any similar oligomer species form in vivo in diseased brains and whether these 
species have toxic and or transmissible properties and whether metals or GAGs are 
associated with those structures. Data from such experiments could potentially resolve 
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two likely theories – the first stating that oligomers are toxic and thereby contribute to 
neurodegeneration seen in prion diseases, and the second arguing that oligomers are in 
fact the transmissible agents. Indeed both scenarios may be true. Whatever the case, 
the link between PrP oligomers and disease progression needs to be established in order 
to fully understand how PrP interactions with both metals and GAGs contribute to a 
disease state. 
There are many candidates and arguments for each proposed normal function of the 
prion protein, elucidation of the normal function of PrPC is instrumental to 
understanding prion disease and for any significant contribution that elucidating the 
role of metals and glycosaminoglycans might have for treatment of the disease. With 
more detailed understanding of how these compounds interact with and influence the 
prion protein during its normal cellular activities, we will better be able to understand 
the mechanisms behind prion pathogenesis and related neurodegenerative disorders. 
This increased understanding of how these diseases arise and cause neurodegeneration 
will lead to the development of more effective therapies and treatments, which is all the 
more pertinent given that greater proportions of the population have been diagnosed 
with such degenerative conditions. Consequently, the study of prion disease remains a 
valid field to research in view of its contribution to the understanding of 
neurodegenerative diseases and effective therapies for their treatment. 
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This could be done by using further deleted regions such as Δ35-45 and Δ106-126, as 
well as a further N-terminally truncation mutation such as 113-231 to confirm where 
binding sites are. This could be done with ITC if an appropriate calculation could be 
made to allow for any aggregation seen, and confirmed with other binding methods 
such as 2-dimensional nuclear magnetic resonance, enzyme-linked immunosorbant 
assay and surface plasmon resonance. Once this has been done it would be interesting 
to express these mutants in a cell culture infection model, similar to the one in this 
study but possibly utilising cells with a PrP null background. This could help determine 
the key heparin binding region responsible for the increased susceptibility to infection 
seen in section 5.4, and at what minimum heparin concentration is required for the 
effect. If these experiments were successful it would be very interesting to go on to 
determine which binding region is responsible for PrP-GAG interaction that clears cells 
of prion disease/delays onset. 
Furthermore as in Chapter 4, it would be interesting to further characterise the 
aggregates formed in this study with and without heparin, by size-exclusion 
chromatography and imaging techniques including atomic force microscopy. It would 
then be interesting to identify whether the non-fibril aggregates produced in the 
aggregation reactions here had any neurotoxic effects, and if the presence of heparin 
was able to modulate the toxicity. 
To clarify the role of metals in PrP-GAG interactions, it would be prudent to determine 
the key region where copper/heparin interaction occurs, whether this is centred around 
the region 95-110 or whether this interaction occurs within the OR region. This could 
provide further insight into the normal function of PrP, especially given that both GAG 
and copper can stimulate internalisation of PrP (Shyng et al., 1995; Pauly and Harris, 
1998). It would be interesting to potentially discover whether GAG and metals are 
mutually required for or inhibit each other in prion infection by utilising the appropriate 
mutants and in a cell culture system background. 
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Appendix I 
Sequences for pET3a-mPrP(23-231). pET3a-mPrP(Δ51-89), pET3a-mPrP(Δ67-90). 
Alignments were performed using CLUSTALW (http://align.genome.jp/). All 
ambiguous bases (N) were double checked to ensure they were correct. 
I. pET3a-mPrP(23-231) sequencing results. Alignment was performed using mPrP 23­
231 sequence from mPrP (NM_0011170). 
CLUSTAL W (1.81) multiple sequence alignment

mPrP_23-231_ --------------------------------------------------------ATGA

23-231_sequencing NNANNNNNNNNNNNNNANTNNNNNNNNTTNNNTTTAANAAGGAGATATACATATGA

****

mPrP_23-231_ AAAAGCGGCCAAAGCCTGGAGGGTGGAACACCGGTGGAAGCCGGTATCCCGGGCAGGGAA

23-231_sequencing AAAAGCGGCCAAAGCCTGGAGGGTGGAACACCGGTGGAAGCCGGTATCCCGGGCAGGGAA

************************************************************

mPrP_23-231_ GCCCTGGAGGCAACCGTTACCCACCTCAGGGTGGCACCTGGGGGCAGCCCCACGGTGGTG

23-231_sequencing GCCCTGGAGGCAACCGTTACCCACCTCAGGGTGGCACCTGGGGGCAGCCCCACGGTGGTG

************************************************************

mPrP_23-231_ GCTGGGGACAACCCCATGGGGGCAGCTGGGGACAACCTCATGGTGGTAGTTGGGGTCAGC

23-231_sequencing GCTGGGGACAACCCCATGGGGGCAGCTGGGGACAACCTCATGGTGGTAGTTGGGGTCAGC

************************************************************

mPrP_23-231_ CCCATGGCGGTGGATGGGGCCAAGGAGGGGGTACCCATAATCAGTGGAACAAGCCCAGCA

23-231_sequencing CCCATGGCGGTGGATGGGGCCAAGGAGGGGGTACCCATAATCAGTGGAACAAGNCCAGCA

***************************************************** ******

mPrP_23-231_ AACCAAAAACCAACCTCAAGCATGTGGCAGGGGCTGCGGCAGCTGGGGCAGTAGTGGGGG

23-231_sequencing AACCAAAAACCAACCTCAAGCATGTGGCAGGGGCTGCGGCAGCTGGGGCAGTAGTGGGGG

************************************************************

mPrP_23-231_ GCCTTGGTGGCTACATGCTGGGGAGCGCCATGAGCAGGCCCATGATCCATTTTGGCAACG

23-231_sequencing GCCTTGGTGGCTACATGCTGGGGAGCGCCATGAGCAGGCCCATGATCCATTTTGGCAACG

************************************************************

mPrP_23-231_ ACTGGGAGGACCGCTACTACCGTGAAAACATGTACCGCTACCCTAACCAAGTGTACTACA

23-231_sequencing ACTGGGAGGACCGCTACTACCGTGAAAACATGTACCGCTACCCTAACCAAGTGTACTACA

************************************************************

mPrP_23-231_ GGCCAGTGGATCAGTACAGCAACCAGAACAACTTCGTGCACGACTGCGTCAATATCACCA

23-231_sequencing GGCCAGTGGATCAGTACAGCAACCAGAACAACTTCGTGCACGACTGCGTCAATATCACCA

************************************************************

mPrP_23-231_ TCAAGCAGCACACGGTCACCACCACCACCAAGGGGGAGAACTTCACCGAGACCGATGTGA

23-231_sequencing NNAAGCAGCACACGGTCACCACCACCACCAAGGGGGAGAACTTCACCGAGACCGATGTGA

**********************************************************

mPrP_23-231_ AGATGATGGAGCGCGTGGTGGAGCAGATGTGCGTCACCCAGTACCAGAAGGAGTCCCAGG

23-231_sequencing AGATGATGGAGCGCGNGGTGGAGCAGATGTGCGNCACCCAGTACCAGAAGGAGTCCCAGG

*************** ***************** **************************

mPrP_23-231_ CCTATTACGACGGGAGAAGATCCAGCTAG

23-231_sequencing CCTATTACGACGGGAGAAGATCCAGCTAG

*****************************
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------------------------------------------------------------
II. Sequence alignments for pET3a-mPrP(Δ51-89) in blue, and pET3a-mPrP(Δ67-90) 
in red as compared to the wild type pET3a-mPrP(23-231). Start and stop codons are 
highlighted in underlined bold. 
pET3a-mPrP_d51-89_ NNNTTNNNNNTANCTTTAAGAAGGAGATATACATAT

pET3a-mPrP_d67-90_ NNNNNTTGTTTAACTTTAAGAAGGAGATATACATAT

mPrP_23-231_ TNNNNNNNNTTNNNTTTAANAAGGAGATATACATAT

****************

GAAAAAGCGGCCAAAGCCTNNNNNNNGNAACACCGGTGGAAGCCGGTATCCCGGGCAGGG

GAAAAAGCGGCCAAAGCCTGGANNNNGGAACACCGGTGGAAGCCGGTATCCCGGGCAGGG

GAAAAAGCGGCCAAAGCCTGGAGGGTGGAACACCGGTGGAAGCCGGTATCCCGGGCAGGG

******************* * ********************************

NNNNCCTGGAGGCAACCGTTACCCA----------------------------------­

NAGNCCTGGAGGCAACCGTTACCCACCTCAGGGTGGCACCTGGGGGCAGCCCCACGGTGG

AAGCCCTGGAGGCAACCGTTACCCACCTCAGGGTGGCACCTGGGGGCAGCCCCACGGTGG

**********

TGGCTGGGGACAA----------------------------------------------­

TGGCTGGGGACAACCCCATGGGGGCAGCTGGGGACAACCTCATGGTGGTAGTTGGGGTCA

*************

-------------------------GGAGGGGGTACCCATAATCAGTGGAACAAGCCCAG

-------------------------GGAGGGGGTACCCATAATCAGTGGAACAAGCCCAG

GCCCCATGGCGGTGGATGGGGCCAAGGAGGGGGTACCCATAATCAGTGGAACAAGNCCAG

****************************** ****

CAAACCAAAAACCAACCTCAAGCATGTGGCAGGGGCTGCGGCAGCTGGGGCAGTAGTGGG

CAAACCAAAAACCAACCTCAAGCATGTGGCAGGGGCTGCGGCAGCTGGGGCAGTAGTGGG

CAAACCAAAAACCAACCTCAAGCATGTGGCAGGGGCTGCGGCAGCTGGGGCAGTAGTGGG

************************************************************

GGGCCTTGGTGGCTACATGCTGGGGAGCGCCATGAGCAGGCCCATGATCCATTTTGGCAA

GGGCCTTGGTGGCTACATGCTGGGGAGCGCCATGAGCAGGCCCATGATCCATTTTGGCAA

GGGCCTTGGTGGCTACATGCTGGGGAGCGCCATGAGCAGGCCCATGATCCATTTTGGCAA

************************************************************

CGACTGGGAGGACCGCTACTACCGTGAAAACATGTACCGCTACCCTAACCAAGTGTACTA

CGACTGGGAGGACCGCTACTACCGTGAAAACATGTACCGCTACCCTAACCAAGTGTACTA

CGACTGGGAGGACCGCTACTACCGTGAAAACATGTACCGCTACCCTAACCAAGTGTACTA

************************************************************

CAGGCCAGTGGATCAGTACAGCAACCAGAACAACTTCGTGCACGACTGCGTCAATATCAC

CAGGCCAGTGGATCAGTACAGCAACCAGAACAACTTCGTGCACGACTGCGTCAATATCAC

CAGGCCAGTGGATCAGTACAGCAACCAGAACAACTTCGTGCACGACTGCGTCAATATCAC

************************************************************

CATCAAGCAGCACACGGTCACCACCACCACCAAGGGGGAGAACTTCACCGAGACCGATGT

CATCAAGCAGCACACGGTCACCACCACCACCAAGGGGGAGAACTTCACCGAGACCGATGT

CANNAAGCAGCACACGGTCACCACCACCACCAAGGGGGAGAACTTCACCGAGACCGATGT

** ********************************************************

GAAGATGATGGAGCGCGTGGTGGAGCAGATGTGCGTCACCCAGTACCAGAAGGAGTCCCA

GAAGATGATGGAGCGCGTGGTGGAGCAGATGTGCGTCACCCAGTACCAGAAGGAGTCCCA

GAAGATGATGGAGCGCGNGGTGGAGCAGATGTGCGNCACCCAGTACCAGAAGGAGTCCCA

***************** ***************** ************************

GGCCTATTACGACGGGAGAAGATCCAGCTAGTAAGGATCCGGCTGCTAACA

GGCCTATTACGACGGGAGAAGATCCAGCTAGTAAGGATCCGGCTGCTAACA
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GGCCTATTACGACGGGAGAAGATCCAGCTAGTAAGGATCCGGCTGCTAACA

***************************************************
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